

COPY NUMBER VARIATIONS PREDICTIVE OF RISK OF SCHIZOPHRENIA

INTRODUCTION

Genetic risk is conferred by subtle differences in individual genomes within a population. Genes differ between individuals due to genomic variability, most frequently due to single nucleotide polymorphisms (SNPs). SNPs are located on average every 500-1000 base pairs in the human genome. Additional genetic polymorphisms in the human genome are caused by duplications, insertion, deletion, translocation or inversion of either short or long stretches of DNA. Genetic variability among individuals thus in general occurs on many other scales, ranging from single nucleotide changes to gross, microscopically visible, alterations in chromosomal structure and function. Recently, an abundance of submicroscopic copy number variations (CNVs) of DNA segments ranging from a few kilobases to megabases in size have been discovered (summarized in Redon, R. et al. *Nature* 444:444-54 (2006) and Estivill, X. & Armengol, L. *PLoS Genetics* 3:e190 (2007)). These CNVs include deletions, insertions, duplications and complex multi-site variants. To date, known CNVs account for over 15% of the assembled human genome (Estivill, X. Armengol, L. *PLoS Genetics* 3:e190 (2007)), although most of these variants are so rare that they cover only a small percentage of the human genome of any particular individual.

As genetic polymorphisms conferring risk of common diseases are uncovered, genetic testing for such risk factors is becoming important for clinical medicine. Examples are Apolipoprotein E testing to identify genetic carriers of the ApoE4 polymorphism in dementia patients for the differential diagnosis of Alzheimer's disease, and of Factor V Leiden testing for predisposition to deep venous thrombosis. More importantly, in the treatment of cancer, diagnosis of genetic variants in tumor cells is used for the selection of the most appropriate treatment regime for the individual patient. In breast cancer, genetic variation in estrogen receptor expression or heregulin type 2 (Her2) receptor tyrosine kinase expression determine if anti-estrogenic drugs (tamoxifen) or anti-Her2 antibody (Herceptin) will be incorporated into the treatment plan. In chronic myeloid leukemia (CML) diagnosis of the Philadelphia chromosome genetic translocation fusing the genes encoding the Bcr and Abl receptor tyrosine kinases indicates that Gleevec (STI571), a specific inhibitor of the Bcr-Abl kinase should be used for treatment of the cancer. For CML patients with such a genetic alteration, inhibition of the Bcr-Abl kinase leads to rapid elimination of the tumor cells and remission from leukemia.

Schizophrenia is a heritable, highly debilitating psychotic disorder that affects 0.5 to 1% of the general population. The illness is characterized by a variety of positive and negative signs and symptoms, as well as cognitive dysfunction that typically commence in early adulthood and often continue throughout life. The broad phenotypic presentation and a lack of complete disease concordance in monozygotic twins (~50-60%) imply that a multitude of environmental and/or genetic factors might contribute to disease manifestation (Coyle et al., *Ann. NY Acad. Sci.* 1003: 318-27, 2003). Twin and adoption studies suggest that both genetic and environmental factors

influence susceptibility (see, e.g., Tsuang, M.T. et al., *Schizophr. Res.* 4(2):157-71 (1991); Tienari, P.J. and Wynne, L.C., *Ann. Med.* 26(4):233-7 (1994); Franzek, E. and Beckmann, H., *Am. J. Psychiatry* 155(1):76-83 (1998); Tsuang, M. T., *J. Biomed. Sci.* 5(1):28-30 (1998)).

Among first-degree relatives, the genetic risk for schizophrenia has been reported to vary from 5 6% in parents, to 10% in siblings, and to 13% in children of schizophrenic individuals; if one of the parents is also schizophrenic, the risk to siblings increases to 17%, and children of two schizophrenics have a risk of 46% of developing the illness (McGue, M. and Gottesmann, I.I., *Eur. Arch. Psychiatry Clin. Neurosci* 240:174-181 (1991); see also, e.g., Lim, L.C. and Sim, L.P., *Singapore Med. J.* 33(6):645-7 (1992)). The mode of transmission, however, remains 10 uncertain.

A large number of chromosomal regions have been implicated to be involved in the pathogenesis of schizophrenia, through linkage studies. Reports of suggestive linkage to several loci have been published, including loci on chromosomes 3, 5, 6, 8, 10, 13, 20, 22 and the X chromosome (see, e.g., for chromosomes 3p and 8p, Pulver, A.E., et al., *Am J Med Genet* 60(4):252-60 15 (1995); for chromosomes 5q, 6p and 8p, Kendler, K.S. et al., *Am J Med Genet* 88(1):29-33 (1999); for chromosomes 5q, 6p, 8p, 20p and 22q, Hovatta, I. et al., *Mol Psychiatry* 3(5):452-7 (1998); for chromosome 6p, Schwab, S.G. et al., *Nat Genet* 11(3):325-7 (1995), Brzustowicz, L.M. et al., *Am J Hum Genet* 61(6):1388-96 (1997) and Cao, Q. et al., *Genomics* 43(1):1-8 (1997); for chromosomes 6 and 8, Straub, R.E. et al., *Cold Spring Harbor Symp Quant Biol* 20 61:823-33 (1996); for chromosome 8, Kendler, K.S. et al., *Am J Psychiatry* 153(12):1534-40 (1996); for chromosome 10, Straub, R.E. et al., *Am J Med Genet* 81(4):296-301 (1998) and Schwab, S.G. et al., *Am J Med Genet* 81(4):302-307 (1998); for chromosome 13, Lin, M.W. et al., *Psychiatr Genet* 5(3):117-26 (1995); Lin, M.W. et al., *Hum Genet* 99(3):417-420 (1997) and Blouin, J.L. et al., *Nat Genet* 20(1):70-73 (1993) (8 and 13); for chromosome 22, Gill, M. et al., 25 *Am J Med Genet* 67(1):40-45 (1996) and Bassett, A.S. et al., *Am J Med Genet* 81(4):328-37 (1998); and for the X chromosome, Milunsky, J. et al., *Clin Genet* 55(6):455-60 (1999)). However, many of these studies remain to be validated, and evidence for individual underlying genetic variants has not emerged.

Several of the genes recently described as susceptibility candidates for schizophrenia are 30 believed to affect neuroplasticity, as well as glutamatergic neurotransmission (Harrison & Owen, *Lancet* 361: 417-9, 2003). With the discovery of a number of schizophrenia susceptibility genes, a molecular hypothesis has begun to emerge.

In a genome wide scan of schizophrenia families carried out in Iceland, a susceptibility gene was mapped to chromosome 8p21. Haplotype analysis identified Neuregulin 1 (NRG1) as a gene 35 conferring susceptibility to schizophrenia (Stefansson et al., *Am. J. Hum. Genet.*, 72: 83-7, 2003). NRG1 as a schizophrenia disease gene has been replicated in multiple populations (Stefansson et al., *Am. J. Hum. Genet.* 72: 83-7, 2003; Williams et al., *Mol. Psychiatry* 8:485-7, 2003; Yang et al., *Mol. Psychiatry* 8:706-9, 2003). NRG1 is a polypeptide growth factor

implicated in the modulation of neurotransmission in developing and adult synapses. Early studies focused on the neuromuscular junction, where NRG1 was identified as acetylcholine receptor-inducing activity (ARIA) factor (Jessell et al., Proc. Natl. Acad. Sci., 76: 5397-5401, 1979; Falls et al., J. Neurocytol., 32: 619-647, 2003).

- 5 Dopamine receptor antagonists, primarily D2 receptor selective antagonists, are used clinically for the control of the positive signs of schizophrenia, suggesting that the misregulation of dopamine neurotransmission contributes to disease pathophysiology (Freedman, N. Engl. J. Med., 349: 1738-1749, 2003). However, the dissociative anesthetics that block the NMDA receptor, such as phencyclidine (PCP) and ketamine, produce a schizophrenia-like disorder.
- 10 Hence, a role for NMDA receptor hypofunction in the disease has also been suggested. (Reviewed in Konradi & Heckers Pharmacology & Therapeutics, 97: 153-197, 2003) Unlike manipulation of dopamine, for example by chronic exposure to amphetamines creating positive symptoms, exposure to dissociative anesthetics acutely reproduces the negative and cognitive signs of schizophrenia. NMDA receptors are ion channels that function as coincidence detectors.
- 15 They are simultaneously gated by voltage, as well as by two ligands, glutamate and glycine. Serine/threonine and tyrosine phosphorylation also strongly regulate NMDA receptor function (Yu et al., Science, 275: 674-678, 1997; Wang et al., Nature, 369: 233-235, 1994; Slater et al., Nat. Rev. Neurosci., 5: 317-328, 2004). Subtle misregulation of either membrane potential, ligand binding or tyrosine phosphorylation may therefore have profound effects on the
- 20 probability and duration of NMDA channel opening, thus influencing behavior modulated by the NMDA receptor (Moghaddam, Neuron, 40: 881-884, 2003).

- Despite these advances towards an understanding of the etiology of schizophrenia, there are many questions still unanswered, and a large fraction of the genetic contribution to the disease remains unaccounted for. Identification of underlying genetic variants will aid in the
- 25 identification of those individuals who are at particular risk of developing the disease, and will be useful in a diagnostic setting and for disease management. There is also a great need to identify new treatments for schizophrenia, and the identification of novel genetic risk factors may assist in the development of potential therapeutics and anti-schizophrenic agents, as well as accurate and informative *in vitro* and *in vivo* assays for predicting and elucidating the effectiveness of
- 30 potential treatments.

SUMMARY OF THE INVENTION

- The present inventors have discovered that certain copy number variations are present in increased frequency in individuals diagnosed with schizophrenia than in the general population.
- 35 These copy number variations are therefore predictive of schizophrenia in carriers. The copy number variations are useful in various methods and kits that are useful for risk management of schizophrenia and related conditions, as described further herein.

In a first aspect, the invention provides a method of determining a susceptibility to a schizophrenia condition in a human individual, the method comprising:

obtaining nucleic acid sequence information about a human individual identifying at least one copy number variation polymorphism selected from the group consisting of the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion and the chromosome 16p13.1 duplication in the genome of the individual, wherein the presence and absence of the at least one copy number variation polymorphism are associated with different susceptibilities to the condition in humans, and

determining a susceptibility to the condition for the individual from the nucleic acid sequence data.

Obtaining sequence information can in general be done by any method known to the skilled person, including use of polymorphic markers, nucleotide probes and other methods as further described herein.

In some embodiments, the 1q21.1 deletion is the short form 1q21.1 deletion. In some other embodiments, the 1q21.1 deletion is the long form 1q21.1 deletion.

In some embodiments, determination of a susceptibility comprises comparing the nucleic acid sequence information to a database containing correlation data between copy number variation polymorphisms and susceptibility to the condition. The database can for example comprise a look-up table comprising information about sequence in individuals. Correlation data can for example be a risk measure of schizophrenia for individuals who carry particular copy number variations in the genome. Such risk measures can for example be represented by an odds ratio (OR), a risk ratio (RR), or an increase in percentage. Other suitable measures known to the skilled person may also be used for this purpose, and are within scope of the invention.

In certain embodiments, obtaining nucleic acid sequence information comprises obtaining a biological sample from the human individual and analyzing at least one polymorphic marker in a nucleic acid in the sample. In particular embodiments, analyzing the at least one polymorphic marker comprises analyzing at least one polymorphic marker representative of the at least one copy number variation. In certain such embodiments, the at least one polymorphic marker is in linkage disequilibrium with the at least one copy number variation. The marker may be in linkage disequilibrium as determined by values for the r^2 measure of at least 0.2 to the copy number variation. In other embodiments, other suitable values can be representative of LD, such as r^2 greater than 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9 are contemplated and are within scope of the invention.

In certain embodiments, the at least one polymorphic marker is located within the copy number variation polymorphism. Thus the polymorphic is in such embodiments a physical representative of the copy number variation, since the presence or absence of the segment defining the copy

number variation translates directly into the presence of at least one particular allele of the polymorphism. In preferred embodiment, the polymorphism is a SNP, wherein a particular allele of the SNP is representative of the copy number variation.

In preferred embodiments, analyzing the at least one polymorphic marker comprises obtaining dosage measurement data for the at least one polymorphic marker representative of the at least one copy number variation. Dosage data is data that is indicative of the quantitative amount of particular alleles of polymorphic markers, such as data indicative of the amount of a particular allele of a SNP. Such dosage data is in certain embodiments data comprising a fluorescence signal from a nucleotide probe indicative of a particular allele of a SNP that is representative of the copy number variation.

In certain embodiments, obtaining nucleic acid sequence information comprises obtaining a nucleic acid sample from the individual and identifying at least one copy number variation using a nucleic acid probe selective for a nucleic acid segment that comprises the copy number variation. In such embodiments, the nucleotide probe is representative of a particular genomic segment, such as the CNV itself. The nucleotide probe may or may not be representative of a polymorphic marker such as a SNP. In certain embodiments, the nucleic acid probe comprises a label, and wherein identifying at least one copy number variation comprises allowing the nucleic acid probe to hybridize to the nucleic acid segment, such that when bound to the nucleic acid segment, the label is representative of the number of copies of the segment in the individual.

The sequence data representative of at least one copy number variation can in certain embodiments be obtained from a preexisting record. Such preexisting record can be any table, such as a look-up table, database or other storage media or record containing such sequence data.

The method of determining a susceptibility to a schizophrenia condition can include a further step comprising reporting the susceptibility to at least one entity selected from the group consisting of the individual, a guardian of the individual, a representative of the individual, a genetic service provider, a physician, a medical organization, and a medical insurer. Other single entities, including any one of the above-mentioned entities may be targeted by such reporting in particular embodiments, as can any combination of the above-mentioned entities.

Genetic marker in linkage disequilibrium with the copy number variation are representative of the copy number variation by virtue of the LD. Such markers are useful in certain embodiments of the invention. In some embodiments, the genetic marker is a single nucleotide polymorphism. In some embodiments, the genetic marker rs2283508 (SEQ ID NO:23) is indicative of the presence of the 16p13.1 duplication.

The invention also provides a method of determining a susceptibility to schizophrenia in a human individual, the method comprising (1) obtaining nucleic acid sequence information about a human individual identifying at least one allele of at least one polymorphic marker, wherein different alleles

of the at least one polymorphism are associated with different susceptibilities to schizophrenia in humans, and (ii) determining a susceptibility to schizophrenia for the individual from the nucleic acid sequence data, wherein the at least one polymorphic is selected from the group consisting of rs2283508, and markers in linkage disequilibrium therewith. In a preferred embodiment, the at least one polymorphism is rs2283508. In one embodiment, determination of the presence of allele C of rs2283508 is indicative of increased susceptibility to schizophrenia in the individual.

The markers and CNVs described herein can be combined with other risk factors for schizophrenia. Thus, certain embodiments combine assessment of particular CNVs, as described herein, with assessment of at least one additional genetic risk variant for schizophrenia, so as to determine overall risk in the individual. In certain embodiments, such additional risk factors are selected from SNPs, microsatellites or insertion/deletion polymorphisms.

The invention also provides computer-implemented aspects. In one such aspect, a computer-readable medium is provided, the medium having computer executable instructions for determining susceptibility to a schizophrenia condition in a human individual, the computer readable medium comprising:

data indicative of at least one copy number variation;

a routine stored on the computer readable medium and adapted to be executed by a processor to determine risk of developing a schizophrenia condition for the at least one polymorphic marker;

wherein the at least one copy number variation is selected from the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion and the chromosome 16p13.1 duplication.

In some embodiments, the computer readable medium contains data indicative of at least one polymorphic marker that is indicative of the at least one copy number variation. In some other embodiments, the at least one polymorphic marker is in linkage disequilibrium with the at least one copy number variation. In particular embodiments, data indicative of at least one haplotype comprising two or more polymorphic markers are included.

Another aspect relates to an apparatus for determining a genetic indicator for a schizophrenia condition in a human individual, comprising (i) a processor; (ii) a computer readable memory having computer executable instructions adapted to be executed on the processor to analyze information about at least one copy number variation in the human individual, selected from the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion and the chromosome 16p13.1 duplication, and (iii) generate an output based on the information about the at least one copy number variation, wherein the output comprises a risk measure of the at least one copy number variation as a genetic indicator the schizophrenia condition for the human individual.

- In certain embodiments, the computer readable memory further comprises data for at least one polymorphic marker in a plurality of individuals diagnosed with the schizophrenia condition, and data for the at least one polymorphic marker in a plurality of reference individuals, wherein the data is representative of at least one copy number variation, and wherein a risk measure is based on a comparison of marker data for the at least one marker for the human individual to marker data for the plurality of individuals with the schizophrenia condition. In some embodiments, the data for the at least one polymorphic marker is dosage data for the at least one marker. In some embodiments, the computer readable memory further comprises data indicative of the risk of developing the schizophrenia condition associated with at least one copy number variation, and wherein a risk measure for the human individual is based on a comparison of status of the at least one copy number variation for the human individual to the risk associated with the at least one copy number variation. In some embodiments, the computer readable memory further comprises data indicative of the frequency of at least one copy number variation in a plurality of individuals diagnosed with the schizophrenia condition, and data indicative of the frequency of at the least one copy number variation in a plurality of reference individuals, and wherein risk of developing the schizophrenia condition is based on a comparison of the frequency of the at least one copy number variation in individuals diagnosed with the schizophrenia condition and reference individuals. In preferred embodiments, the risk measure is characterized by an Odds Ratio (OR) or a Relative Risk (RR).
- The invention also provides kits useful in the methods described herein. In one aspect, the invention provides a kit for assessing susceptibility to schizophrenia in a human individual, the kit comprising reagents for selectively detecting at least one copy number variation polymorphism selected from the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion and the chromosome 16p13.1 duplication in the genome of the individual. In some embodiments, the kit further comprises reagents for detecting at least one polymorphic marker in linkage disequilibrium with the at least one copy number variation polymorphism. In some embodiments, the at least one polymorphic marker is located within the at least copy number variation. In other embodiments, the reagents comprise at least one contiguous oligonucleotide that hybridizes to a fragment of the genome of the individual comprising the at least one polymorphic marker, a buffer and a detectable label. Certain embodiments comprise at least one labelled oligonucleotide probe that is capable of selectively hybridizing to a genomic region comprising the at least one copy number variation. In certain such embodiments, the at least one oligonucleotide probe is from about 18 to about 50 nucleotides in length.
- The invention also provides a method of determining a susceptibility to a schizophrenia condition in a human individual, the method comprising determining whether a copy number variation polymorphism is present in the genome of the individual, wherein the copy number variation is selected from the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion and the chromosome 16p13.1

duplication, and wherein the presence of the copy number variation in the genome of the individual is indicative of an increased susceptibility to the condition.

Also within scope of the invention are novel human genomic copy number variations as described herein. In one such aspect, the invention provides a human genomic copy number variation on chromosome 5q35.2 flanked by markers rs1545976 and rs2220368.

In certain embodiments of the invention, the schizophrenia condition is schizophrenia. It should be understood that all combinations of features described herein are contemplated, even if the combination of feature is not specifically found in the same sentence or paragraph herein. This includes in particular the use of all markers disclosed herein, alone or in combination, for analysis individually or in haplotypes, in all aspects of the invention as described herein.

This description may contain subject matter that falls outside the scope of the claims. This subject matter is included to aid understanding of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG 1 shows the genomic architecture of the 1q21.1, 15q11.2 and 15q13.3 deletions. (A) DosageMiner output showing the shorter form of the 1q21 deletion (horizontal line with vertical lines representing the start and end of the deletion). Ninety-nine SNPs on the HumanHap300 chip are affected by the deletion which spans 1.38 Mb. (B) DosageMiner output showing the 15q11.2 deletion. 54 SNPs on the HumanHap300 chip are affected by the deletion which spans 580 kb. (C) DosageMiner output showing the 15q13.3 deletion. One-hundred-sixty-six SNPs on the HumanHap300 chip are affected by the deletion which spans 1.57 Mb. Genes affected by the deletions are shown (Coordinates are based on Build 36 of the human genome and positions of genes derived from the UCSC genome browser). LCRs flank all three deletions.

FIG 2 shows the genomic architecture of the 1q21.1 deletions. Many large low copy repeats (LCR) with high homology are found at the 1q21.1 locus. LCRs (large arrows) on the picture may mediate NAHR accounting for the larger form of the 1q21.1 deletion. There are though many smaller repeats, 1,000-10,000 bp (not shown on the figure) that potentially could mediate the formation of the deletion. A smaller repeat marked by arrowheads in the figure may assist NAHR accounting for the smaller form of the deletion. Again, for this form of the deletion there are other smaller LCR that potentially could assist with the formation of the deletion (not shown on the figure). Segments that contain SNPs on the Illumina HumanHap300 chip are also indicated. Note that there are no SNPs on 1q on the Illumina HumanHap300 chip centromeric to the larger form of the 1q21.1 deletion. Thus, exact size of the larger form of the deletion is not precisely known, the minimum size is 2.19 Mb. Markers on the p-arm are not deleted in the four cases or the control with the larger form of the 1q21.1 deletion.

FIG 3 shows (A) DosageMiner output showing the shorter form of the 1q21 deletion (horizontal line with vertical lines representing the start and end of the deletion). Ninety-nine SNPs on the HumanHap300 chip are affected by the deletion which spans 1.38 Mb. B) DosageMiner output showing the larger form of the 1q21.1 deletion. C) Affected genes by both deletions (within shorter form of the deletion; coordinates are based on Build 36 of the human genome and positions of genes derived from the UCSC genome browser). LCRs flank both deletions (see FIG 2); (D) Analysis of the 1q21.1 deletion with fluorescence in situ hybridization (FISH). Two BAC probes, RP11-431G14 (cover the *PRK* gene on chromosome 1q21) labeled with biotin and an anchor BAC, RP11-458I7 labeled with digoxigenin were used as probes for FISH analysis. A cell from a normal control (left) in interphase shows normal FISH signals, one biotin probe and one digoxigenin probe per chromosome. A cell from a schizophrenia patient (center) with the 1q21.1 deletion shows aberrant FISH signal, the biotin signal is missing for one of the chromosomes. A cell from a schizophrenia patient with the 1q21.1 region duplicated (right), two biotin signals are seen for one of the two chromosomes.

FIG 4 shows (A) LCRs flanking the deletion at 15q11.2. Several LCR at this locus can mediate the formation of the deletion. The grey horizontal bar shows the minimum size of the deletion, and vertical arrows point to the regions with longest homologous sequences on both sides of the deletion, harbouring possible breakpoints. Coordinates are in line with Build 36 of the human genome.

FIG 5 shows LCRs flanking the deletion at 15q11.2. It is not clear which LCR might mediating the formation of the recurrent deletion. Grey horizontal bar shows the minimum size of the deletion, and vertical arrows point to the only high homology sequence with same orientation on both sides of the deletion in the UCSC human genome reference sequence. Coordinates are in line with Build 36 of the human genome.

FIG 6 shows a genome browser view showing the positions of the 16p13.1 CNV relative to genes in the region, and the duplications and deletions found in the present study. Known segmental duplications of >1000 bp is also shown. The region is divided into three intervals called 1, 2 and 3. Trace 1 shows deletion interval of interval 2, trace 2 shows duplication of interval 2, trace 3 shows deletion of intervals 1 and 2, trace 4 shows duplication of intervals 1 and 2, trace 5 shows deletion of intervals 2 and 3, and trace 6 shows duplication of intervals 2 and 3.

FIG 7 shows a genome browser view of the chr 5q35.2 duplicated region. The figure is taken from the UCSC Browser, genome Build 36, and shows the position and orientation of genes in the region, as well as position of SNP markers on the Illumina HumanHap300 chip in this region.

FIG 8 shows an exemplary computer environment on which the methods and apparatus as described and claimed herein can be implemented.

DETAILED DESCRIPTION*Definitions*

Unless otherwise indicated, nucleic acid sequences are written left to right in a 5' to 3' orientation. Numeric ranges recited within the specification are inclusive of the numbers defining the range and include each integer or any non-integer fraction within the defined range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by the ordinary person skilled in the art to which the invention pertains.

The following terms shall, in the present context, have the meaning as indicated:

A "polymorphic marker", sometime referred to as a "marker", as described herein, refers to a genomic polymorphic site. Each polymorphic marker has at least two sequence variations characteristic of particular alleles at the polymorphic site. Thus, genetic association to a polymorphic marker implies that there is association to at least one specific allele of that particular polymorphic marker. The marker can comprise any allele of any variant type found in the genome, including SNPs, mini- or microsatellites, translocations and copy number variations (insertions, deletions, duplications). Polymorphic markers can be of any measurable frequency in the population. For mapping of disease genes, polymorphic markers with population frequency higher than 5-10% are in general most useful. However, polymorphic markers may also have lower population frequencies, such as 1-5% frequency, or even lower frequency, in particular copy number variations (CNVs). The term shall, in the present context, be taken to include polymorphic markers with any population frequency.

An "allele" refers to the nucleotide sequence of a given locus (position) on a chromosome. A polymorphic marker allele thus refers to the composition (i.e., sequence) of the marker on a chromosome. Genomic DNA from an individual contains two alleles (e.g., allele-specific sequences) for any given polymorphic marker, representative of each copy of the marker on each chromosome. Sequence codes for nucleotides used herein are: A = 1, C = 2, G = 3, T = 4. For microsatellite alleles, the CEPH sample (Centre d'Etudes du Polymorphisme Humain, genomics repository, CEPH sample 1347-02) is used as a reference, the shorter allele of each microsatellite in this sample is set as 0 and all other alleles in other samples are numbered in relation to this reference. Thus, e.g., allele 1 is 1 bp longer than the shorter allele in the CEPH sample, allele 2 is 2 bp longer than the shorter allele in the CEPH sample, allele 3 is 3 bp longer than the lower allele in the CEPH sample, etc., and allele -1 is 1 bp shorter than the shorter allele in the CEPH sample, allele -2 is 2 bp shorter than the shorter allele in the CEPH sample, etc.

Sequence conucleotide ambiguity as described herein is as proposed by IUPAC-IUB. These codes are compatible with the codes used by the EMBL, GenBank, and PIR databases.

IUB code	Meaning
A	Adenosine
C	Cytidine
G	Guanine
T	Thymidine
R	G or A
Y	T or C
K	G or T
M	A or C
S	G or C
W	A or T
B	C G or T
D	A G or T
H	A C or T
V	A C or G
N	A C G or T (Any base)

A nucleotide position at which more than one sequence is possible in a population (either a natural population or a synthetic population, *e.g.*, a library of synthetic molecules) is referred to herein as a "polymorphic site".

A "Single Nucleotide Polymorphism" or "SNP" is a DNA sequence variation occurring when a single nucleotide at a specific location in the genome differs between members of a species or between paired chromosomes in an individual. Most SNP polymorphisms have two alleles. Each individual is in this instance either homozygous for one allele of the polymorphism (i.e. both chromosomal copies of the individual have the same nucleotide at the SNP location), or the individual is heterozygous (i.e. the two sister chromosomes of the individual contain different nucleotides). The SNP nomenclature as reported herein refers to the official Reference SNP (rs) ID identification tag as assigned to each unique SNP by the National Center for Biotechnological Information (NCBI).

A "variant", as described herein, refers to a segment of DNA that differs from the reference DNA. A "marker" or a "polymorphic marker", as defined herein, is a variant. Alleles that differ from the reference are referred to as "variant" alleles.

A "microsatellite" is a polymorphic marker that has multiple small repeats of bases that are 2-8 nucleotides in length (such as CA repeats) at a particular site, in which the number of repeat lengths varies in the general population. An "indel" is a common form of polymorphism comprising a small insertion or deletion that is typically only a few nucleotides long.

A "haplotype," as described herein, refers to a segment of genomic DNA that is characterized by a specific combination of alleles arranged along the segment. For diploid organisms such as humans, a haplotype comprises one member of the pair of alleles for each polymorphic marker or locus along the segment. In a certain embodiment, the haplotype can comprise two or more

alleles, three or more alleles, four or more alleles, or five or more alleles. Haplotypes are described herein in the context of the marker name and the allele of the marker in that haplotype, e.g., "2 rs2283508" refers to the 2 allele of marker rs2283508 being in the haplotype, and is equivalent to "rs2283508 allele 2". Furthermore, allelic codes in haplotypes are as for individual markers, i.e. 1 = A, 2 = C, 3 = G and 4 = T.

The term "susceptibility", as described herein, refers to the proneness of an individual towards the development of a certain state (e.g., a certain trait, phenotype or disease), or towards being less able to resist a particular state than the average individual. The term encompasses both increased susceptibility and decreased susceptibility. Thus, particular alleles at polymorphic markers and/or haplotypes of the invention as described herein may be characteristic of increased susceptibility (i.e., increased risk) of schizophrenia, as characterized by a relative risk (RR) or odds ratio (OR) of greater than one for the particular allele or haplotype. Alternatively, the markers and/or haplotypes of the invention are characteristic of decreased susceptibility (i.e., decreased risk) of schizophrenia, as characterized by a relative risk of less than one.

The term "and/or" shall in the present context be understood to indicate that either or both of the items connected by it are involved. In other words, the term herein shall be taken to mean "one or the other or both".

The term "look-up table", as described herein, is a table that correlates one form of data to another form, or one or more forms of data to a predicted outcome to which the data is relevant, such as phenotype or trait. For example, a look-up table can comprise a correlation between allelic data for at least one polymorphic marker and a particular trait or phenotype, such as a particular disease diagnosis, that an individual who comprises the particular allelic data is likely to display, or is more likely to display than individuals who do not comprise the particular allelic data. Look-up tables can be multidimensional, i.e. they can contain information about multiple alleles for single markers simultaneously, or they can contain information about multiple markers, and they may also comprise other factors, such as particulars about diseases diagnoses, racial information, biomarkers, biochemical measurements, therapeutic methods or drugs, etc.

A "computer-readable medium", is an information storage medium that can be accessed by a computer using a commercially available or custom-made interface. Exemplary computer-readable media include memory (e.g., RAM, ROM, flash memory, etc.), optical storage media (e.g., CD-ROM), magnetic storage media (e.g., computer hard drives, floppy disks, etc.), punch cards, or other commercially available media. Information may be transferred between a system of interest and a medium, between computers, or between computers and the computer-readable medium for storage or access of stored information. Such transmission can be electrical, or by other available methods, such as IR links, wireless connections, etc.

A "nucleic acid sample" as described herein, refers to a sample obtained from an individual that contains nucleic acid (DNA or RNA). In certain embodiments, i.e. the detection of specific

polymorphic markers and/or haplotypes, the nucleic acid sample comprises genomic DNA. Such a nucleic acid sample can be obtained from any source that contains genomic DNA, including a blood sample, sample of amniotic fluid, sample of cerebrospinal fluid, or tissue sample from skin, muscle, buccal or conjunctival mucosa, placenta, gastrointestinal tract or other organs.

5 The term "schizophrenia therapeutic agent" refers to an agent that can be used to ameliorate or prevent symptoms associated with schizophrenia.

The term "schizophrenia-associated nucleic acid", as described herein, refers to a nucleic acid that has been found to be associated to schizophrenia. This includes, but is not limited to, the markers and haplotypes described herein and markers and haplotypes in strong linkage
10 disequilibrium (LD) therewith.

The term "low copy repeat", or "LCR", as described herein, refers to chromosomal segments that are present in multiple (two or more) copies within a short interval. The repeated segment is usually a relatively short segment of 10-100,000 nucleotides, and is typically present in few copies, typically less than 10 copies. Some CNVs, including some of those described herein, are
15 flanked by LCR regions.

The term "schizophrenia condition", as described herein, refers to the spectrum of mental disorders that includes schizophrenia and related psychotic disorders. The term is meant to include in particular schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder and brief psychotic disorder, as defined in the Diagnostic and
20 Statistical Manual of Mental Disorder, fourth edition (DSM-IV-TR).

The present inventors have detected certain copy number variations (CNVs) in the human genome that confer risk of schizophrenia. The copy number variations were defined based on analysis of SNP genotypes obtained using the HumanHap317 chip (Illumina), as explained in
25 more detail in Examples 1 - 3 herein.

The nature of the CNVs described herein is such that certain regions of the human genome is present in alternate copy number in certain individuals. The segment may be deleted, or it may be present in more than one copy on each particular chromosome. The segments are in general quite large, ranging from a few thousand nucleotides to over one million nucleotides in size. The
30 absolute breakpoint at which the variation begins and ends can be difficult to define due to experimental limitations. Experimentally, what is determined is the last polymorphism (or probe) that is outside the CNV segment upstream (5') of the segment, the first polymorphism within the CNV segment, the last polymorphism within the CNV segment and the first polymorphism outside the CNV segment downstream (3') of the segment. Normally, the first
35 two markers and the last two markers (or nucleotide probes) in the above will be adjacent markers. Thus the resulting CNV can be defined minimally as including the segment that begins

with the first marker consistent with the CNV and ends with the last marker consistent with the CNV. Such a definition is however not inclusive of the physical boundaries of the CNV segment. An alternative way of defining the CNV is provided by the region flanked by the two polymorphisms that are inconsistent with the CNV (*i.e.* outside the CNV segment), but adjacent to the two polymorphisms corresponding to the first and last polymorphisms assayed within the CNV segment. The latter definition is inclusive of the actual boundaries of the CNV.

The following CNV table provides such definitions of the copy number variations described herein.

10 **CNV Table**

Copy number variation	First upstream marker outside CNV	Position Build 36	First marker within CNV	Position Build 36	Last marker within CNV	Position Build 36	First downstream marker outside CNV	Position Build 36
1q21.1 deletion short form	rs1284300 SEQ ID NO:1	144458820	rs6656361 SEQ ID NO:2	144943150	rs2932454 SEQ ID NO:3	146293282	rs11587304 SEQ ID NO:4	147414362
1q21.1 deletion long form	rs11249395* SEQ ID NO:5	121013322*	rs10797649 SEQ ID NO:6	144106312	rs2932454 SEQ ID NO:3	146293282	rs11587304 SEQ ID NO:4	147414362
15q11.2 deletion	rs17728289 SEQ ID NO:7	19869474	rs8040193 SEQ ID NO:8	20306549	rs3883043 SEQ ID NO:9	20777695	rs4778531 SEQ ID NO:10	21240037
15q13.3 deletion	rs10152753 SEQ ID NO:11	28153539	rs2046382 SEQ ID NO:12	28723577	rs4779984 SEQ ID NO:13	30302218	rs11635997 SEQ ID NO:14	30721385
16p13.1 duplication	rs8062460 SEQ ID NO:15	14667269	rs4985124 SEQ ID NO:16	15032942	rs2547728 SEQ ID NO:17	18174650	rs2641892 SEQ ID NO:18	18707116
5q35.2 duplication	rs4888651 SEQ ID NO:19	175921634	rs1545976 SEQ ID NO:20	175939217	rs2220368 SEQ ID NO:21	176073058	rs10035561 SEQ ID NO:22	176081374

*The rs11249395 marker is on the p-side of the centromere on chromosome 1, which explains the large span of the region over which the 1q21.1 deletion could potentially stretch

As described herein, the 1q21.1 deletion, both long and short forms, the 15q11.2 deletion, the 15q13.3 deletion, the 16p13.1 duplication and the 5q35.2 duplication minimally span the regions between the first marker within the CNV and the last marker within the CNV, as described in the CNV table. Thus, the 1q21.1 deletion short form is defined as the region flanked by rs6656361 and rs2932454 (between position 144,943,150 and 146,293,282 on chr 1 of NCBI Build 36), the 1q21.1 deletion long form is defined as the region flanked by rs10797649 and rs2932454 (between position 144,106,312 and 146,293,282 on chr 1 of NCBI Build 36), the 15q11.2

deletion is defined as the region flanked by rs8040193 and rs3883043 (between position 20,306,549 and 20,777,695 on chr 15 of NCBI Build 36), the 15q13.3 deletion is defined as the region flanked by rs2046362 and rs4779984 (between position 28,723,577 and 30,302,218 on chr 15 of NCBI Build 36), the 16p13.1 duplication is defined as the region flanked by rs4985124 and rs2547728 (between position 15,032,942 and 18,174,650 on chr 16 of NCBI Build 36), and the 5q35.2 duplication is defined as the region flanked by rs1545976 and rs2220368 (between position 175,939,217 and 176,073,058 on chr 5 of NCBI Build 36).

However, it should be appreciated that the CNVs as defined may in fact stretch over a larger genomic region, and in fact are likely to do so, since the definitions as provided are confined to the markers that have been assessed. Thus, in an alternative fashion, the CNVs can be defined as maximally spanning a region that includes up to, but not including, the next marker assessed that is not consistent with the CNV. Therefore, in an alternative fashion, the 1q21.1 deletion, both long and short forms, the 15q11.2 deletion, the 15q13.3 deletion, the 16p13.1 duplication and the 5q35.2 duplication can be defined to span the regions between the first upstream marker outside the CNV and the first downstream marker outside the CNV, as further described in the CNV table above. Thus, the 1q21.1 deletion short form is in this context defined as the region flanked by rs1284300 and rs11587304, the 1q21.1 deletion long form is defined as the region flanked by rs11249395 and rs11587304, the 15q11.2 deletion is defined as the region flanked by rs11728289 and rs4778531, the 15q13.3 deletion is defined as the region flanked by rs10152753 and rs11635997, 16p13.1 duplication is defined as the region flanked by rs8062460 and rs2641892, and the 5q35.2 duplication is defined as the region flanked by rs4868651 and rs10035561.

Assessment for markers and haplotypes

The genomic sequence within populations is not identical when individuals are compared. Rather, the genome exhibits sequence variability between individuals at many locations in the genome. Such variations in sequence are commonly referred to as polymorphisms, and there are many such sites within each genome. For example, the human genome exhibits sequence variations which occur on average every 500 base pairs. The most common sequence variant consists of base variations at a single base position in the genome, and such sequence variants, or polymorphisms, are commonly called Single Nucleotide Polymorphisms ("SNPs"). These SNPs are believed to have occurred in a single mutational event, and therefore there are usually two possible alleles possible at each SNP site; the original allele and the mutated allele. Due to natural genetic drift and possibly also selective pressure, the original mutation has resulted in a polymorphism characterized by a particular frequency of its alleles in any given population. Many other types of sequence variants are found in the human genome, including mini- and microsatellites, and insertions, deletions and inversions (also called copy number variations (CNVs)). A polymorphic microsatellite has multiple small repeats of bases (such as CA repeats, TG on the complementary strand) at a particular site in which the number of repeat lengths

varies in the general population. In general terms, each version of the sequence with respect to the polymorphic site represents a specific allele of the polymorphic site. These sequence variants can all be referred to as polymorphisms, occurring at specific polymorphic sites characteristic of the sequence variant in question. In general terms, polymorphisms can comprise any number of specific alleles. Thus in one embodiment of the invention, the polymorphism is characterized by the presence of two or more alleles in any given population. In another embodiment, the polymorphism is characterized by the presence of three or more alleles. In other embodiments, the polymorphism is characterized by four or more alleles, five or more alleles, six or more alleles, seven or more alleles, nine or more alleles, or ten or more alleles. All such polymorphisms can be utilized in the methods and kits of the present invention, and are thus within the scope of the invention.

Due to their abundance, SNPs account for a majority of sequence variation in the human genome. Over 6 million SNPs have been validated to date (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi). However, CNVs are receiving increased attention. These large-scale polymorphisms (typically 1kb or larger) account for polymorphic variation affecting a substantial proportion of the assembled human genome; known CNVs cover over 15% of the human genome sequence (Estivill, X Armengol; L., *PLoS Genetics* **3**:1787-99 (2007); <http://projects.tcag.ca/variation/>). Most of these polymorphisms are however very rare, and on average affect only a fraction of the total genomic sequence of each individual. CNVs are known to affect gene expression, phenotypic variation and adaptation by disrupting gene dosage, and are also known to cause disease (microdeletion and microduplication disorders) and confer risk of common complex diseases, including HIV-1 infection and glomerulonephritis (Redon, R., *et al. Nature* **23**:444-454 (2006)). Methods for detecting CNVs include comparative genomic hybridization (CGH) and genotyping, including use of genotyping arrays, as described by Carter (*Nature Genetics* **39**:S16-S21 (2007)). The Database of Genomic Variants (<http://projects.tcag.ca/variation/>) contains updated information about the location, type and size of described CNVs. The database currently contains data for over 15,000 CNVs.

In some instances, reference is made to different alleles at a polymorphic site without choosing a reference allele. Alternatively, a reference sequence can be referred to for a particular polymorphic site. The reference allele is sometimes referred to as the "wild-type" allele and it usually is chosen as either the first sequenced allele or as the allele from a "non-affected" individual (e.g., an individual that does not display a trait or disease phenotype).

Alleles for SNP markers as referred to herein refer to the bases A, C, G or T as they occur at the polymorphic site in the SNP assay employed. The allele codes for SNPs used herein are as follows: 1=A, 2=C, 3=G, 4=T. The person skilled in the art will however realize that by assaying or reading the opposite DNA strand, the complementary allele can in each case be measured. Thus, for a polymorphic site (polymorphic marker) characterized by an A/G polymorphism, the assay employed may be designed to specifically detect the presence of one or

both of the two bases possible, i.e. A and G. Alternatively, by designing an assay that is designed to detect the complimentary strand on the DNA template, the presence of the complementary bases T and C can be measured. Quantitatively (for example, in terms of relative risk), identical results would be obtained from measurement of either DNA strand (+ strand or - strand).

Typically, a reference sequence is referred to for a particular sequence. Alleles that differ from the reference are sometimes referred to as "variant" alleles. A variant sequence, as used herein, refers to a sequence that differs from the reference sequence but is otherwise substantially similar. Alleles at the polymorphic genetic markers described herein are variants. Variants can include changes that affect a polypeptide. Sequence differences, when compared to a reference nucleotide sequence, can include the insertion or deletion of a single nucleotide, or of more than one nucleotide, resulting in a frame shift; the change of at least one nucleotide, resulting in a change in the encoded amino acid; the change of at least one nucleotide, resulting in the generation of a premature stop codon; the deletion of several nucleotides, resulting in a deletion of one or more amino acids encoded by the nucleotides; the insertion of one or several nucleotides, such as by unequal recombination or gene conversion, resulting in an interruption of the coding sequence of a reading frame; duplication of all or a part of a sequence; transposition; or a rearrangement of a nucleotide sequence,. Such sequence changes can alter the polypeptide encoded by the nucleic acid. For example, if the change in the nucleic acid sequence causes a frame shift, the frame shift can result in a change in the encoded amino acids, and/or can result in the generation of a premature stop codon, causing generation of a truncated polypeptide. Alternatively, a polymorphism associated with a disease or trait can be a synonymous change in one or more nucleotides (i.e., a change that does not result in a change in the amino acid sequence). Such a polymorphism can, for example, alter splice sites, affect the stability or transport of mRNA, or otherwise affect the transcription or translation of an encoded polypeptide. It can also alter DNA to increase the possibility that structural changes, such as amplifications or deletions, occur at the somatic level. The polypeptide encoded by the reference nucleotide sequence is the "reference" polypeptide with a particular reference amino acid sequence, and polypeptides encoded by variant alleles are referred to as "variant" polypeptides with variant amino acid sequences.

A haplotype refers to a segment of DNA that is characterized by a specific combination of alleles arranged along the segment. For diploid organisms such as humans, a haplotype comprises one member of the pair of alleles for each polymorphic marker or locus. In a certain embodiment, the haplotype can comprise two or more alleles, three or more alleles, four or more alleles, or five or more alleles, each allele corresponding to a specific polymorphic marker along the segment. Haplotypes can comprise a combination of various polymorphic markers, e.g., SNPs and microsatellites, having particular alleles at the polymorphic sites. The haplotypes thus comprise a combination of alleles at various genetic markers.

Detecting specific polymorphic markers and/or haplotypes can be accomplished by methods known in the art for detecting sequences at polymorphic sites. For example, standard techniques for genotyping for the presence of SNPs and/or microsatellite markers can be used, such as fluorescence-based techniques (e.g., Chen, X. *et al.*, *Genome Res.* 9(5): 492-98 (1999);

5 Kutyavin *et al.*, *Nucleic Acid Res.* 34:e128 (2006)), utilizing PCR, LCR, Nested PCR and other techniques for nucleic acid amplification. Specific commercial methodologies available for SNP genotyping include, but are not limited to, TaqMan genotyping assays and SNPlex platforms (Applied Biosystems), gel electrophoresis (Applied Biosystems), mass spectrometry (e.g., MassARRAY system from Sequenom), minisequencing methods, real-time PCR, Bio-Plex system

10 (BioRad), CEQ and SNPstream systems (Beckman), array hybridization technology (e.g., Affymetrix GeneChip; Perlegen), BeadArray Technologies (e.g., Illumina GoldenGate and Infinium assays), array tag technology (e.g., Parallele), and endonuclease-based fluorescence hybridization technology (Invader; Third Wave). Some of the available array platforms, including Affymetrix SNP Array 6.0 and Illumina CNV370-Duo and 1M BeadChips, include SNPs

15 that tag certain CNVs. This allows detection of CNVs via surrogate SNPs included in these platforms. Thus, by use of these or other methods available to the person skilled in the art, one or more alleles at polymorphic markers, including microsatellites, SNPs or other types of polymorphic markers, can be identified.

In the methods described herein, an individual at risk for a schizophrenia condition is one in

20 whom a particular polymorphism, such as a copy number variation (CNV) is present. The copy number variation confers a particular risk of the condition; carriers of the CNV are at a different risk of the condition than non-carriers. In other words, the CNV is indicative of susceptibility or risk of the schizophrenia condition. In certain embodiments, significance associated with risk of a copy number variation is measured by a relative risk (RR). In another embodiment,

25 significance associated with a copy number variation is measured by an odds ratio (OR). In a further embodiment, the significance is measured by a percentage. In one embodiment, a significant increased risk is measured as a risk (relative risk and/or odds ratio) of at least 1.2, including but not limited to: at least 1.5, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, 1.8, at least 1.9, at least 2.0, at least 2.5, at least 3.0, at least 4.0, at least 5.0, at

30 least 6.0, at least 7.0, at least 8.0, at least 9.0, at least 10.0, and at least 15.0. In a particular embodiment, a risk (relative risk and/or odds ratio) of at least 2.0 is significant. In another particular embodiment, a risk of at least 3.0 is significant. In yet another embodiment, a risk of at least 4.0 is significant. In a further embodiment, a relative risk of at least 5.0 is significant. In another further embodiment, a significant increase in risk is at least 10.0 is significant.

35 However, other values for significant risk are also contemplated, e.g., at least 2.5, 3.5, 4.5, 5.5, or any suitable other numerical values, and such values are also within scope of the present invention. In other embodiments, a significant increase in risk is at least about 20%, including but not limited to about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%,

40 1000%, and 1500%. In one particular embodiment, a significant increase in risk is at least 100%. In other embodiments, a significant increase in risk is at least 200%, at least 300%, at

least 400%, at least 500%, at least 700%, at least 800%, at least 900% and at least 1000%. Other cutoffs or ranges as deemed suitable by the person skilled in the art to characterize the invention are however also contemplated, and those are also within scope of the present invention. In certain embodiments, a significant increase in risk is characterized by a p-value, such as a p-value of less than 0.05, less than 0.01, less than 0.001, less than 0.0001, less than 0.00001, less than 0.000001, less than 0.0000001, or less than 0.00000001.

A copy number variation (CNV) predictive of risk of a schizophrenia condition, as described herein, is one where the particular CNV is more frequently present in an individual with the condition (affected), compared to the frequency of its presence in a comparison group (control), such that the presence of the CNV is indicative of susceptibility to the schizophrenia condition. The control group may in one embodiment be a population sample, i.e. a random sample from the general population. In another embodiment, the control group is represented by a group of individuals who are disease-free. Such disease-free control may in one embodiment be characterized by the absence of one or more specific disease-associated symptoms, e.g. individuals who have not experienced symptoms associated with schizophrenia. In another embodiment, the disease-free control group is characterized by the absence of one or more disease-specific risk factors. Such risk factors are in one embodiment at least one environmental risk factor. As an example of a simple test for correlation would be a Fisher-exact test on a two by two table. Given a cohort of chromosomes, the two by two table is constructed out of the number of chromosomes that include both of the markers or haplotypes, one of the markers or haplotypes but not the other and neither of the markers or haplotypes. Other statistical tests of association known to the skilled person are also contemplated and are also within scope of the invention.

In other embodiments of the invention, an individual who is at a decreased susceptibility (i.e., at a decreased risk) for a schizophrenia condition is an individual in whom at least one CNV, or one specific allele at one or more polymorphic marker or haplotype conferring decreased susceptibility for the disease or trait is identified. The marker alleles and/or haplotypes conferring decreased risk are also said to be protective. In one aspect, the protective marker or haplotype is one that confers a significant decreased risk (or susceptibility) of the disease or trait. In one embodiment, significant decreased risk is measured as a relative risk (or odds ratio) of less than 0.9, including but not limited to less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2 and less than 0.1. In one particular embodiment, significant decreased risk is less than 0.7. In another embodiment, significant decreased risk is less than 0.5. In yet another embodiment, significant decreased risk is less than 0.3. In another embodiment, the decrease in risk (or susceptibility) is at least 20%, including but not limited to at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% and at least 98%. In one particular embodiment, a significant decrease in risk is at least about 30%. In another embodiment, a significant decrease in risk is at least about 50%. In another embodiment, the decrease in risk is at least about 70%. Other cutoffs or ranges as deemed suitable by the person

skilled in the art to characterize the invention are however also contemplated, and those are also within scope of the present invention.

The person skilled in the art will appreciate that for markers with two alleles present in the population being studied (such as SNPs), and wherein one allele is found in increased frequency in a group of individuals with a trait or disease in the population, compared with controls, the other allele of the marker will be found in decreased frequency in the group of individuals with the trait or disease, compared with controls. In such a case, one allele of the marker (the one found in increased frequency in individuals with the trait or disease) will be the at-risk allele, while the other allele will be a protective allele.

10 A genetic variant associated with a disease or a trait can be used alone to predict the risk of the disease for a given genotype. For a biallelic marker, such as a SNP, there are 3 possible genotypes: homozygote for the at risk variant, heterozygote, and non carrier of the at risk variant. Risk associated with variants at multiple loci can be used to estimate overall risk. For multiple SNP variants, there are k possible genotypes $k = 3^n \times 2^p$; where n is the number
15 autosomal loci and p the number of gonosomal (sex chromosomal) loci. Overall risk assessment calculations usually assume that the relative risks of different genetic variants multiply, i.e. the overall risk (e.g., RR or OR) associated with a particular genotype combination is the product of the risk values for the genotype at each locus. If the risk presented is the relative risk for a person, or a specific genotype for a person, compared to a reference population with matched
20 gender and ethnicity, then the combined risk – is the product of the locus specific risk values – and which also corresponds to an overall risk estimate compared with the population. If the risk for a person is based on a comparison to non-carriers of the at risk allele, then the combined risk corresponds to an estimate that compares the person with a given combination of genotypes at all loci to a group of individuals who do not carry risk variants at any of those loci. The group of
25 non-carriers of any at risk variant has the lowest estimated risk and has a combined risk, compared with itself (i.e., non-carriers) of 1.0, but has an overall risk, compare with the population, of less than 1.0. It should be noted that the group of non-carriers can potentially be very small, especially for large number of loci, and in that case, its relevance is correspondingly small.

30 The multiplicative model is a parsimonious model that usually fits the data of complex traits reasonably well. Deviations from multiplicity have been rarely described in the context of common variants for common diseases, and if reported are usually only suggestive since very large sample sizes are usually required to be able to demonstrate statistical interactions between loci.

35 By way of an example, let us consider a total of eight variants that have been described to associate with prostate cancer (Gudmundsson, J., *et al.*, *Nat Genet* 39:631-7 (2007), Gudmundsson, J., *et al.*, *Nat Genet* 39:977-83 (2007); Yeager, M., *et al.*, *Nat Genet* 39:645-49 (2007), Amundadottir, L., *et al.*, *Nat Genet* 38:652-8 (2006); Haiman, C.A., *et al.*, *Nat Genet*

39:638-44 (2007)). Seven of these loci are on autosomes, and the remaining locus is on chromosome X. The total number of theoretical genotypic combinations is then $3^7 \times 2^1 = 4374$. Some of those genotypic classes are very rare, but are still possible, and should be considered for overall risk assessment. It is likely that the multiplicative model applied in the case of multiple genetic variant will also be valid in conjugation with non-genetic risk variants assuming that the genetic variant does not clearly correlate with the "environmental" factor. In other words, genetic and non-genetic at-risk variants can be assessed under the multiplicative model to estimate combined risk, assuming that the non-genetic and genetic risk factors do not interact.

Using the same quantitative approach, the combined or overall risk associated with a plurality of variants associated with schizophrenia may be assessed. For example, the CNVs described herein to be associated with risk of schizophrenia may be combined with other common genetic risk factors. Combined risk for such genetic variants may be estimated in an analogous fashion to that described above.

Linkage Disequilibrium

The natural phenomenon of recombination, which occurs on average once for each chromosomal pair during each meiotic event, represents one way in which nature provides variations in sequence (and biological function by consequence). It has been discovered that recombination does not occur randomly in the genome; rather, there are large variations in the frequency of recombination rates, resulting in small regions of high recombination frequency (also called recombination hotspots) and larger regions of low recombination frequency, which are commonly referred to as Linkage Disequilibrium (LD) blocks (Myers, S. *et al.*, *Biochem Soc Trans* 34:526-530 (2006); Jeffreys, A.J., *et al.*, *Nature Genet* 29:217-222 (2001); May, C.A., *et al.*, *Nature Genet* 31:272-275(2002)).

Linkage Disequilibrium (LD) refers to a non-random assortment of two genetic elements. For example, if a particular genetic element (*e.g.*, an allele of a polymorphic marker, or a haplotype) occurs in a population at a frequency of 0.50 (50%) and another element occurs at a frequency of 0.50 (50%), then the predicted occurrence of a person's having both elements is 0.25 (25%), assuming a random distribution of the elements. However, if it is discovered that the two elements occur together at a frequency higher than 0.25, then the elements are said to be in linkage disequilibrium, since they tend to be inherited together at a higher rate than what their independent frequencies of occurrence (*e.g.*, allele or haplotype frequencies) would predict. Roughly speaking, LD is generally correlated with the frequency of recombination events between the two elements. Allele or haplotype frequencies can be determined in a population by genotyping individuals in a population and determining the frequency of the occurrence of each allele or haplotype in the population. For populations of diploids, *e.g.*, human populations,

Individuals will typically have two alleles or allelic combinations for each genetic element (e.g., a marker, haplotype or gene).

LD can be assessed between polymorphic markers, such as two SNPs. Alternatively, LD can be assessed between other genetic elements, such as larger structural units and particular SNPs. For example, LD can be assessed between CNVs and particular SNPs. Particular SNPs may be indicative of (surrogates of) the status of an individual at a particular CNV. Such SNPs are useful in for example the methods described herein, since surrogate SNPs in linkage with a CNV polymorphism represent a convenient tool for assessing whether particular individuals have the CNV polymorphisms. In particular embodiments, surrogate SNPs in LD with a particular CNV can be useful to assess whether an individual is likely to have the CNV, based on his/her genotype at the SNP. Carriers for the allele associating with the CNV can subsequently be selected for detailed assessment of the presence or absence of the CNV, by any method suitable, as known to the skilled person and described herein (e.g., FISH, genotype dosage measurements, TaqMan assays, etc.).

Many different measures have been proposed for assessing the strength of linkage disequilibrium (LD; reviewed in Devlin, B. & Risch, N., *Genomics* 29:311-22 (1995)). Most capture the strength of association between pairs of biallelic sites. Two important pairwise measures of LD are r^2 (sometimes denoted Δ^2) and $|D'|$ (Lewontin, R., *Genetics* 49:49-67 (1964); Hill, W.G. & Robertson, A. *Theor. Appl. Genet.* 22:226-231 (1968)). Both measures range from 0 (no disequilibrium) to 1 ('complete' disequilibrium), but their interpretation is slightly different. $|D'|$ is defined in such a way that it is equal to 1 if just two or three of the possible haplotypes are present, and it is <1 if all four possible haplotypes are present. Therefore, a value of $|D'|$ that is <1 indicates that historical recombination may have occurred between two sites (recurrent mutation can also cause $|D'|$ to be <1 , but for single nucleotide polymorphisms (SNPs) this is usually regarded as being less likely than recombination). The measure r^2 represents the statistical correlation between two sites, and takes the value of 1 if only two haplotypes are present.

The r^2 measure is arguably the most relevant measure for association mapping, because there is a simple inverse relationship between r^2 and the sample size required to detect association between susceptibility loci and SNPs. These measures are defined for pairs of sites, but for some applications a determination of how strong LD is across an entire region that contains many polymorphic sites might be desirable (e.g., testing whether the strength of LD differs significantly among loci or across populations, or whether there is more or less LD in a region than predicted under a particular model). Measuring LD across a region is not straightforward, but one approach is to use the measure r , which was developed in population genetics. Roughly speaking, r measures how much recombination would be required under a particular population model to generate the LD that is seen in the data. This type of method can potentially also provide a statistically rigorous approach to the problem of determining whether LD data provide evidence for the presence of recombination hotspots. For the methods described herein, a

significant r^2 value can be at least 0.1 such as at least 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, or at least 0.99. In one preferred embodiment, the significant r^2 value can be at least 0.2.

Alternatively, linkage disequilibrium as described herein, refers to linkage disequilibrium characterized by values of $|D'|$ of at least 0.2, such as 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.85, 0.9, 0.95, 0.96, 0.97, 0.98, or at least 0.99. Thus, linkage disequilibrium represents a correlation between alleles of distinct markers. It is measured by correlation coefficient or $|D'|$ (r^2 up to 1.0 and $|D'|$ up to 1.0). In certain embodiments, linkage disequilibrium is defined in terms of values for both the r^2 and $|D'|$ measures. In one such embodiment, a significant linkage disequilibrium is defined as $r^2 > 0.1$ and $|D'| > 0.8$. In another embodiment, a significant linkage disequilibrium is defined as $r^2 > 0.2$ and $|D'| > 0.9$. Other combinations and permutations of values of r^2 and $|D'|$ for determining linkage disequilibrium are also contemplated, and are also within the scope of the invention. Linkage disequilibrium can be determined in a single human population, as defined herein, or it can be determined in a collection of samples comprising individuals from more than one human population. In one embodiment of the invention, LD is determined in a sample from one or more of the HapMap populations (caucasian, african, japanese, chinese), as defined (<http://www.hapmap.org>). In one such embodiment, LD is determined in the CEU population of the HapMap samples. In another embodiment, LD is determined in the YRI population. In yet another embodiment, LD is determined in samples from the Icelandic population.

If all polymorphisms in the genome were independent at the population level (*i.e.*, no LD), then every single one of them would need to be investigated in association studies, to assess all the different polymorphic states. However, due to linkage disequilibrium between polymorphisms, tightly linked polymorphisms are strongly correlated, which reduces the number of polymorphisms that need to be investigated in an association study to observe a significant association. Another consequence of LD is that many polymorphisms may give an association signal due to the fact that these polymorphisms are strongly correlated.

Genomic LD maps have been generated across the genome, and such LD maps have been proposed to serve as framework for mapping disease-genes (Risch, N. & Merikangas, K, *Science* 273:1516-1517 (1996); Maniatis, N., *et al.*, *Proc Natl Acad Sci USA* 99:2228-2233 (2002); Reich, DE *et al.*, *Nature* 411:199-204 (2001)).

It is now established that many portions of the human genome can be broken into series of discrete haplotype blocks containing a few common haplotypes; for these blocks, linkage disequilibrium data provides little evidence indicating recombination (see, *e.g.*, Wall, J.D. and Pritchard, J.K., *Nature Reviews Genetics* 4:587-597 (2003); Daly, M. *et al.*, *Nature Genet.* 29:229-232 (2001); Gabriel, S.B. *et al.*, *Science* 296:2225-2229 (2002); Patil, N. *et al.*, *Science* 294:1719-1723 (2001); Dawson, E. *et al.*, *Nature* 418:544-548 (2002); Phillips, M.S. *et al.*, *Nature Genet.* 33:382-387 (2003)).

There are two main methods for defining these haplotype blocks: blocks can be defined as regions of DNA that have limited haplotype diversity (see, e.g., Daly, M. et al., *Nature Genet.* 29:229-232 (2001); Patil, N. et al., *Science* 294:1719-1723 (2001); Dawson, E. et al., *Nature* 418:544-548 (2002); Zhang, K. et al., *Proc. Natl. Acad. Sci. USA* 99:7335-7339 (2002)), or as regions between transition zones having extensive historical recombination, identified using linkage disequilibrium (see, e.g., Gabriel, S.B. et al., *Science* 296:2225-2229 (2002); Phillips, M.S. et al., *Nature Genet.* 33:382-387 (2003); Wang, N. et al., *Am. J. Hum. Genet.* 71:1227-1234 (2002); Stumpf, M.P., and Goldstein, D.B., *Curr. Biol.* 13:1-8 (2003)). More recently, a fine-scale map of recombination rates and corresponding hotspots across the human genome has been generated (Myers, S., et al., *Science* 310:321-32324 (2005); Myers, S. et al., *Biochem Soc Trans* 34:526530 (2006)). The map reveals the enormous variation in recombination across the genome, with recombination rates as high as 10-60 cM/Mb in hotspots, while closer to 0 in intervening regions, which thus represent regions of limited haplotype diversity and high LD. The map can therefore be used to define haplotype blocks/LD blocks as regions flanked by recombination hotspots. As used herein, the terms "haplotype block" or "LD block" includes blocks defined by any of the above described characteristics, or other alternative methods used by the person skilled in the art to define such regions.

Haplotype blocks (LD blocks) can be used to map associations between phenotype and haplotype status, using single markers or haplotypes comprising a plurality of markers. The main haplotypes can be identified in each haplotype block, and then a set of "tagging" SNPs or markers (the smallest set of SNPs or markers needed to distinguish among the haplotypes) can then be identified. These tagging SNPs or markers can then be used in assessment of samples from groups of individuals, in order to identify association between phenotype and haplotype. If desired, neighboring haplotype blocks can be assessed concurrently, as there may also exist linkage disequilibrium among the haplotype blocks.

It has thus become apparent that for any given observed association to a polymorphic marker (such as CNVs) in the genome, it is likely that additional markers in the genome also show association. This is a natural consequence of the uneven distribution of LD across the genome, as observed by the large variation in recombination rates. The markers used to detect association thus in a sense represent "tags" for a genomic region (i.e., a haplotype block or LD block) that is associating with a given disease or trait, and as such are useful for use in the methods and kits of the present invention. One or more causative (functional) variants or mutations may reside within the region found to be associating to the disease or trait. The functional variant may be another SNP, a tandem repeat polymorphism (such as a minisatellite or a microsatellite), a transposable element, or a copy number variation, such as an inversion, deletion or insertion. Such variants in LD with the variants described herein may confer a higher relative risk (RR) or odds ratio (OR) than observed for the tagging markers used to detect the association. The present invention thus refers to the markers used for detecting association to the disease, as described herein, as well as markers in linkage disequilibrium with the markers. Thus, in certain embodiments of the invention, markers that are in LD with the markers and/or

haplotypes of the invention, as described herein, may be used as surrogate markers. The surrogate markers have in one embodiment relative risk (RR) and/or odds ratio (OR) values smaller than for the markers or haplotypes initially found to be associating with the disease, as described herein. In other embodiments, the surrogate markers have RR or OR values greater than those initially determined for the markers initially found to be associating with the disease, as described herein. An example of such an embodiment would be a rare, or relatively rare (such as < 10% allelic population frequency) variant in LD with a more common variant (> 10% population frequency) initially found to be associating with the disease, such as the variants described herein. Identifying and using such markers for detecting the association discovered by the inventors as described herein can be performed by routine methods well known to the person skilled in the art, and are therefore within the scope of the present invention.

Identification and assessment of Copy Number Variations

De novo Identification of CNVs

Identification of novel copy number variations can in general be done by methods for assessing genomic copy number changes. Such methods include methods that quantitatively estimate the number of copies of a particular genomic segment, but also include methods that indicate whether a particular segment is present in a sample or not. The latter include for example hybridization techniques such as FISH.

In one method, *de novo* CNVs genome-wide are detected by following transmissions of genotypes in parent-offspring samples. Ideally, a triad of samples from the blood parent of an individual, as well as the individual (the offspring). The genotypes may be obtained for any informative polymorphic marker. Conveniently, the marker is a single nucleotide polymorphism (SNP). To identify *de novo* deletions, two complementary methods can for example be used, alone or in combination. One relies on a program developed by deCODE Genetics, called DosageMiner. The program includes a Hidden Markov Model algorithm based on intensity data for particular genetic markers, such as SNPs, that is similar to that reported by Colella et al. (Colella, A. et al. *Nucleic Acids Res* 35:2013-25 (2007)). The other method involves a procedure utilizing inheritance errors and the neighboring genotype configurations comparable to that described by Conrad et al. (Conrad, D.F. et al. *Nat Genet* 38:75-81 (2006)). When only one parent is typed, genotype information allows identification of deletions as putatively *de novo* by assessment of regional parental heterozygosity. To identify *de novo* duplications we can also analyze genotype data from trios (parents plus their offspring) using DosageMiner. CNV events stand out in the data from two perspectives. First, all sample intensities for SNPs/probes within a CNV should be increased or decreased relative to neighboring SNPs/probes that are not in a CNV region, secondly CNVs can be detected from the transmission from parent to child. To determine deviations in signal intensity we start by normalizing the intensities. The normalized

intensities for each color channel of a marker or probe can be determined by a fit of the following equation:

$$\log(x_{ij}) = f(\alpha_i, gc(j)) + \mu_{j, gen(i,j)} + \beta_i + \varepsilon_{ij}$$

- 5 where i is sample index, j is SNP index, x_{ij} is colour intensity for sample i in SNP j , $gc(j)$ is an indicator of GC-content around SNP j , f is a smooth function of GC-content, α_i are sample specific parameters for GC content, $gen(i,j)$ is the genotype for sample i for SNP j , $\mu_{j,gt}$ is the SNP effect for genotype gt and SNP j , β_i is sample effect, ε_{ij} is the unexplained part of the signal, including noise. The same model with another set of parameters is used for the other colour y_{ij} . A
- 10 generalized additive model (Hastie, T. *Statist Sci* 1:297-318 (1986)) can be used to fit the smooth function f . After fitting the model, the data is normalized by removing the systematic model components. A region can be considered to be deleted/duplicated if the average intensity over at least ten markers in a region falls below/above an empirically determined threshold.

- To identify regions demonstrating loss of heterozygosity (LOH), markers can be split into three
- 15 classes: 1) Markers that show LOH, 2) Markers that are inconsistent with LOH and 3) Markers that are consistent with LOH. Class 3 can be further split into these subclasses: a) markers that are consistent with transmitted LOH; b) markers that are consistent with *de novo* LOH. A particular marker shows LOH if a child is homozygous for one allele and a parent is homozygous for the other allele. A marker is inconsistent with LOH if the child is heterozygous. A marker is
- 20 consistent with LOH if the child is homozygous and the parent is homozygous for the same allele or heterozygous. In case the parent is homozygous for the same allele as the child the marker is consistent with transmitted LOH and in case the parent is homozygous for the other allele the marker is only consistent with *de novo* LOH.

- A stretch containing a single marker showing LOH is likely to be due to a genotyping error. In
- 25 general, modern genotyping technology has a low error rate, and usually independent of position on the genome; as a consequence, the occurrence of more than one marker showing LOH in a consecutive stretch on the genome is more likely to be evidence of a deletion in the child. A region can be considered to be a putative deletion if at least two markers are showing LOH and *de novo* if consistent with *de novo* LOH.

- 30 In certain embodiments, using LOH analysis we can define a candidate deleted region if more than one marker shows inheritance error within a region of homozygous markers. The genotyping data can be further inspected to determine if the error is due to uniparental disomy. Once such individuals are removed, remaining putative *de novo* deletions can be combined with the output of DosageMiner, and look for deletions that are consistently identified
- 35 by both approaches. Such deletions are likely to represent real *de novo* deletions.

Detection of CNVs

Detection of CNVs can be done by a range of techniques suitable for such purpose. In general, techniques that can selectively determine whether a particular chromosomal segment is present or absent in an individual can be used for genotyping CNVs. Ideally, the technique is able to quantify the amount of segment present, i.e. determine whether a segment is deleted, duplicated, triplicated, etc. in the individual. For example, Taqman assays can be used (Bieche, I. *et al. Int J Cancer* 78:661-6 (1998)), as well as Fluorescent In Situ Hybridization (FISH) techniques. A range of genotyping technologies can also be used, such as Molecular Inversion Probe array technology (e.g., Affymetrix SNP Array 6.0), and BeadArray Technologies (e.g., Illumina GoldenGate and Infinium assays, e.g. HumanHap chips, Human 1M-Duo), as can other platforms such as Nimblegen HD2.1, High-Definition CGH arrays (Agilent Technologies), tiling array technology (Affymetrix). Information about amplitude of particular probes, which is representative of particular alleles, provides a quantitative dosage information for the particular allele, and by consequence dosage information about the CNV in question, since the marker is selected as a marker representative of the CNV and is typically physically located within the CNV. If the CNV is a deletion, then the absence of particular marker alleles is representative of the deletion. If the CNV is a duplication (or a higher order copy number variation), then the signal intensity representative of the allele correlating with the CNV is representative of the copy number. A summary of methodologies commonly used is provided in Perkel (Perkel. *J Nature Methods* 5:447-453 (2008)). Other suitable methods available to the skilled person can also be used, and are within scope of the present invention.

Polymorphic markers that are in linkage disequilibrium with particular CNVs can be used as surrogates for the CNV. Such markers are useful in a diagnostic setting for determining whether a particular CNV is present in an individual or not, since they can be used in lieu of the CNV itself. In certain embodiments, the polymorphic marker is a SNP. In preferred embodiment, the SNP is located within the CNV. Thus, in certain embodiments of the methods of the invention, markers within the CNV are used to detect the presence or absence of the CNV. In certain embodiments, markers selected from the group consisting of the markers set forth in Table 6, which are markers within the chromosome 1q21.1 deletion, are useful for determining a susceptibility to schizophrenia or a related condition. In certain other embodiments, markers selected from the group consisting of the markers set forth in Table 7, which are markers within the 15q11.2 deletion, are useful for determining a susceptibility to schizophrenia or a related condition. In certain other embodiments, markers selected from the group consisting of the markers set forth in Table 8, which are markers within the 15q13.3 deletion, are useful for determining a susceptibility to schizophrenia or a related condition. In such embodiments, determination of the presence or absence of a particular allele is indicative of the CNV, i.e. indicative of whether the CNV is present in the individual or not.

Haplotype Analysis

One general approach to haplotype analysis involves using likelihood-based inference applied to NESTED MODELS (Gretarsdottir S., *et al.*, *Nat. Genet.* 35:131-38 (2003)). The method is implemented in the program NEMO, which allows for many polymorphic markers, SNPs and microsatellites. The method and software are specifically designed for case-control studies where the purpose is to identify haplotype groups that confer different risks. It is also a tool for studying LD structures. In NEMO, maximum likelihood estimates, likelihood ratios and p-values are calculated directly, with the aid of the EM algorithm, for the observed data treating it as a missing-data problem.

Even though likelihood ratio tests based on likelihoods computed directly for the observed data, which have captured the information loss due to uncertainty in phase and missing genotypes, can be relied on to give valid p-values, it would still be of interest to know how much information had been lost due to the information being incomplete. The information measure for haplotype analysis is described in Nicolae and Kong (Technical Report 537, Department of Statistics, University of Statistics, University of Chicago; *Biometrics*, 60(2):368-75 (2004)) as a natural extension of information measures defined for linkage analysis, and is implemented in NEMO.

For single marker association to a disease, the Fisher exact test can be used to calculate two-sided p-values for each individual allele. Usually, all p-values are presented unadjusted for multiple comparisons unless specifically indicated. The presented frequencies (for microsatellites, SNPs and haplotypes) are allelic frequencies as opposed to carrier frequencies. To minimize any bias due to the relatedness of the patients who were recruited as families to the study, first and second-degree relatives can be eliminated from the patient list. Furthermore, the test can be repeated for association correcting for any remaining relatedness among the patients, by extending a variance adjustment procedure previously described (Risch, N. & Teng, J. *Genome Res.*, 8:1273-1288 (1998)) for sibships so that it can be applied to general familial relationships, and present both adjusted and unadjusted p-values for comparison. The method of genomic controls (Devlin, B. & Roeder, K. *Biometrics* 55:997 (1999)) can also be used to adjust for the relatedness of the individuals and possible stratification. The differences are in general very small as expected. To assess the significance of single-marker association corrected for multiple testing we can carry out a randomization test using the same genotype data. Cohorts of patients and controls can be randomized and the association analysis redone multiple times (e.g., up to 500,000 times) and the p-value is the fraction of replications that produced a p-value for some marker allele that is lower than or equal to the p-value we observed using the original patient and control cohorts.

For both single-marker and haplotype analyses, relative risk (RR) and the population attributable risk (PAR) can be calculated assuming a multiplicative model (haplotype relative risk model) (Terwilliger, J.D. & Ott, J., *Hum. Hered.* 42:337-46 (1992) and Falk, C.T. & Rubinstein, P., *Ann. Hum. Genet.* 51 (Pt 3):227-33 (1987)), i.e., that the risks of the two alleles/haplotypes a

person carries multiply. For example, if RR is the risk of A relative to a, then the risk of a person homozygote AA will be RR times that of a heterozygote Aa and RR^2 times that of a homozygote aa. The multiplicative model has a nice property that simplifies analysis and computations — haplotypes are independent, *i.e.*, in Hardy-Weinberg equilibrium, within the affected population as well as within the control population. As a consequence, haplotype counts of the affecteds and controls each have multinomial distributions, but with different haplotype frequencies under the alternative hypothesis. Specifically, for two haplotypes, h_i and h_j , $\text{risk}(h_i)/\text{risk}(h_j) = (f_i/p_i)/(f_j/p_j)$, where f and p denote, respectively, frequencies in the affected population and in the control population. While there is some power loss if the true model is not multiplicative, the loss tends to be mild except for extreme cases. Most importantly, p-values are always valid since they are computed with respect to null hypothesis.

An association signal detected in one association study may be replicated in a second cohort, ideally from a different population (*e.g.*, different region of same country, or a different country) of the same or different ethnicity. The advantage of replication studies is that the number of tests performed in the replication study, and hence the less stringent the statistical measure that is applied. Replication studies in one or even several additional case-control cohorts have the added advantage of providing assessment of the association signal in additional populations, thus simultaneously confirming the initial finding and providing an assessment of the overall significance of the genetic variant(s) being tested in human populations in general.

The results from several case-control cohorts can also be combined to provide an overall assessment of the underlying effect. The methodology commonly used to combine results from multiple genetic association studies is the Mantel-Haenszel model (Mantel and Haenszel, *J Natl Cancer Inst* 22:719-48 (1959)). The model is designed to deal with the situation where association results from different populations, with each possibly having a different population frequency of the genetic variant, are combined. The model combines the results assuming that the effect of the variant on the risk of the disease, as measured by the OR or RR, is the same in all populations, while the frequency of the variant may differ between the populations. Combining the results from several populations has the added advantage that the overall power to detect a real underlying association signal is increased, due to the increased statistical power provided by the combined cohorts. Furthermore, any deficiencies in individual studies, for example due to unequal matching of cases and controls or population stratification will tend to balance out when results from multiple cohorts are combined, again providing a better estimate of the true underlying genetic effect.

Risk assessment and Diagnostics

Within any given population, there is an absolute risk of developing a disease or trait, defined as the chance of a person developing the specific disease or trait over a specified time-period. For

example, a woman's lifetime absolute risk of breast cancer is one in nine. That is to say, one woman in every nine will develop breast cancer at some point in their lives. Risk is typically measured by looking at very large numbers of people, rather than at a particular individual. Risk is often presented in terms of Absolute Risk (AR) and Relative Risk (RR). Relative Risk is used to compare risks associating with two variants or the risks of two different groups of people. For example, it can be used to compare a group of people with a certain genotype with another group having a different genotype. For a disease, a relative risk of 2 means that one group has twice the chance of developing a disease as the other group. The Risk presented is usually the relative risk for a person, or a specific genotype of a person, compared to the population with matched gender and ethnicity. Risks of two individuals of the same gender and ethnicity could be compared in a simple manner. For example, if, compared to the population, the first individual has relative risk 1.5 and the second has relative risk 0.5, then the risk of the first individual compared to the second individual is $1.5/0.5 = 3$.

As described herein, certain copy number variations (CNVs) are found to be useful for risk assessment of schizophrenia. Risk assessment can involve detecting particular CNVs in the genome of individuals undergoing assessment. Particular CNVs are found more frequently in individuals with schizophrenia, than in individuals without diagnosis of schizophrenia. Therefore, these CNVs have predictive value for detecting schizophrenia, or a susceptibility to schizophrenia, in an individual. Tagging markers in linkage disequilibrium with the CNVs can be used as surrogates for the CNVs and can thus be used for risk assessment. Markers with values of r^2 equal to 1 are perfect surrogates for the at-risk CNVs, i.e. genotypes for the surrogate marker perfectly predicts the occurrence of the CNV. Markers with smaller values of r^2 than 1 can also be surrogates for the CNV, but the detected risk will tend to be lower than for the CNV itself, unless the risk conferred by the marker, or another genetic variant in LD with the marker, is higher than for the CNV. Without intending to be limited by theory, it is believed that the CNVs described herein to be associated with risk of schizophrenia represent functional variants predisposing to the disease. Alternatively, the CNVs are in linkage disequilibrium with a functional variant that is functionally causing the increased risk. In certain embodiments, the functional variant, in LD with the CNV, resides within the segment that defines the CNV, i.e. within the CNV itself. In other embodiments, the functional variant is in LD with the CNV, while physically located outside the CNV region. The functional variant may for example be a tandem repeat, such as a minisatellite or a microsatellite, a single base polymorphism (SNP), or a transposable element (e.g., an *Alu* element). The present invention encompasses the assessment of such surrogate markers for the CNVs as disclosed herein. Such markers are annotated, mapped and listed in public databases, as well known to the skilled person, or can alternatively be readily identified by sequencing the region or a part of the region identified by the markers of the present invention in a group of individuals, and identify polymorphisms in the resulting group of sequences. As a consequence, the person skilled in the art can readily and without undue experimentation genotype surrogate markers in linkage disequilibrium with the markers and CNVs described herein. The tagging or surrogate markers in LD with the at-risk

CNVs also have predictive value for detecting association to schizophrenia, or a susceptibility to schizophrenia, in an individual.

The present invention can in certain embodiments be practiced by assessing a sample comprising genomic DNA from an individual for the presence of CNVs described herein to be associated with risk of schizophrenia. Such assessment includes steps of detecting the presence or absence of a particular CNV, or at least one polymorphic marker in linkage disequilibrium with the CNV, using methods well known to the skilled person and further described herein, and based on the outcome of such assessment, determine whether the individual from whom the sample is derived is at increased or decreased risk (increased or decreased susceptibility) of schizophrenia. The presence of the CNV conferring increased risk of schizophrenia is indicative of the individual being at increased risk (increased susceptibility) to schizophrenia. The absence of the CNV conferring increased risk of schizophrenia in the individual is indicative of the individual not being at increased risk of schizophrenia conferred by the CNV assessed.

Alternatively, the invention can be practiced utilizing a dataset comprising information about the genotype status of at least one CNV (or at least polymorphic marker in linkage disequilibrium with the at least CNV) for at least one individual. In other words, a dataset containing information about such genetic status, for example in the form of genotype counts at certain polymorphic markers, an indication about the presence or absence of a particular CNV, an quantitative assessment of a CNV (such as number of copies of a particular region in the genome of the individual), or actual genotypes for one or more markers, can be queried for the presence or absence of particular CNVs shown by the present inventors to be associated with risk of schizophrenia. A positive result for the CNV, as shown herein, is indicative of the individual from which the dataset is derived is at increased susceptibility (increased risk) of schizophrenia. A negative result, is indicative of the individual not having the elevated susceptibility (elevated risk) by the CNV. The dataset can in certain embodiments be comprised in a database containing genotype/CNV data for at least one individual.

In certain embodiments of the invention, a polymorphic marker is correlated to schizophrenia by referencing CNV data to a look-up table that comprises correlations between the CNV and schizophrenia. The CNV in certain embodiments comprises at least one indication of the CNV, i.e. an indication of the presence or absence of the CNV, or a quantitative numerical value representative of the CNV. In some embodiments, the table comprises a correlation for one CNV. In other embodiments, the table comprises a correlation for a plurality of CNVs. In both scenarios, by referencing to a look-up table that gives an indication of a correlation between a CNV and schizophrenia, a risk for schizophrenia, or a susceptibility to schizophrenia, can be identified in the individual from whom the sample is derived. In some embodiments, the correlation is reported as a statistical measure. The statistical measure may be reported as a risk measure, such as a relative risk (RR), an absolute risk (AR) or an odds ratio (OR).

In general, the CNVs of described herein as conferring risk of schizophrenia, can be useful for risk assessment and diagnostic purposes for schizophrenia, either alone or in combination. The

risk conferred by particular CNVs is quite high, and their frequency in the population quite low (see e.g. Tables 4 and 12). As a consequence, if the occurrence of multiple CNVs is independent, the likelihood of more than one CNV being present in one particular individual is correspondingly. Nevertheless, risk assessment for multiple CNVs can be performed using standard methodology. For example, if the CNVs are independent, their risk is expected to roughly multiply in carriers with more than one CNV present.

Likewise, the CNVs described herein can form the basis of risk analysis that combines other CNVs known to increase risk of schizophrenia, or other genetic risk variants (such as SNPs) for schizophrenia. Appropriate models, such as the multiplicative model, can be used for estimating overall risk.

Thus, in certain embodiments of the invention, a plurality of variants (CNVs, genetic markers, and/or haplotypes) is used for overall risk assessment. These variants are in one embodiment selected from the CNVs as disclosed herein. Other embodiments include the use of the variants of the present invention in combination with other variants known to be useful for diagnosing a susceptibility to schizophrenia. In such embodiments, the genotype status of a plurality of CNVs, markers and/or haplotypes is determined in an individual, and the status of the individual compared with the population frequency of the associated variants, or the frequency of the variants in clinically healthy subjects, such as age-matched and sex-matched subjects. Methods known in the art, such as multivariate analyses or joint risk analyses, including the use of multiplicative model for overall risk assessment, may subsequently be used to determine the overall risk conferred based on the genotype status at the multiple loci. Assessment of risk based on such analysis may subsequently be used in the methods, uses and kits of the invention, as described herein.

As described in the above, the LD structure of the human genome has the effect that a large number of variants (markers and/or haplotypes) in linkage disequilibrium with the variant originally associated with a disease or trait may be used as surrogate markers for assessing association to the disease or trait. The number of such surrogate markers will depend on factors such as the historical recombination rate in the region, the mutational frequency in the region (i.e., the number of polymorphic sites or markers in the region), and the extent of LD (size of the LD block) in the region. These markers are usually located within the physical boundaries of the LD block or haplotype block in question as defined using the methods described herein, or by other methods known to the person skilled in the art. However, sometimes marker and haplotype association is found to extend beyond the physical boundaries of the haplotype block as defined. Such markers and/or haplotypes may in those cases be also used as surrogate markers and/or haplotypes for the markers and/or haplotypes physically residing within the haplotype block as defined. As a consequence, markers and haplotypes in LD (typically characterized by r^2 greater than 0.1, such as r^2 greater than 0.2, including r^2 greater than 0.3, also including r^2 greater than 0.4) with the CNVs shown by the present inventors to confer increased risk of schizophrenia are also within the scope of the invention, even if they are

physically located beyond the boundaries of the CNV, or a haplotype bloc that includes the CNV. Genetic elements that have for whatever reason been preserved together will lead to observable LD. While it is most common that this occurs within relatively small genomic regions flanked by recombination hotspots (LD blocks or haplotype blocks), it is also possible that elements located further apart may be in LD. This could for example occur if the elements have similar biological function which is interrelated in such a way that one variant influences the occurrence of the other.

For the SNP markers described herein, the opposite allele to the allele found to be in excess in patients (at-risk allele) is found in decreased frequency in schizophrenia. These markers and haplotypes in LD and/or comprising such markers, are thus protective for schizophrenia, i.e. they confer a decreased risk or susceptibility of individuals carrying these markers and/or haplotypes developing schizophrenia.

Certain variants of the present invention, including certain haplotypes comprise, in some cases, a combination of various genetic markers, e.g., SNPs and microsatellites. Detecting haplotypes can be accomplished by methods known in the art and/or described herein for detecting sequences at polymorphic sites. Furthermore, correlation between certain haplotypes or sets of markers and disease phenotype can be verified using standard techniques. A representative example of a simple test for correlation would be a Fisher-exact test on a two by two table.

In specific embodiments, a CNV found to be associated with schizophrenia is one in which the schizophrenia (or a marker allele or haplotype in LD with the CNV) is more frequently present in an individual at risk for (or diagnosed with) schizophrenia (affected), compared to the frequency of its presence in a healthy individual (control), wherein the presence of the marker allele or haplotype is indicative of schizophrenia or a susceptibility to schizophrenia. In other embodiments, at-risk markers in linkage disequilibrium with one or more CNVs shown herein to be associated with schizophrenia are tagging markers that are more frequently present in an individual at risk for schizophrenia (affected), compared to the frequency of their presence in a healthy individual (control), wherein the presence of the tagging markers is indicative of increased susceptibility to schizophrenia. In a further embodiment, at-risk markers alleles (i.e. conferring increased susceptibility) in linkage disequilibrium with one or more markers found to be associated with schizophrenia, are markers comprising one or more allele that is more frequently present in an individual at risk for schizophrenia, compared to the frequency of their presence in a healthy individual (control), wherein the presence of the markers is indicative of increased susceptibility to schizophrenia.

Study population

In a general sense, the methods and kits of the invention can be utilized from samples containing nucleic acid material (DNA or RNA) from any source and from any individual. In

preferred embodiments, the individual is a human individual. The individual can be an adult, child, or fetus. The nucleic acid source may be any sample comprising nucleic acid material, including biological samples, or a sample comprising nucleic acid material derived therefrom. The present invention also provides for assessing CNVs, markers and/or haplotypes in individuals who are members of a target population. Such a target population is in one embodiment a population or group of individuals at risk of developing the disease, based on other genetic factors, biomarkers, biophysical parameters, family history of schizophrenia or related diseases, previous diagnosis or medical history, etc.

The invention provides for embodiments that include individuals from specific age subgroups, such as those over the age of 15, over the age of 20, over the age of 25, over the age of 30, over the age of 35, over the age of 40, over the age of 45, or over the age of 50, 55, 60, 65, 70, 75, 80, or 85. Other embodiments of the invention pertain to other age groups, such as individuals aged less than 85, such as less than age 80, less than age 75, or less than age 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, or 15. Other embodiments relate to individuals with age at onset of the disease in any of particular age or age ranges defined by the numerical values described in the above or other numerical values bridging these numbers. It is also contemplated that a range of ages may be relevant in certain embodiments, such as age at onset at more than age 15 but less than age 20. Other age ranges are however also contemplated, including all age ranges bracketed by the age values listed in the above. The invention furthermore relates to individuals of either gender, males or females.

The Icelandic population is a Caucasian population of Northern European ancestry. A large number of studies reporting results of genetic linkage and association in the Icelandic population have been published in the last few years. Many of those studies show replication of variants, originally identified in the Icelandic population as being associating with a particular disease, in other populations (Sulem, P., *et al. Nat Genet* May 17 2009 (Epub ahead of print); Rafnar, T., *et al. Nat Genet* 41:221-7 (2009); Gretarsdottir, S., *et al. Ann Neurol* 64:402-9 (2008); Stacey, S.N., *et al. Nat Genet* 40:1313-18 (2008); Gudbjartsson, D.F., *et al. Nat Genet* 40:886-91 (2008); Styrkarsdottir, U., *et al. N Engl J Med* 358:2355-65 (2008); Thorgeirsson, T., *et al. Nature* 452:638-42 (2008); Gudmundsson, J., *et al. Nat Genet.* 40:281-3 (2008); Stacey, S.N., *et al., Nat Genet.* 39:865-69 (2007); Helgadóttir, A., *et al., Science* 316:1491-93 (2007); Steinthorsdóttir, V., *et al., Nat Genet.* 39:770-75 (2007); Gudmundsson, J., *et al., Nat Genet.* 39:631-37 (2007); Frayling, T.M., *Nature Reviews Genet* 8:657-662 (2007); Amundadóttir, L.T., *et al., Nat Genet.* 38:652-58 (2006); Grant, S.F., *et al., Nat Genet.* 38:320-23 (2006)). Thus, genetic findings in the Icelandic population have in general been replicated in other populations, including populations from Africa and Asia.

The CNVs of the present invention found to be associated with schizophrenia are believed to show similar association in other human populations. Particular embodiments comprising individual human populations are thus also contemplated and within the scope of the invention. Such embodiments relate to human subjects that are from one or more human population

including, but not limited to, Caucasian populations, European populations, American populations, Eurasian populations, Asian populations, Central/South Asian populations, East Asian populations, Middle Eastern populations, African populations, Hispanic populations, and Oceanian populations. European populations include, but are not limited to, Swedish,
5 Norwegian, Finnish, Russian, Danish, Icelandic, Irish, Kelt, English, Scottish, Dutch, Belgian, French, German, Spanish, Portugues, Italian, Polish, Bulgarian, Slavic, Serbian, Bosnian, Czech, Greek and Turkish populations. In certain embodiments, the invention relates to individuals of Caucasian origin.

The racial contribution in individual subjects may also be determined by genetic analysis.
10 Genetic analysis of ancestry may be carried out using unlinked microsatellite markers such as those set out in Smith *et al.* (*Am J Hum Genet* **74**, 1001-13 (2004)).

In certain embodiments, the invention relates to CNVs, markers and/or haplotypes identified in specific populations, as described in the above. The person skilled in the art will appreciate that measures of linkage disequilibrium (LD) may give different results when applied to different
15 populations. This is due to different population history of different human populations as well as differential selective pressures that may have led to differences in LD in specific genomic regions. It is also well known to the person skilled in the art that certain genetic markers, e.g. CNVs or SNP markers, have different population frequency in different populations, or are polymorphic in one population but not in another. The person skilled in the art will however apply the methods
20 available and as thought herein to practice the present invention in any given human population. This may include assessment of polymorphic markers in the LD region of the present invention, so as to identify those markers that give strongest association within the specific population. Thus, the at-risk variants of the present invention may reside on different haplotype background and in different frequencies in various human populations. However, utilizing methods known in
25 the art and the markers of the present invention, the invention can be practiced in any given human population.

Utility of Genetic Testing

The person skilled in the art will appreciate and understand that the CNV variants described
30 herein in general do not, by themselves, provide an absolute identification of individuals who will develop schizophrenia or related conditions. The variants described herein do however indicate increased and/or decreased likelihood that individuals carrying the at-risk or protective variants of the invention will develop symptoms associated with schizophrenia. This information is however extremely valuable in itself, as outlined in more detail in the below, as it can be used
35 to, for example, initiate preventive measures at an early stage, perform regular physical and/or mental exams to monitor the progress and/or appearance of symptoms, or to schedule exams at a regular interval to identify early symptoms, so as to be able to apply treatment at an early

stage. This is in particular important since schizophrenia and related disorders are heterogeneous disorders with symptoms that are individually vague. Diagnostic criteria require a number of symptoms to be present over a period of time; therefore, it is important to be able to establish additional risk factors that may aid in the diagnosis, or facilitate the diagnosis
5 through in-depth phenotyping and/or more frequent examination, or both.

Thus, the knowledge about a genetic variant that confers a risk of developing schizophrenia offers the opportunity to apply a genetic test to identify those individuals with particularly increased risk of developing schizophrenia or a related condition (i.e. carriers of the at-risk variant). The CNV variants described herein confer high risk of developing schizophrenia; for
10 example, the chr 15 deletion confers an 11-fold increased risk of schizophrenia, compared with the general population. This is a very significant effect, and is useful in a diagnostic setting. For example, individuals with early symptoms that typically are not individually associated with a clinical diagnosis of schizophrenia and carry an at-risk CNV may benefit from early therapeutic treatment, or other preventive measure, or more rigorous supervision or more frequent
15 examination. Likewise, individuals that have a family history of the disease, or are carriers of other risk factors associated with schizophrenia may, in the context of additionally carrying at least one at-risk CNV benefit from early therapy or other treatment. The core values of genetic testing lie in the possibilities of being able to diagnose schizophrenia, or a predisposition to schizophrenia, at an early stage and provide such information to the appropriate person – such
20 as a clinician, the individual him/herself, a genetic counselor, or guardian, in order to be able to apply the most appropriate therapeutic measure at an early disease stage.

Early symptoms of behavioural disorders such as schizophrenia and related conditions are usually not sufficient to fulfill standardized diagnostic criteria; to fulfill those, a certain pattern of symptoms and behavioural disturbance needs to manifest itself over a period of time.
25 Sometimes, certain physical characteristics may also be present. This makes at-risk genetic variants valuable in a diagnostic setting, in particular high-risk variants. Determination of the presence of such variants warrants increased monitoring of the individual in question. Appearance of behavioural symptoms combined with the presence of such variants facilitates early diagnosis, which makes early treatment possible. Genetic testing may thus be used to aid
30 in the diagnosis of disease in its early stages, before all criteria for formal diagnostic criteria are all fulfilled. It is well established that early treatment is extremely important for disorders on the schizophrenic spectrum, which lends further support to the value of genetic testing for early diagnosis of these disorders.

35 METHODS

Methods for risk assessment and risk management of schizophrenia are described herein and are encompassed by the invention. The invention also encompasses methods of assessing an

individual for probability of response to a therapeutic agent for schizophrenia, methods for predicting the effectiveness of a therapeutic agent for a schizophrenia disorder, nucleic acids, polypeptides and antibodies and computer-implemented functions. Kits for assaying a sample from a subject to detect susceptibility to a schizophrenia disorder are also encompassed by the invention.

Diagnostic and screening methods

In certain embodiments, the present invention pertains to methods of diagnosing, or aiding in the diagnosis of, schizophrenia or a susceptibility to schizophrenia, by detecting particular copy number variations that appear more frequently in schizophrenia subjects or subjects who are susceptible to schizophrenia. In particular embodiments, the invention is a method of determining a susceptibility to schizophrenia by detecting at least CNV as described herein. In other embodiments, the invention relates to a method of determining or diagnosing a susceptibility to schizophrenia by detecting at least one allele of at least one polymorphic marker. The present invention describes methods whereby detection of particular alleles of particular markers or haplotypes is indicative of a susceptibility to schizophrenia. Such prognostic or predictive assays can also be used to determine prophylactic treatment of a subject prior to the onset of symptoms of schizophrenia. The present invention pertains in some embodiments to methods of clinical applications of diagnosis, e.g., diagnosis performed by a medical professional. In other embodiments, the invention pertains to methods of diagnosis or determination of a susceptibility performed by a layman. The layman can be the customer of a genotyping service. The layman may also be a genotype service provider, who performs genotype analysis on a DNA sample from an individual, in order to provide service related to genetic risk factors for particular traits or diseases, based on the genotype status of the individual (i.e., the customer). Recent technological advances in genotyping technologies, including high-throughput genotyping of SNP markers, such as Molecular Inversion Probe array technology (e.g., Affymetrix GeneChip), and BeadArray Technologies (e.g., Illumina GoldenGate and Infinium assays) have made it possible for individuals to have their own genome assessed for up to one million SNPs simultaneously, at relatively little cost. As described herein, certain of the commonly available SNP genotyping platforms include SNPs that represent tags for particular copy number variations. These platforms therefore are suitable for the detection of particular CNVs in an individual. The resulting genotype information, which can be made available to the individual, can be compared to information about disease or trait risk associated with various CNVs, or alternatively surrogate SNPs for particular CNVs, including information from public literature and scientific publications. The diagnostic application of disease-associated alleles as described herein, can thus for example be performed by the individual, through analysis of his/her genotype data, by a health professional based on results of a clinical test, or by a third party, including the genotype service provider. The third party may also be service provider who interprets genotype information from the customer to provide service related to specific genetic

risk factors, including the genetic markers described herein. In other words, the diagnosis or determination of a susceptibility of genetic risk can be made by health professionals, genetic counselors, third parties providing genotyping service, third parties providing risk assessment service or by the layman (e.g., the Individual), based on information about the genotype status of an Individual and knowledge about the risk conferred by particular genetic risk factors (e.g., particular SNPs). The information derived from analyzing sequence data, including assessment of particular SNPs and/or CNVs can be communicated to any particular body, including the Individual from which the sample, or sequence data, is derived, a guardian or representative of the individual, a clinician, a service provider, including a genotyping service provider, and a medical insurer or insurance company. In the present context, the term "diagnosing", "diagnose a susceptibility" and "determine a susceptibility" is meant to refer to any available diagnostic method, including those mentioned above.

In certain embodiments, a sample containing genomic DNA from an individual is collected. Such sample can for example be a buccal swab, a saliva sample, a blood sample, or other suitable samples containing genomic DNA, as described further herein. The genomic DNA is then analyzed using any common technique available to the skilled person, such as high-throughput array technologies that can also include CNV-specific probes or SNPs. Results from such genotyping are stored in a convenient data storage unit, such as a data carrier, including computer databases, data storage disks, or by other convenient data storage means. In certain embodiments, the computer database is an object database, a relational database or a post-relational database. The genotype data is subsequently analyzed for the presence of certain variants known to be susceptibility variants for particular human conditions, such as the genetic variants (CNVs and/or their surrogates) described herein. Genotype data can be retrieved from the data storage unit using any convenient data query method. Calculating risk conferred by a particular genotype for the individual can be based on comparing the genotype of the individual to previously determined risk (expressed as a relative risk (RR) or and odds ratio (OR), for example) for the genotype, for example for a heterozygous carrier of an at-risk variant for schizophrenia. The calculated risk for the Individual can be the relative risk for a person, or for a specific genotype of a person, compared to the average population with matched gender and ethnicity. The average population risk can be expressed as a weighted average of the risks of different genotypes, using results from a reference population, and the appropriate calculations to calculate the risk of a genotype group relative to the population can then be performed. Alternatively, the risk for an individual is based on a comparison of particular genotypes, for example heterozygous carriers of an at-risk allele of a marker compared with non-carriers of the at-risk allele. Using the population average may in certain embodiments be more convenient, since it provides a measure which is easy to interpret for the user, i.e. a measure that gives the risk for the individual, based on his/her genotype, compared with the average in the population. The calculated risk estimated can be made available to the customer via a website, preferably a secure website.

In certain embodiments, a service provider will include in the provided service all of the steps of isolating genomic DNA from a sample provided by the customer, performing genotyping of the isolated DNA, calculating genetic risk based on the genotype data, and report the risk to the customer. In some other embodiments, the service provider will include in the service the interpretation of genotype data for the individual, *i.e.*, risk estimates for particular genetic variants based on the genotype data for the individual. In some other embodiments, the service provider may include service that includes genotyping service and interpretation of the genotype data, starting from a sample of isolated DNA from the individual (the customer).

Overall risk for multiple risk variants can be performed using standard methodology. For example, assuming a multiplicative model, *i.e.* assuming that the risk of individual risk variants multiply to establish the overall effect, allows for a straight-forward calculation of the overall risk for multiple markers.

As described and exemplified herein, particular CNVs are associated with schizophrenia, in particular the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion and the chromosome 16p13.1 duplication. In one embodiment, the CNV is one that confers a significant risk or susceptibility to schizophrenia. In another embodiment, the invention relates to a method of diagnosing a susceptibility to schizophrenia in a human individual, the method comprising determining the presence or absence of at least one CNV in a nucleic acid sample obtained from the individual, wherein the at least one CNV is selected from the group consisting of the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion and the chromosome 16p13.1 duplication. In another embodiment, the invention pertains to methods of diagnosing a susceptibility to schizophrenia in a human individual, by screening for at least one CNV selected from the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion and the chromosome 16p13.1 duplication. In another embodiment, the CNV is more frequently present in a subject having, or who is susceptible to, schizophrenia (affected), as compared to the frequency of its presence in a healthy subject (control, such as population controls). In certain embodiments, marker rs2283508 is useful for determining an increased susceptibility to schizophrenia, due to it being in linkage disequilibrium with the 16p13.1 duplication. In certain embodiments, the significance of association of the at least one marker allele or haplotype is characterized by a p value < 0.05. In other embodiments, the significance of association is characterized by smaller p-values, such as < 0.01, <0.001, <0.0001, <0.00001, <0.000001, <0.0000001, <0.00000001 or <0.000000001.

In these embodiments, the presence of the at least one CNV is indicative of increased susceptibility to schizophrenia. Detecting the presence or absence of the at least one CNV selected from the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion and the chromosome 16p13.1 duplication provides information about whether the particular susceptibility conferred by the CNV

is present in the individual. The presence of particular CNVs, or markers in LD with the CNVs, can be detected at the nucleic acid level (e.g., by direct nucleotide sequencing or by other means known to the skilled in the art) in a sample from the individual. The presence can also be determined by investigating a dataset or a database comprising information about the sequence
5 of the individual with respect to the CNVs, or markers in LD with any one of the CNVs.

In certain embodiments, diagnosis susceptibility can be accomplished using hybridization methods. (see Current Protocols in Molecular Biology, Ausubel, F. *et al.*, eds., John Wiley & Sons, including all supplements). The presence of a specific marker allele or a particular genomic segment comprising a CNV, or representative of a CNV, can be indicated by sequence-specific
10 hybridization of a nucleic acid probe specific for the particular allele or the CNV. The presence of more than one specific marker allele or several CNVs can be indicated by using several sequence-specific nucleic acid probes, each being specific for a particular allele and/or CNV. A sequence-specific probe can be directed to hybridize to genomic DNA, RNA, or cDNA. A "nucleic acid probe", as used herein, can be a DNA probe or an RNA probe that hybridizes to a
15 complementary sequence. One of skill in the art would know how to design such a probe so that sequence specific hybridization will occur only if a particular allele is present in a genomic sequence from a test sample. The invention can also be reduced to practice using any convenient genotyping method, including commercially available technologies and methods for genotyping particular polymorphic markers.

20 Susceptibility to schizophrenia can be determined by a hybridization sample can be formed by contacting the test sample containing schizophrenia-associated nucleic acid, such as a genomic DNA sample, with at least one nucleic acid probe. A non-limiting example of a probe for detecting mRNA or genomic DNA is a labeled nucleic acid probe that is capable of hybridizing to mRNA or genomic DNA sequences described herein. The nucleic acid probe can be, for example,
25 a full-length nucleic acid molecule, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length that is sufficient to specifically hybridize under stringent conditions to appropriate mRNA or genomic DNA. For example, the nucleic acid probe can comprise all or a portion of the nucleotide sequence of chromosomal segments comprising the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2
30 deletion, the chromosome 15q13.3 deletion or the chromosome 16p13.1 duplication, as described herein, or the probe can be the complementary sequence of such a sequence. Other suitable probes for use in the diagnostic assays of the invention are described herein. Hybridization can be performed by methods well known to the person skilled in the art (see, e.g., Current Protocols in Molecular Biology, Ausubel, F. *et al.*, eds., John Wiley & Sons, including all
35 supplements). In one embodiment, hybridization refers to specific hybridization, i.e., hybridization with no mismatches (exact hybridization). In one embodiment, the hybridization conditions for specific hybridization are high stringency.

Specific hybridization, if present, is detected using standard methods. If specific hybridization occurs between the nucleic acid probe and the nucleic acid in the test sample, then the sample

- contains the sequence that is complementary to the nucleotide that is present in the nucleic acid probe. If the nucleic acid probe contains a particular allele of a polymorphic marker, or particular alleles for a plurality of markers, then specific hybridization is indicative of the nucleic acid being completely complementary to the nucleic acid probe, including the particular alleles at polymorphic markers within the probe. It is also possible to design a single probe containing more than one marker alleles of a particular haplotype (e.g., a probe containing alleles complementary to 2, 3, 4, 5 or all of the markers that make up a particular haplotype). Detection of the particular markers of the haplotype in the sample is indicative that the source of the sample has the particular haplotype (e.g., a haplotype).
- 10 In one preferred embodiment of allele-specific hybridization, a method utilizing a detection oligonucleotide probe comprising a fluorescent moiety or group at its 3' terminus and a quencher at its 5' terminus, and an enhancer oligonucleotide, is employed, as described by Kutayavin *et al.* (*Nucleic Acid Res.* 34:e128 (2006)). The fluorescent moiety can be Giga Harbor Green or Yakima Yellow, or other suitable fluorescent moieties. The detection probe is designed to hybridize to a
- 15 short nucleotide sequence that includes the SNP polymorphism to be detected. Preferably, the SNP is anywhere from the terminal residue to -6 residues from the 3' end of the detection probe. The enhancer is a short oligonucleotide probe which hybridizes to the DNA template 3' relative to the detection probe. The probes are designed such that a single nucleotide gap exists between the detection probe and the enhancer nucleotide probe when both are bound to the template.
- 20 The gap creates a synthetic abasic site that is recognized by an endonuclease, such as Endonuclease IV. The enzyme cleaves the dye off the fully complementary detection probe, but cannot cleave a detection probe containing a mismatch. Thus, by measuring the fluorescence of the released fluorescent moiety, assessment of the presence of a particular allele defined by nucleotide sequence of the detection probe can be performed.
- 25 The detection probe can be of any suitable size, although preferably the probe is relatively short. In one embodiment, the probe is from 5-100 nucleotides in length. In another embodiment, the probe is from 10-50 nucleotides in length, and in another embodiment, the probe is from 12-30 nucleotides in length. Other lengths of the probe are possible and within scope of the skill of the average person skilled in the art.
- 30 In a preferred embodiment, the DNA template containing the SNP polymorphism is amplified by Polymerase Chain Reaction (PCR) prior to detection. In such an embodiment, the amplified DNA serves as the template for the detection probe and the enhancer probe.
- Certain embodiments of the detection probe, the enhancer probe, and/or the primers used for amplification of the template by PCR include the use of modified bases, including modified A and
- 35 modified G. The use of modified bases can be useful for adjusting the melting temperature of the nucleotide molecule (probe and/or primer) to the template DNA, for example for increasing the melting temperature in regions containing a low percentage of G or C bases, in which modified A with the capability of forming three hydrogen bonds to its complementary T can be

used, or for decreasing the melting temperature in regions containing a high percentage of G or C bases, for example by using modified G bases that form only two hydrogen bonds to their complementary C base in a double stranded DNA molecule. In a preferred embodiment, modified bases are used in the design of the detection nucleotide probe. Any modified base
5 known to the skilled person can be selected in these methods, and the selection of suitable bases is well within the scope of the skilled person based on the teachings herein and known bases available from commercial sources as known to the skilled person.

Additionally, or alternatively, a peptide nucleic acid (PNA) probe can be used in addition to, or instead of, a nucleic acid probe in the hybridization methods described herein. A PNA is a DNA
10 mimic having a peptide-like, inorganic backbone, such as N-(2-aminoethyl)glycine units, with an organic base (A, G, C, T or U) attached to the glycine nitrogen via a methylene carbonyl linker (see, for example, Nielsen, P., *et al.*, *Bioconjug. Chem.* 5:3-7 (1994)). The PNA probe can be designed to specifically hybridize to a molecule in a sample suspected of containing one or more of the marker alleles or haplotypes that are associated with schizophrenia. Hybridization of the
15 PNA probe is thus diagnostic for a susceptibility to schizophrenia.

In one embodiment of the invention, a test sample containing genomic DNA obtained from the subject is collected and the polymerase chain reaction (PCR) is used to amplify a fragment of nucleic acid that comprises one or more polymorphic marker that is indicative of a susceptibility to schizophrenia. As described herein, identification of a particular marker alleles can be
20 accomplished using a variety of methods (e.g., sequence analysis, analysis by restriction digestion, specific hybridization, single stranded conformation polymorphism assays (SSCP), electrophoretic analysis, etc.). In another embodiment, diagnosis is accomplished by expression analysis, for example by using quantitative PCR (kinetic thermal cycling). This technique can, for example, utilize commercially available technologies, such as TaqMan® (Applied Biosystems,
25 Foster City, CA). The technique can assess the presence of an alteration in the expression or composition of a polypeptide or splicing variant(s) that is encoded by a nucleic acid associated with schizophrenia. Further, the expression of the variant(s) can be quantified as physically or functionally different.

In another embodiment of the methods of the invention, analysis by restriction digestion can be
30 used to detect a particular allele if the allele results in the creation or elimination of a restriction site relative to a reference sequence. Restriction fragment length polymorphism (RFLP) analysis can be conducted, e.g., as described in Current Protocols In Molecular Biology, *supra*. The digestion pattern of the relevant DNA fragment indicates the presence or absence of the particular allele in the sample.

35 Sequence analysis can also be used to detect specific alleles or haplotypes associated. Therefore, in one embodiment, determination of the presence or absence of a particular marker alleles or haplotypes comprises sequence analysis of a test sample of DNA or RNA obtained from a subject or individual. PCR or other appropriate methods can be used to amplify a portion of a

nucleic acid comprising at least one polymorphic marker, and the presence of a specific allele can then be detected directly by sequencing the polymorphic site (or multiple polymorphic sites in a haplotype) of the genomic DNA in the sample.

- In another embodiment, arrays of oligonucleotide probes that are complementary to target
 5 nucleic acid sequence segments from a subject, can be used to identify polymorphisms in a nucleic acid. For example, an oligonucleotide array can be used. Oligonucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. These arrays can generally be produced using mechanical synthesis methods or light directed synthesis methods that incorporate a combination of
 10 photolithographic methods and solid phase oligonucleotide synthesis methods, or by other methods known to the person skilled in the art (see, e.g., Blier, F.F., *et al. Adv Biochem Eng Biotechnol* 109:433-53 (2008); Hohelsel, J.D., *Nat Rev Genet* 7:200-10 (2006); Fan, J.B., *et al. Methods Enzymol* 410:57-73 (2006); Raquousis, J. & Elvidge, G., *Expert Rev Mol Diagn* 6:145-52 (2006); Mockler, T.C., *et al Genomics* 85:1-15 (2005), and references cited therein, the entire
 15 teachings of each of which are incorporated by reference herein). Many additional descriptions of the preparation and use of oligonucleotide arrays for detection of polymorphisms can be found, for example, in US 6,858,394, US 6,429,027, US 5,445,934, US 5,700,637, US 5,744,305, US 5,945,334, US 6,054,270, US 6,300,063, US 6,733,977, US 7,364,858, EP 619 321, and EP 373 203, the entire teachings of which are incorporated by reference herein.
- 20 Other methods of nucleic acid analysis that are available to those skilled in the art can be used to detect a particular allele at a polymorphic site. Representative methods include, for example, direct manual sequencing (Church and Gilbert, *Proc. Natl. Acad. Sci. USA*, 81: 1991-1995 (1988); Sanger, F., *et al., Proc. Natl. Acad. Sci. USA*, 74:5463-5467 (1977); Beavis, *et al.*, U.S. Patent No. 5,288,644); automated fluorescent sequencing; single-stranded conformation
 25 polymorphism assays (SSCP); clamped denaturing gel electrophoresis (CDGE); denaturing gradient gel electrophoresis (DGGE) (Sheffield, V., *et al., Proc. Natl. Acad. Sci. USA*, 86:232-236 (1989)), mobility shift analysis (Orita, M., *et al., Proc. Natl. Acad. Sci. USA*, 86:2766-2770 (1989)), restriction enzyme analysis (Flavell, R., *et al., Cell*, 15:25-41 (1978); Geever, R., *et al., Proc. Natl. Acad. Sci. USA*, 78:5081-5085 (1981)); heteroduplex analysis; chemical mismatch
 30 cleavage (CMC) (Cotton, R., *et al., Proc. Natl. Acad. Sci. USA*, 85:4397-4401 (1985)); RNase protection assays (Myers, R., *et al., Science*, 230:1242-1246 (1985); use of polypeptides that recognize nucleotide mismatches, such as *E. coli* mutS protein; and allele-specific PCR.

- In another embodiment of the invention, diagnosis of schizophrenia can be made by examining expression and/or composition of a polypeptide encoded by a nucleic acid associated with
 35 schizophrenia in those instances where the copy number variation of the present invention results in a change in the composition or expression of the polypeptide. Thus, diagnosis of a susceptibility to schizophrenia can be made by examining expression and/or composition of one of these polypeptides, or another polypeptide encoded by a nucleic acid associated with schizophrenia, in those instances where the genetic marker or haplotype of the present invention

results in a change in the composition or expression of the polypeptide. The CNVs described herein that show association to schizophrenia may play a role through their effect on one or more of these nearby genes. For example, while not intending to be limited by theory, it is generally expected that a deletion of a chromosomal segment comprising a particular gene, or a
5 fragment of a gene, will either result in a altered composition or expression, or both, of the encoded protein. Likewise, duplications (or high number copy number variations, such as triplications, etc.) are in general expected to result in increased expression of encoded polypeptide. Other possible mechanisms affecting genes within CNV region include, e.g., effects on transcription, effects on RNA splicing, alterations in relative amounts of alternative splice
10 forms of mRNA, effects on RNA stability, effects on transport from the nucleus to cytoplasm, and effects on the efficiency and accuracy of translation.

Thus, in another embodiment, the CNV variants (or tagging markers or haplotypes) of the invention showing association to schizophrenia affect the expression of a gene within the CNV region, or a gene in LD with the CNV region. Certain CNV regions have flanking duplicated
15 segments, and genes within such segments can have altered expression and/or composition as a result of such genomic alterations. It is also well known that regulatory element affecting gene expression may be located far away, even as far as tenths or hundreds of kilobases away, from the promoter region of a gene. Thus, regulatory elements for genes that are located outside the CNV region may be located within the CNV, and thus be affected by the copy number variation.
20 It is thus contemplated that the detection of the CNVs described herein, or markers or haplotypes in LD with any one of those CNVs, can be used for assessing expression for one or more of associated genes.

A variety of methods can be used for detecting protein expression levels, including enzyme linked immunosorbent assays (ELISA), Western blots, immunoprecipitations and
25 immunofluorescence. A test sample from a subject is assessed for the presence of an alteration in the expression and/or an alteration in composition of the polypeptide encoded by a nucleic acid associated with schizophrenia. Such alteration can, for example, be an alteration in the quantitative polypeptide expression (i.e., the amount of polypeptide produced). An alteration in the composition of a polypeptide can be an alteration in the qualitative polypeptide expression
30 (e.g., expression of a mutant polypeptide or of a different splicing variant). In one embodiment, diagnosis of a susceptibility to schizophrenia is made by detecting a particular splicing variant encoded by a nucleic acid associated with schizophrenia, or a particular pattern of splicing variants.

Both such alterations (quantitative and qualitative) can also be present. An "alteration" in the
35 polypeptide expression or composition, as used herein, refers to an alteration in expression or composition in a test sample, as compared to the expression or composition of the polypeptide in a control sample. A control sample is a sample that corresponds to the test sample (e.g., is from the same type of cells), and is from a subject who is not affected by, and/or who does not have a susceptibility to, or who has not been diagnosed with schizophrenia. In one embodiment, the

control sample is from a subject that does not have a particular CNV (or a marker allele or haplotype in LD therewith) associated with schizophrenia, as described herein. Similarly, the presence of one or more different splicing variants in the test sample, or the presence of significantly different amounts of different splicing variants in the test sample, as compared with the control sample, can be indicative of a susceptibility to schizophrenia. An alteration in the expression or composition of the polypeptide in the test sample, as compared with the control sample, can be the result of a particular CNV. Various means of examining expression or composition of a polypeptide encoded by a nucleic acid are known to the person skilled in the art and can be used, including spectroscopy, colorimetry, electrophoresis, isoelectric focusing, and immunoassays (e.g., David *et al.*, U.S. Pat. No. 4,376,110) such as immunoblotting (see, e.g., Current Protocols in Molecular Biology, particularly chapter 10, *supra*).

For example, in one embodiment, an antibody (e.g., an antibody with a detectable label) that is capable of binding to a particular target polypeptide (e.g., a polypeptide encoded by a nucleic acid associated with a CNV as described herein) can be used. Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (e.g., Fv, Fab, Fab', F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a labeled secondary antibody (e.g., a fluorescently-labeled secondary antibody) and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin.

In one embodiment of this method, the level or amount of polypeptide in a test sample is compared with the level or amount of the polypeptide in a control sample. A level or amount of the polypeptide in the test sample that is higher or lower than the level or amount of the polypeptide in the control sample, such that the difference is statistically significant, is indicative of an alteration in the expression of the polypeptide encoded by the nucleic acid, and is diagnostic for a particular allele or haplotype responsible for causing the difference in expression. Alternatively, the composition of the polypeptide in a test sample is compared with the composition of the polypeptide in a control sample. In another embodiment, both the level or amount and the composition of the polypeptide can be assessed in the test sample and in the control sample.

In another embodiment, the diagnosis of a susceptibility to schizophrenia is made by detecting at least one marker or haplotype in LD with at least one CNV of the present invention, in combination with an additional protein-based, RNA-based or DNA-based assay.

Kits

Kits useful in the methods of the invention comprise components useful in any of the methods described herein, including for example, primers for nucleic acid amplification, hybridization probes for CNV or other marker detection, restriction enzymes (e.g., for RFLP analysis), nucleic acid probes, optionally labelled with suitable labels (e.g., fluorescent labels), allele-specific oligonucleotides (e.g., SNP-allele specific, or CNV-allele specific probes), antibodies that bind to an altered polypeptide encoded by a nucleic acid of the invention as described herein or to a non-altered (native) polypeptide encoded by a nucleic acid of the invention as described herein, means for amplification of CNVs or fragments of CNVs as described herein, means for analyzing the nucleic acid sequence of nucleic acids comprising CNVs as described herein, means for analyzing the amino acid sequence of a polypeptide encoded by a CNV, or a nucleic acid associated with (in LD with) a CNV, etc. The kits can for example include necessary buffers, nucleic acid primers for amplifying nucleic acids, and reagents for allele-specific detection of the fragments amplified using such primers and necessary enzymes (e.g., DNA polymerase). Additionally, kits can provide reagents for assays to be used in combination with the methods of the present invention, e.g., reagents for use with other diagnostic assays for schizophrenia.

In one embodiment, the invention pertains to a kit for assaying a sample from a subject to detect the presence of a CNV, wherein the kit comprises reagents necessary for selectively detecting at least one particular CNV in the genome of the individual. In another embodiment, the invention pertains to a kit for assaying a sample from a subject to detect the presence of at least one particular allele of at least one polymorphism associated with a CNV in the genome of the individual. In a particular embodiment, the reagents comprise at least one contiguous oligonucleotide that hybridizes to a fragment of the genome of the individual comprising at least one CNV, or at least one polymorphism in LD with a CNV. In another embodiment, the reagents comprise at least one pair of oligonucleotides that hybridize to opposite strands of a genomic segment obtained from a subject, wherein each oligonucleotide primer pair is designed to selectively amplify a fragment of the genome of the individual that includes at least one CNV, or a fragment of a CNV. In certain embodiments, the fragment is at least 20 nucleotides in size. In other embodiments, the fragment is at least 30 nucleotides in size, at least 50 nucleotides in size, at least 100 nucleotides in size, at least 200 nucleotides in size, at least 300 nucleotides in size, at least 500 nucleotides in size, at least 1000 nucleotides in size, at least 5000 nucleotides in size, or at least 10000 nucleotides in size. It is however contemplated that the fragment can be of any other suitable size appropriate for use in kits useful to practice the present invention. Such oligonucleotides or nucleic acids (e.g., labelled oligonucleotide probes, oligonucleotide primers) can be designed using portions of the nucleic acid sequence of a CNV, or of a genomic region of a CNV that is LD with the CNV (e.g., a flanking region of a CNV). In another embodiment, the kit comprises one or more labeled nucleic acids capable of allele-specific detection of one or more specific polymorphic markers or haplotypes in LD with a CNV, and reagents for detection of the label. Suitable labels include, e.g., a radioisotope, a fluorescent label, an enzyme label, an enzyme co-factor label, a magnetic label, a spin label, an epitope label.

In one preferred embodiment, the kit for detecting SNP markers comprises a detection oligonucleotide probe, that hybridizes to a segment of template DNA containing a SNP polymorphisms to be detected, an enhancer oligonucleotide probe and an endonuclease. As explained in the above, the detection oligonucleotide probe comprises a fluorescent moiety or group at its 3' terminus and a quencher at its 5' terminus, and an enhancer oligonucleotide, is employed, as described by Kutayavin *et al.* (*Nucleic Acid Res.* 34:e128 (2006)). The fluorescent moiety can be GIG Harbor Green or Yakima Yellow, or other suitable fluorescent moieties. The detection probe is designed to hybridize to a short nucleotide sequence that includes the SNP polymorphism to be detected. Preferably, the SNP is anywhere from the terminal residue to -6 residues from the 3' end of the detection probe. The enhancer is a short oligonucleotide probe which hybridizes to the DNA template 3' relative to the detection probe. The probes are designed such that a single nucleotide gap exists between the detection probe and the enhancer nucleotide probe when both are bound to the template. The gap creates a synthetic abasic site that is recognized by an endonuclease, such as Endonuclease IV. The enzyme cleaves the dye off the fully complementary detection probe, but cannot cleave a detection probe containing a mismatch. Thus, by measuring the fluorescence of the released fluorescent moiety, assessment of the presence of a particular allele defined by nucleotide sequence of the detection probe can be performed.

The detection probe can be of any suitable size, although preferably the probe is relatively short. In one embodiment, the probe is from 5-100 nucleotides in length. In another embodiment, the probe is from 10-50 nucleotides in length, and in another embodiment, the probe is from 12-30 nucleotides in length. Other lengths of the probe are possible and within scope of the skill of the average person skilled in the art.

In a preferred embodiment, the DNA template containing the SNP polymorphism is amplified by Polymerase Chain Reaction (PCR) prior to detection, and primers for such amplification are included in the reagent kit. In such an embodiment, the amplified DNA serves as the template for the detection probe and the enhancer probe.

In one embodiment, the DNA template is amplified by means of Whole Genome Amplification (WGA) methods, prior to assessment for the presence of specific polymorphic markers as described herein. Standard methods well known to the skilled person for performing WGA may be utilized, and are within scope of the invention. In one such embodiment, reagents for performing WGA are included in the reagent kit.

Certain embodiments of the detection probe, the enhancer probe, and/or the primers used for amplification of the template by PCR include the use of modified bases, including modified A and modified G. The use of modified bases can be useful for adjusting the melting temperature of the nucleotide molecule (probe and/or primer) to the template DNA, for example for increasing the melting temperature in regions containing a low percentage of G or C bases, in which modified A with the capability of forming three hydrogen bonds to its complementary T can be

used, or for decreasing the melting temperature in regions containing a high percentage of G or C bases, for example by using modified G bases that form only two hydrogen bonds to their complementary C base in a double stranded DNA molecule. In a preferred embodiment, modified bases are used in the design of the detection nucleotide probe. Any modified base known to the skilled person can be selected in these methods, and the selection of suitable bases is well within the scope of the skilled person based on the teachings herein and known bases available from commercial sources as known to the skilled person.

In one of such embodiments, the presence of the marker or haplotype is indicative of a the presence of a particular CNV, and thus indicative of an increased susceptibility to schizophrenia. In another embodiment, the presence of the marker or haplotype is indicative of response to a therapeutic agent schizophrenia. In another embodiment, the presence of the marker or haplotype is indicative of prognosis of schizophrenia. In yet another embodiment, the presence of the marker or haplotype is indicative of progress of treatment of schizophrenia. Such treatment may include intervention by surgery, medication or by other means (e.g., lifestyle changes).

In a further aspect of the present invention, a pharmaceutical pack (kit) is provided, the pack comprising a therapeutic agent and a set of instructions for administration of the therapeutic agent to humans diagnostically tested for one or more variants (CNVs, or polymorphic markers in LD with certain CNVs) of the present invention, as disclosed herein. The therapeutic agent can be a small molecule drug, an antibody, a peptide, an antisense or RNAi molecule, or other therapeutic molecules. In one embodiment, an individual identified as a carrier of at least one variant of the present invention is instructed to take a prescribed dose of the therapeutic agent. In one such embodiment, an individual identified as a homozygous carrier of at least one variant of the present invention is instructed to take a prescribed dose of the therapeutic agent. In another embodiment, an individual identified as a non-carrier of at least one variant of the present invention is instructed to take a prescribed dose of the therapeutic agent.

In certain embodiments, the kit further comprises a set of instructions for using the reagents comprising the kit.

Therapeutic agents

The CNVs described herein can be used to identify novel therapeutic targets for schizophrenia. For example, genes containing, or in linkage disequilibrium with, the CNVs, or their products, as well as genes or their products that are directly or indirectly regulated by or interact with these variant genes or their products, can be targeted for the development of therapeutic agents to treat schizophrenia, or prevent or delay onset of symptoms associated with schizophrenia. Therapeutic agents may comprise one or more of, for example, small non-protein and non-

nucleic acid molecules, proteins, peptides, protein fragments, nucleic acids (DNA, RNA), PNA (peptide nucleic acids), or their derivatives or mimetics which can modulate the function and/or levels of the target genes or their gene products.

The nucleic acids and/or variants of the invention, or nucleic acids comprising their
5 complementary sequence, may be used as antisense constructs to control gene expression in cells, tissues or organs. The methodology associated with antisense techniques is well known to the skilled artisan, and is described and reviewed in *Antisense Drug Technology: Principles, Strategies, and Applications*, Crooke, ed., Marcel Dekker Inc., New York (2001). In general, antisense nucleic acid molecules are designed to be complementary to a region of mRNA
10 expressed by a gene, so that the antisense molecule hybridizes to the mRNA, thus blocking translation of the mRNA into protein. Several classes of antisense oligonucleotide are known to those skilled in the art, including cleavers and blockers. The former bind to target RNA sites, activate intracellular nucleases (e.g., RNaseH or RNase L), that cleave the target RNA. Blockers bind to target RNA, inhibit protein translation by steric hindrance of the ribosomes. Examples of
15 blockers include nucleic acids, morpholino compounds, locked nucleic acids and methylphosphonates (Thompson, *Drug Discovery Today*, 7:912-917 (2002)). Antisense oligonucleotides are useful directly as therapeutic agents, and are also useful for determining and validating gene function, for example by gene knock-out or gene knock-down experiments. Antisense technology is further described in Lavery *et al.*, *Curr. Opin. Drug Discov. Devel.* 6:561-
20 569 (2003), Stephens *et al.*, *Curr. Opin. Mol. Ther.* 5:118-122 (2003), Kurreck, *Eur. J. Biochem.* 270:1628-44 (2003), Dias *et al.*, *Mol. Cancer Ther.* 1:347-55 (2002), Chen, *Methods Mol. Med.* 75:621-636 (2003), Wang *et al.*, *Curr. Cancer Drug Targets* 1:177-96 (2001), and Bennett, *Antisense Nucleic Acid Drug Dev.* 12:215-24 (2002)

The variants described herein can be used for the selection and design of antisense reagents that
25 are specific for particular variants (e.g., particular CNVs, or polymorphic markers in LD with particular CNVs). Using information about the variants described herein, antisense oligonucleotides or other antisense molecules that specifically target mRNA molecules that contain one or more variants of the invention can be designed. In this manner, expression of mRNA molecules that contain one or more variant of the present invention (markers and/or
30 haplotypes) can be inhibited or blocked. In one embodiment, the antisense molecules are designed to specifically bind a particular allelic form (i.e., one or several variants (alleles and/or haplotypes)) of the target nucleic acid, thereby inhibiting translation of a product originating from this specific allele or haplotype, but which do not bind other or alternate variants at the specific polymorphic sites of the target nucleic acid molecule.

35 As antisense molecules can be used to inactivate mRNA so as to inhibit gene expression, and thus protein expression, the molecules can be used to treat a disease or disorder, such as schizophrenia. The methodology can involve cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Such mRNA regions include, for example, protein-coding

regions, in particular protein-coding regions corresponding to catalytic activity, substrate and/or ligand binding sites, or other functional domains of a protein.

The phenomenon of RNA interference (RNAi) has been actively studied for the last decade, since its original discovery in *C. elegans* (Fire *et al.*, *Nature* 391:806-11 (1998)), and in recent years its potential use in treatment of human disease has been actively pursued (reviewed in Kim & Rossi, *Nature Rev. Genet.* 8:173-204 (2007)). RNA Interference (RNAi), also called gene silencing, is based on using double-stranded RNA molecules (dsRNA) to turn off specific genes. In the cell, cytoplasmic double-stranded RNA molecules (dsRNA) are processed by cellular complexes into small interfering RNA (siRNA). The siRNA guide the targeting of a protein-RNA complex to specific sites on a target mRNA, leading to cleavage of the mRNA (Thompson, *Drug Discovery Today*, 7:912-917 (2002)). The siRNA molecules are typically about 20, 21, 22 or 23 nucleotides in length. Thus, one aspect of the invention relates to isolated nucleic acid molecules, and the use of those molecules for RNA interference, i.e. as small interfering RNA molecules (siRNA). In one embodiment, the isolated nucleic acid molecules are 18-26 nucleotides in length, preferably 19-25 nucleotides in length, more preferably 20-24 nucleotides in length, and more preferably 21, 22 or 23 nucleotides in length.

Another pathway for RNAi-mediated gene silencing originates in endogenously encoded primary microRNA (pri-miRNA) transcripts, which are processed in the cell to generate precursor miRNA (pre-miRNA). These miRNA molecules are exported from the nucleus to the cytoplasm, where they undergo processing to generate mature miRNA molecules (miRNA), which direct translational inhibition by recognizing target sites in the 3' untranslated regions of mRNAs, and subsequent mRNA degradation by processing P-bodies (reviewed in Kim & Rossi, *Nature Rev. Genet.* 8:173-204 (2007)).

Clinical applications of RNAi include the incorporation of synthetic siRNA duplexes, which preferably are approximately 20-23 nucleotides in size, and preferably have 3' overlaps of 2 nucleotides. Knockdown of gene expression is established by sequence-specific design for the target mRNA. Several commercial sites for optimal design and synthesis of such molecules are known to those skilled in the art.

Other applications provide longer siRNA molecules (typically 25-30 nucleotides in length, preferably about 27 nucleotides), as well as small hairpin RNAs (shRNAs; typically about 29 nucleotides in length). The latter are naturally expressed, as described in Amarzguloui *et al.* (*FEBS Lett.* 579:5974-81 (2005)). Chemically synthetic siRNAs and shRNAs are substrates for *in vivo* processing, and in some cases provide more potent gene-silencing than shorter designs (Kim *et al.*, *Nature Biotechnol.* 23:222-226 (2005); Siolas *et al.*, *Nature Biotechnol.* 23:227-231 (2005)). In general siRNAs provide for transient silencing of gene expression, because their intracellular concentration is diluted by subsequent cell divisions. By contrast, expressed shRNAs mediate long-term, stable knockdown of target transcripts, for as long as transcription of the

shRNA takes place (Marques *et al.*, *Nature Biotechnol.* 23:559-565 (2006); Brummelkamp *et al.*, *Science* 296: 550-553 (2002)).

Since RNAi molecules, including siRNA, miRNA and shRNA, act in a sequence-dependent manner, variants described herein can be used to design RNAi reagents that recognize specific nucleic acid molecules comprising specific CNVs, alleles and/or haplotypes, while not recognizing nucleic acid molecules not comprising the CNV, or comprising other alleles or haplotypes. These RNAi reagents can thus recognize and destroy the target nucleic acid molecules. As with antisense reagents, RNAi reagents can be useful as therapeutic agents (i.e., for turning off disease-associated genes or disease-associated gene variants), but may also be useful for characterizing and validating gene function (e.g., by gene knock-out or gene knock-down experiments).

Delivery of RNAi may be performed by a range of methodologies known to those skilled in the art. Methods utilizing non-viral delivery include cholesterol, stable nucleic acid-lipid particle (SNALP), heavy-chain antibody fragment (Fab), aptamers and nanoparticles. Viral delivery methods include use of lentivirus, adenovirus and adeno-associated virus. The siRNA molecules are in some embodiments chemically modified to increase their stability. This can include modifications at the 2' position of the ribose, including 2'-O-methylpurines and 2'-fluoropyrimidines, which provide resistance to RNase activity. Other chemical modifications are possible and known to those skilled in the art.

The following references provide a further summary of RNAi, and possibilities for targeting specific genes using RNAi: Kim & Rossi, *Nat. Rev. Genet.* 8:173-184 (2007), Chen & Rajewsky, *Nat. Rev. Genet.* 8: 93-103 (2007), Reynolds, *et al.*, *Nat. Biotechnol.* 22:326-330 (2004), Chi *et al.*, *Proc. Natl. Acad. Sci. USA* 100:6343-6346 (2003), Vickers *et al.*, *J. Biol. Chem.* 278:7108-7118 (2003), Agami, *Curr. Opin. Chem. Biol.* 6:829-834 (2002), Lavery, *et al.*, *Curr. Opin. Drug Discov. Devel.* 6:561-569 (2003), Shi, *Trends Genet.* 19:9-12 (2003), Shuey *et al.*, *Drug Discov. Today* 7:1040-46 (2002), McManus *et al.*, *Nat. Rev. Genet.* 3:737-747 (2002), Xia *et al.*, *Nat. Biotechnol.* 20:1006-10 (2002), Plasterk *et al.*, *curr. Opin. Genet. Dev.* 10:562-7 (2000), Boshier *et al.*, *Nat. Cell Biol.* 2:E31-6 (2000), and Hunter, *Curr. Biol.* 9:R440-442 (1999).

A genetic defect leading to increased predisposition or risk for development of a disease, including schizophrenia, or a defect causing the disease, may be corrected permanently by administering to a subject carrying the defect a nucleic acid fragment that incorporates a repair sequence that supplies the normal/wild-type nucleotide(s) at the site of the genetic defect. Such site-specific repair sequence may encompass an RNA/DNA oligonucleotide that operates to promote endogenous repair of a subject's genomic DNA. The administration of the repair sequence may be performed by an appropriate vehicle, such as a complex with polyethelenimine, encapsulated in anionic liposomes, a viral vector such as an adenovirus vector, or other pharmaceutical compositions suitable for promoting intracellular uptake of the administered nucleic acid. The genetic defect may then be overcome, since the chimeric oligonucleotides induce the incorporation of the normal sequence into the genome of the subject,

leading to expression of the normal/wild-type gene product. The replacement is propagated, thus rendering a permanent repair and alleviation of the symptoms associated with the disease or condition.

The present invention provides methods for identifying compounds or agents that can be used to
5 treat schizophrenia. Thus, the CNVs of the invention are useful as targets for the identification
and/or development of therapeutic agents. In certain embodiments, such methods include
assaying the ability of an agent or compound to modulate the activity and/or expression of a
nucleic acid that is associated with at least one CNV described herein, or the encoded product of
the nucleic acid. This in turn can be used to identify agents or compounds that inhibit or alter
10 the undesired activity or expression of the encoded nucleic acid product. Assays for performing
such experiments can be performed in cell-based systems or in cell-free systems, as known to
the skilled person. Cell-based systems include cells naturally expressing the nucleic acid
molecules of interest, or recombinant cells that have been genetically modified so as to express
a certain desired nucleic acid molecule.

15 Variant gene expression in a patient can be assessed by expression of a variant-containing
nucleic acid sequence (for example, a gene containing at least one variant of the present
invention, which can be transcribed into RNA containing the at least one variant, and in turn
translated into protein), or by altered expression of a normal/wild-type nucleic acid sequence
due to variants affecting the level or pattern of expression of the normal transcripts, for example
20 variants in the regulatory or control region of the gene. Assays for gene expression include
direct nucleic acid assays (mRNA), assays for expressed protein levels, or assays of collateral
compounds involved in a pathway, for example a signal pathway. Furthermore, the expression
of genes that are up- or down-regulated in response to the signal pathway can also be assayed.
One embodiment includes operably linking a reporter gene, such as luciferase, to the regulatory
25 region of the gene(s) of interest.

Modulators of gene expression can in one embodiment be identified when a cell is contacted with
a candidate compound or agent, and the expression of mRNA is determined. The expression
level of mRNA in the presence of the candidate compound or agent is compared to the
expression level in the absence of the compound or agent. Based on this comparison, candidate
30 compounds or agents for treating schizophrenia can be identified as those modulating the gene
expression of the variant gene. When expression of mRNA or the encoded protein is statistically
significantly greater in the presence of the candidate compound or agent than in its absence,
then the candidate compound or agent is identified as a stimulator or up-regulator of expression
of the nucleic acid. When nucleic acid expression or protein level is statistically significantly less
35 in the presence of the candidate compound or agent than in its absence, then the candidate
compound is identified as an inhibitor or down-regulator of the nucleic acid expression.

The invention further provides methods of treatment using a compound identified through drug (compound and/or agent) screening as a gene modulator (i.e. stimulator and/or inhibitor of gene expression).

5 *Methods of assessing probability of response to therapeutic agents, methods of monitoring progress of treatment and methods of treatment*

Currently, treatment options for schizophrenia include (i) medication, (ii) psychological and social intervention and (iii) other therapies.

- 10 *Medication:* The most common medication is antipsychotic medication, which mainly serves to reduce positive symptoms of the disease. Antipsychotic medications include Chlorpromazine (Largactil, Thorazine), Fluphenazine (Prolixin), Haloperidol (Haldol, Serenace), Molindone, Thiothixene (Navane), Thioridazine (Mellaril), Trifluoperazine (Stelazine), Loxapine (Loxapac, Loxitane), Perphenazine, Prochlorperazine (Compazine, Buccastem, Stemetil), Pimozide (Orap) and Zuclopenthixol (Clopixol). The newer atypical antipsychotic drugs are usually preferred for
- 15 initial treatment since they are often better tolerated and associated with lower rates of tardive dyskinesia, although they are more likely to induce weight gain and obesity-related diseases. Atypical antipsychotic drugs include clozapine (Clozaril), risperidone (Risperdal), Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Abilify), Paliperidone (Invega), Asenapine, Iloperidone (Zomaril), Sertindole (Serlect), Zotepine, Amisulpride,
- 20 Bifeprunox, Melperone. Response of symptoms to medication is variable; "Treatment-resistant schizophrenia" is a term used for the failure of symptoms to respond satisfactorily to at least two different antipsychotics. Patients in this category may be prescribed clozapine a medication of superior effectiveness but several potentially lethal side effects including agranulocytosis and myocarditis.

Psychological and social interventions: Psychotherapy is widely recommended and used in the treatment of schizophrenia, although services may often be confined to pharmacotherapy because of reimbursement problems or lack of training. Cognitive behavioral therapy (CBT) is used to reduce symptoms and improve related issues such as self-esteem, social functioning, and insight. Although the results of early trials were inconclusive, more recent reviews suggest that CBT can be an effective treatment for the psychotic symptoms of schizophrenia. Another approach is cognitive remediation therapy, a technique aimed at remediating the neurocognitive deficits sometimes present in schizophrenia. Based on techniques of neuropsychological rehabilitation, early evidence has shown it to be cognitively effective, with some improvements related to measurable changes in brain activation as measured by functional MRI. A similar approach known as cognitive enhancement therapy, which focuses on social cognition as well as neurocognition, has shown efficacy.

Family Therapy or Education, which addresses the whole family system of an individual with a diagnosis of schizophrenia, has been consistently found to be beneficial, at least if the duration of intervention is longer-term. Aside from therapy, the impact of schizophrenia on families and the burden on carers has been recognized, with the increasing availability of self-help books on the subject. There is also some evidence for benefits from social skills training, although there have also been significant negative findings. Some studies have explored the possible benefits of music therapy and other creative therapies.

The Soteria model is alternative to inpatient hospital treatment using a minimal medication approach. It is described as a milieu-therapeutic recovery method, characterized by its founder as "the 24 hour a day application of interpersonal phenomenologic interventions by a nonprofessional staff, usually without neuroleptic drug treatment, in the context of a small, homelike, quiet, supportive, protective, and tolerant social environment". Although research evidence is limited, a 2008 systematic review found the programme equally as effective as treatment with medication in people diagnosed with first and second episode schizophrenia.

Other treatment options: Electroconvulsive therapy is not considered a first line treatment but may be prescribed in cases where other treatments have failed. It is more effective where symptoms of catatonia are present, and is recommended for use under NICE guidelines in the UK for catatonia if previously effective, though there is no recommendation for use for schizophrenia otherwise. Psychosurgery has now become a rare procedure and is not a recommended treatment for schizophrenia. In one aspect of the invention, the patient's carrier status of any of the CNV risk variants described herein (or surrogate markers in LD with any one of the CNVs) is used to help determine whether a particular treatment modality for schizophrenia, such as any one of the above, or a combination thereof, should be administered. The value lies within the possibilities of being able to diagnose the disease at an early stage, and to select the most appropriate treatment at the earliest possible time point, so as to maximize the likelihood of positive response to the particular therapy.

The present invention also relates to methods of monitoring progress or effectiveness of a treatment option for schizophrenia. The treatment option may include any of the above-mentioned treatment options commonly used. This can be done based on the outcome of determination of the presence of a particular CNV risk variant in the individual, or a genetic marker in LD with the CNV, or by monitoring expression of genes that are associated with the variants (CNVs, or markers and haplotypes in LD therewith) of the present invention. The risk gene mRNA or the encoded polypeptide can be measured in a tissue sample (e.g., a peripheral blood sample, or a biopsy sample). Expression levels and/or mRNA levels can thus be determined before and during treatment to monitor its effectiveness. Alternatively, or concomitantly, the status with respect to a CNV, and or genotype and/or haplotype status of at least one risk variant for schizophrenia presented herein is determined before and during treatment to monitor its effectiveness.

Alternatively, biological networks or metabolic pathways related to the genes within, or associated with, the CNVs described herein can be monitored by determining mRNA and/or polypeptide levels. This can be done for example, by monitoring expression levels or polypeptides for several genes belonging to the network and/or pathway, in samples taken before and during treatment. Alternatively, metabolites belonging to the biological network or metabolic pathway can be determined before and during treatment. Effectiveness of the treatment is determined by comparing observed changes in expression levels/metabolite levels during treatment to corresponding data from healthy subjects.

In a further aspect, the CNVs described herein, or markers in LD therewith, can be used to increase power and effectiveness of clinical trials. Thus, individuals who are carriers of at least one at-risk CNV or a surrogate marker for the CNV may be more likely to respond to a particular treatment modality for schizophrenia. In one embodiment, individuals who carry at-risk variants for gene(s) in a pathway and/or metabolic network for which a particular treatment (e.g., small molecule drug) is targeting, are more likely to be responders to the treatment. In another embodiment, individuals who carry at-risk variants for a gene, which expression and/or function is altered by the at-risk variant, are more likely to be responders to a treatment modality targeting that gene, its expression or its gene product. This application can improve the safety of clinical trials, but can also enhance the chance that a clinical trial will demonstrate statistically significant efficacy, which may be limited to a certain sub-group of the population. Thus, one possible outcome of such a trial is that carriers of certain genetic variants, e.g., the markers and haplotypes of the present invention, are statistically significantly likely to show positive response to the therapeutic agent, i.e. experience alleviation of symptoms associated with schizophrenia when taking the therapeutic agent or drug as prescribed.

In a further aspect, the CNVs described herein can be used for targeting the selection of pharmaceutical agents for specific individuals. The pharmaceutical agent can be any of the agents described in the above (e.g., any of the typical and/or atypical antipsychotic medication described in the above). Personalized selection of treatment modalities, lifestyle changes or

combination of the two, can be realized by the utilization of the at-risk CNVs or surrogate markers in LD with the CNVs. Thus, the knowledge of an individual's status for particular CNVs can be useful for selection of treatment options, for example for treatments that target genes or gene products affected by one or more of the CNVs. Certain combinations of variants, including
5 those described herein, but also combinations with other risk variants for schizophrenia, may be suitable for one selection of treatment options, while other variant combinations may target other treatment options. Such combinations of variants may include one variant, two variants, three variants, or four or more variants, as needed to determine with clinically reliable accuracy the selection of treatment module.

10

Computer-implemented aspects

The CNVs shown herein to be associated with increased susceptibility (e.g., increased risk) of schizophrenia are in certain embodiments useful for interpretation and/or analysis of genotype data. Thus in certain embodiments, an identification of an at-risk allele for schizophrenia, as
15 shown herein, or an allele at a polymorphic marker in LD with any one of the markers shown herein to be associated with schizophrenia, is indicative of the individual from whom the genotype data originates is at increased risk of schizophrenia. In one such embodiment, genotype data is generated for at CNV shown herein to be associated with risk of schizophrenia, or at least one polymorphic marker in LD with the CNV. The genotype data can be subsequently
20 made available to a third person, for example the individual from whom the data originates, or a representative or guardian of the individual, a genotype service provider, a medical professional such as a medical doctor, a genetic counselor, an insurance provider, etc., for example via a user interface accessible over the internet, together with an interpretation of the genotype data, e.g., in the form of a risk measure (such as an absolute risk (AR), risk ratio (RR) or odds ratio (OR))
25 for the disease (e.g., schizophrenia). In another embodiment, at-risk variants (CNVs or markers in LD therewith) identified in a genotype dataset derived from an individual are assessed and results from the assessment of the risk conferred by the presence of such at-risk variants in the dataset are made available, for example via a secure web interface, or by other communication means. The results of such risk assessment can be reported in numeric form (e.g., by risk
30 values, such as absolute risk, relative risk, and/or an odds ratio, or by a percentage increase in risk compared with a reference), by graphical means, or by other means suitable to illustrate the risk to the individual from whom the genotype data is derived.

As understood by those of ordinary skill in the art, the methods and information described herein (CNV association with schizophrenia) may be implemented, in all or in part, as computer
35 executable instructions on known computer readable media. For example, the methods described herein may be implemented in hardware. Alternatively, the method may be implemented in software stored in, for example, one or more memories or other computer readable medium and implemented on one or more processors. As is known, the processors

may be associated with one or more controllers, calculation units and/or other units of a computer system, or implanted in firmware as desired. If implemented in software, the routines may be stored in any computer readable memory such as in RAM, ROM, flash memory, a magnetic disk, a laser disk, or other storage medium, as is also known. Likewise, this software
5 may be delivered to a computing device via any known delivery method including, for example, over a communication channel such as a telephone line, the Internet, a wireless connection, etc., or via a transportable medium, such as a computer readable disk, flash drive, etc.

More generally, and as understood by those of ordinary skill in the art, the various steps
10 described above may be implemented as various blocks, operations, tools, modules and techniques which, in turn, may be implemented in hardware, firmware, software, or any combination of hardware, firmware, and/or software. When implemented in hardware, some or all of the blocks, operations, techniques, etc. may be implemented in, for example, a custom integrated circuit (IC), an application specific integrated circuit (ASIC), a field programmable logic array (FPGA), a programmable logic array (PLA), etc.

15 When implemented in software, the software may be stored in any known computer readable medium such as on a magnetic disk, an optical disk, or other storage medium, in a RAM or ROM or flash memory of a computer, processor, hard disk drive, optical disk drive, tape drive, etc. Likewise, the software may be delivered to a user or a computing system via any known delivery method including, for example, on a computer readable disk or other transportable computer
20 storage mechanism.

Fig. 8 illustrates an example of a suitable computing system environment 100 on which a system for the steps of the claimed method and apparatus may be implemented. The computing system environment 100 is only one example of a suitable computing environment and is not intended to suggest any limitation as to the scope of use or functionality of the method or apparatus of
25 the claims. Neither should the computing environment 100 be interpreted as having any dependency or requirement relating to any one or combination of components illustrated in the exemplary operating environment 100.

The steps of the claimed method and system are operational with numerous other general purpose or special purpose computing system environments or configurations. Examples of well
30 known computing systems, environments, and/or configurations that may be suitable for use with the methods or system of the claims include, but are not limited to, personal computers, server computers, hand-held or laptop devices, multiprocessor systems, microprocessor-based systems, set top boxes, programmable consumer electronics, network PCs, minicomputers, mainframe computers, distributed computing environments that include any of the above
35 systems or devices, and the like.

The steps of the claimed method and system may be described in the general context of computer-executable instructions, such as program modules, being executed by a computer.

Generally, program modules include routines, programs, objects, components, data structures, etc. that perform particular tasks or implement particular abstract data types. The methods and apparatus may also be practiced in distributed computing environments where tasks are performed by remote processing devices that are linked through a communications network. In both integrated and distributed computing environments, program modules may be located in both local and remote computer storage media including memory storage devices.

With reference to Fig. 8, an exemplary system for implementing the steps of the claimed method and system includes a general purpose computing device in the form of a computer 110. Components of computer 110 may include, but are not limited to, a processing unit 120, a system memory 130, and a system bus 121 that couples various system components including the system memory to the processing unit 120. The system bus 121 may be any of several types of bus structures including a memory bus or memory controller, a peripheral bus, and a local bus using any of a variety of bus architectures. By way of example, and not limitation, such architectures include Industry Standard Architecture (ISA) bus, Micro Channel Architecture (MCA) bus, Enhanced ISA (EISA) bus, Video Electronics Standards Association (VESA) local bus, and Peripheral Component Interconnect (PCI) bus also known as Mezzanine bus.

Computer 110 typically includes a variety of computer readable media. Computer readable media can be any available media that can be accessed by computer 110 and includes both volatile and nonvolatile media, removable and non-removable media. By way of example, and not limitation, computer readable media may comprise computer storage media and communication media. Computer storage media includes both volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data. Computer storage media includes, but is not limited to, RAM, ROM, EEPROM, flash memory or other memory technology, CD-ROM, digital versatile disks (DVD) or other optical disk storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium which can be used to store the desired information and which can be accessed by computer 110. Communication media typically embodies computer readable instructions, data structures, program modules or other data in a modulated data signal such as a carrier wave or other transport mechanism and includes any information delivery media. The term "modulated data signal" means a signal that has one or more of its characteristics set or changed in such a manner as to encode information in the signal. By way of example, and not limitation, communication media includes wired media such as a wired network or direct-wired connection, and wireless media such as acoustic, RF, infrared and other wireless media. Combinations of the any of the above should also be included within the scope of computer readable media.

The system memory 130 includes computer storage media in the form of volatile and/or nonvolatile memory such as read only memory (ROM) 131 and random access memory (RAM) 132. A basic input/output system 133 (BIOS), containing the basic routines that help to transfer

information between elements within computer 110, such as during start-up, is typically stored in ROM 131. RAM 132 typically contains data and/or program modules that are immediately accessible to and/or presently being operated on by processing unit 120. By way of example, and not limitation, Fig. 8 illustrates operating system 134, application programs 135, other
5 program modules 136, and program data 137.

The computer 110 may also include other removable/non-removable, volatile/nonvolatile computer storage media. By way of example only, Fig. 8 illustrates a hard disk drive 140 that reads from or writes to non-removable, nonvolatile magnetic media, a magnetic disk drive 151 that reads from or writes to a removable, nonvolatile magnetic disk 152, and an optical disk
10 drive 155 that reads from or writes to a removable, nonvolatile optical disk 156 such as a CD ROM or other optical media. Other removable/non-removable, volatile/nonvolatile computer storage media that can be used in the exemplary operating environment include, but are not limited to, magnetic tape cassettes, flash memory cards, digital versatile disks, digital video tape, solid state RAM, solid state ROM, and the like. The hard disk drive 141 is typically
15 connected to the system bus 121 through a non-removable memory interface such as interface 140, and magnetic disk drive 151 and optical disk drive 155 are typically connected to the system bus 121 by a removable memory interface, such as interface 150.

The drives and their associated computer storage media discussed above and illustrated in Fig. 8, provide storage of computer readable instructions, data structures, program modules and other data for the computer 110. In Fig. 8, for example, hard disk drive 141 is illustrated as
20 storing operating system 144, application programs 145, other program modules 146, and program data 147. Note that these components can either be the same as or different from operating system 134, application programs 135, other program modules 136, and program data 137. Operating system 144, application programs 145, other program modules 146, and
25 program data 147 are given different numbers here to illustrate that, at a minimum, they are different copies. A user may enter commands and information into the computer 110 through input devices such as a keyboard 162 and pointing device 161, commonly referred to as a mouse, trackball or touch pad. Other input devices (not shown) may include a microphone, joystick, game pad, satellite dish, scanner, or the like. These and other input devices are often
30 connected to the processing unit 120 through a user input interface 160 that is coupled to the system bus, but may be connected by other interface and bus structures, such as a parallel port, game port or a universal serial bus (USB). A monitor 191 or other type of display device is also connected to the system bus 121 via an interface, such as a video interface 190. In addition to the monitor, computers may also include other peripheral output devices such as speakers 197
35 and printer 196, which may be connected through an output peripheral interface 190.

The computer 110 may operate in a networked environment using logical connections to one or more remote computers, such as a remote computer 180. The remote computer 180 may be a personal computer, a server, a router, a network PC, a peer device or other common network node, and typically includes many or all of the elements described above relative to the

computer 110, although only a memory storage device 181 has been illustrated in Fig. 8. The logical connections depicted in Fig. 8 include a local area network (LAN) 171 and a wide area network (WAN) 173, but may also include other networks. Such networking environments are commonplace in offices, enterprise-wide computer networks, intranets and the Internet.

- 5 When used in a LAN networking environment, the computer 110 is connected to the LAN 171 through a network interface or adapter 170. When used in a WAN networking environment, the computer 110 typically includes a modem 172 or other means for establishing communications over the WAN 173, such as the Internet. The modem 172, which may be internal or external, may be connected to the system bus 121 via the user input interface 160, or other appropriate
- 10 mechanism. In a networked environment, program modules depicted relative to the computer 110, or portions thereof, may be stored in the remote memory storage device. By way of example, and not limitation, Fig. 8 illustrates remote application programs 185 as residing on memory device 181. It will be appreciated that the network connections shown are exemplary and other means of establishing a communications link between the computers may be used.
- 15 Although the forgoing text sets forth a detailed description of numerous different embodiments of the invention, it should be understood that the scope of the invention is defined by the words of the claims set forth at the end of this patent. The detailed description is to be construed as exemplary only and does not describe every possibly embodiment of the invention because describing every possible embodiment would be impractical, if not impossible. Numerous
- 20 alternative embodiments could be implemented, using either current technology or technology developed after the filing date of this patent, which would still fall within the scope of the claims defining the invention.

- While the risk evaluation system and method, and other elements, have been described as preferably being implemented in software, they may be implemented in hardware, firmware,
- 25 etc., and may be implemented by any other processor. Thus, the elements described herein may be implemented in a standard multi-purpose CPU or on specifically designed hardware or firmware such as an application-specific integrated circuit (ASIC) or other hard-wired device as desired, including, but not limited to, the computer 110 of Fig. 8. When implemented in software, the software routine may be stored in any computer readable memory such as on a
- 30 magnetic disk, a laser disk, or other storage medium, in a RAM or ROM of a computer or processor, in any database, etc. Likewise, this software may be delivered to a user or a diagnostic system via any known or desired delivery method including, for example, on a computer readable disk or other transportable computer storage mechanism or over a communication channel such as a telephone line, the internet, wireless communication, etc.
- 35 (which are viewed as being the same as or interchangeable with providing such software via a transportable storage medium).

Thus, many modifications and variations may be made in the techniques and structures described and illustrated herein without departing from the spirit and scope of the present

Invention. Accordingly, it should be understood that the methods and apparatus described herein are illustrative only and are not limiting upon the scope of the invention.

Nucleic acids and polypeptides

5 The nucleic acids and polypeptides described herein can be used in methods and kits of the present invention. An "isolated" nucleic acid molecule, as used herein, is one that is separated from nucleic acids that normally flank the gene or nucleotide sequence (as in genomic sequences) and/or has been completely or partially purified from other transcribed sequences (e.g., as in an RNA library). For example, an isolated nucleic acid of the invention can be
10 substantially isolated with respect to the complex cellular milieu in which it naturally occurs, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstances, the material can be purified to essential homogeneity, for
15 example as determined by polyacrylamide gel electrophoresis (PAGE) or column chromatography (e.g., HPLC). An isolated nucleic acid molecule of the invention can comprise at least about 50%, at least about 80% or at least about 90% (on a molar basis) of all macromolecular species present. With regard to genomic DNA, the term "isolated" also can refer to nucleic acid molecules that are separated from the chromosome with which the genomic DNA is naturally
20 associated. For example, the isolated nucleic acid molecule can contain less than about 250 kb, 200 kb, 150 kb, 100 kb, 75 kb, 50 kb, 25 kb, 10 kb, 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of the nucleotides that flank the nucleic acid molecule in the genomic DNA of the cell from which the nucleic acid molecule is derived.

The nucleic acid molecule can be fused to other coding or regulatory sequences and still be
25 considered isolated. Thus, recombinant DNA contained in a vector is included in the definition of "isolated" as used herein. Also, isolated nucleic acid molecules include recombinant DNA molecules in heterologous host cells or heterologous organisms, as well as partially or substantially purified DNA molecules in solution. "Isolated" nucleic acid molecules also encompass *in vivo* and *in vitro* RNA transcripts of the DNA molecules of the present invention.
30 An isolated nucleic acid molecule or nucleotide sequence can include a nucleic acid molecule or nucleotide sequence that is synthesized chemically or by recombinant means. Such isolated nucleotide sequences are useful, for example, in the manufacture of the encoded polypeptide, as probes for isolating homologous sequences (e.g., from other mammalian species), for gene mapping (e.g., by *in situ* hybridization with chromosomes), or for detecting expression of the gene in tissue (e.g., human tissue), such as by Northern blot analysis or other hybridization
35 techniques.

The invention also pertains to nucleic acid molecules that hybridize under high stringency hybridization conditions, such as for selective hybridization, to a nucleotide sequence described herein (e.g., nucleic acid molecules that specifically hybridize to a nucleotide sequence containing a polymorphic site associated with a marker or haplotype described herein). Such

5 nucleic acid molecules can be detected and/or isolated by allele- or sequence-specific hybridization (e.g., under high stringency conditions). Stringency conditions and methods for nucleic acid hybridizations are well known to the skilled person (see, e.g., *Current Protocols in Molecular Biology*, Ausubel, F. et al, John Wiley & Sons, (1998), and Kraus, M. and Aaronson, S., *Methods Enzymol.*, 200:546-556 (1991), the entire teachings of which are incorporated by

10 reference herein.

The percent identity of two nucleotide or amino acid sequences can be determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first sequence). The nucleotides or amino acids at corresponding positions are then compared, and the percent identity between the two sequences is a function of the number of identical

15 positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions x 100). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, of the length of the reference sequence. The actual comparison of the two sequences can be accomplished by well-known methods, for example, using a mathematical

20 algorithm. A non-limiting example of such a mathematical algorithm is described in Karlin, S. and Altschul, S., *Proc. Natl. Acad. Sci. USA*, 90:5873-5877 (1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0), as described in Altschul, S. et al., *Nucleic Acids Res.*, 25:3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., NBLAST) can be used. See

25 the website on the world wide web at ncbi.nlm.nih.gov. In one embodiment, parameters for sequence comparison can be set at score=100, wordlength=12, or can be varied (e.g., W=5 or W=20). Another example of an algorithm is BLAT (Kent, W.J. *Genome Res.* 12:656-64 (2002)).

Other examples include the algorithm of Myers and Miller, CABIOS (1989), ADVANCE and ADAM as described in Torellis, A. and Robotti, C., *Comput. Appl. Biosci.* 10:3-5 (1994); and FASTA described in Pearson, W. and Lipman, D., *Proc. Natl. Acad. Sci. USA*, 85:2444-48 (1988). In

30 another embodiment, the percent identity between two amino acid sequences can be accomplished using the GAP program in the GCG software package (Accelrys, Cambridge, UK).

The present invention also provides isolated nucleic acid molecules that contain a fragment or portion that hybridizes under highly stringent conditions to a nucleic acid that comprises, or

35 consists of, the nucleotide sequence of the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion or the chromosome 16p13.1 duplication, or a nucleotide sequence comprising, or consisting of, the complement of the nucleotide sequence of the chromosome 1q21.1 deletion, the chromosome 5q35.2 duplication, the chromosome 15q11.2 deletion, the chromosome 15q13.3 deletion or the

chromosome 16p13.1 duplication, wherein the nucleotide sequence comprises at least one polymorphic allele contained in the markers and haplotypes described herein. The nucleic acid fragments of the invention are at least about 15, at least about 18, 20, 23 or 25 nucleotides, and can be 30, 40, 50, 100, 200, 500, 1000, 10,000 or more nucleotides in length.

- 5 The nucleic acid fragments of the invention are used as probes or primers in assays such as those described herein. "Probes" or "primers" are oligonucleotides that hybridize in a base-specific manner to a complementary strand of a nucleic acid molecule. In addition to DNA and RNA, such probes and primers include polypeptide nucleic acids (PNA), as described in Nielsen, P. *et al.*, *Science* 254:1497-1500 (1991). A probe or primer comprises a region of nucleotide
- 10 sequence that hybridizes to at least about 15, typically about 20-25, and in certain embodiments about 40, 50 or 75, consecutive nucleotides of a nucleic acid molecule. In one embodiment, the probe or primer comprises at least one allele of at least one polymorphic marker or at least one haplotype described herein, or the complement thereof. In particular embodiments, a probe or primer can comprise 100 or fewer nucleotides; for example, in certain embodiments from 6 to 50
- 15 nucleotides, or, for example, from 12 to 30 nucleotides. In other embodiments, the probe or primer is at least 70% identical, at least 80% identical, at least 85% identical, at least 90% identical, or at least 95% identical, to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence. In another embodiment, the probe or primer is capable of selectively hybridizing to the contiguous nucleotide sequence or to the complement of the
- 20 contiguous nucleotide sequence. Often, the probe or primer further comprises a label, e.g., a radioisotope, a fluorescent label, an enzyme label, an enzyme co-factor label, a magnetic label, a spin label, an epitope label.

- The nucleic acid molecules of the invention, such as those described above, can be identified and isolated using standard molecular biology techniques well known to the skilled person. The
- 25 amplified DNA can be labeled (e.g., radiolabeled, fluorescently labeled) and used as a probe for screening a cDNA library derived from human cells. The cDNA can be derived from mRNA and contained in a suitable vector. Corresponding clones can be isolated, DNA obtained following *in vivo* excision, and the cloned insert can be sequenced in either or both orientations by art-recognized methods to identify the correct reading frame encoding a polypeptide of the
- 30 appropriate molecular weight. Using these or similar methods, the polypeptide and the DNA encoding the polypeptide can be isolated, sequenced and further characterized.

Antibodies

- Polyclonal antibodies and/or monoclonal antibodies that specifically bind one form of the gene
- 35 product but not to the other form of the gene product are also provided. Antibodies are also provided which bind a portion of either the variant or the reference gene product that contains the polymorphic site or sites. The term "antibody" as used herein refers to immunoglobulin

molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain antigen-binding sites that specifically bind an antigen. A molecule that specifically binds to a polypeptide of the invention is a molecule that binds to that polypeptide or a fragment thereof, but does not substantially bind other molecules in a sample, *e.g.*, a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind to a polypeptide of the invention. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of a polypeptide of the invention. A monoclonal antibody composition thus typically displays a single binding affinity for a particular polypeptide of the invention with which it immunoreacts.

Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a desired immunogen, *e.g.*, polypeptide of the invention or a fragment thereof. The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules directed against the polypeptide can be isolated from the mammal (*e.g.*, from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, *e.g.*, when the antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein, *Nature* 256:495-497 (1975), the human B cell hybridoma technique (Kozbor *et al.*, *Immunol. Today* 4: 72 (1983)), the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, 1985, Inc., pp. 77-96) or trioma techniques. The technology for producing hybridomas is well known (see generally *Current Protocols in Immunology* (1994) Coligan *et al.*, (eds.) John Wiley & Sons, Inc., New York, NY). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds a polypeptide of the invention.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating a monoclonal antibody to a polypeptide of the invention (see, *e.g.*, *Current Protocols in Immunology*, *supra*; Galfre *et al.*, *Nature* 266:55052 (1977); R.H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); and Lerner, *Yale J. Biol. Med.* 54:387-402 (1981)). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods that also would be useful.

- Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody to a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide to thereby isolate immunoglobulin library members that bind the polypeptide. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™* Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs *et al.*, *Bio/Technology* 9: 1370-1372 (1991); Hay *et al.*, *Hum. Antibod. Hybridomas* 3:81-85 (1992); Huse *et al.*, *Science* 246: 1275-1281 (1989); and Griffiths *et al.*, *EMBO J.* 12:725-734 (1993).
- 15 Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art.
- 20 In general, antibodies of the invention (e.g., a monoclonal antibody) can be used to isolate a polypeptide of the invention by standard techniques, such as affinity chromatography or immunoprecipitation. A polypeptide-specific antibody can facilitate the purification of natural polypeptide from cells and of recombinantly produced polypeptide expressed in host cells. Moreover, an antibody specific for a polypeptide of the invention can be used to detect the polypeptide (e.g., in a cellular lysate, cell supernatant, or tissue sample) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. The antibody can be coupled to a detectable substance to facilitate its detection. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibodies may also be useful in pharmacogenomic analysis. In such embodiments, antibodies against variant proteins encoded by nucleic acids according to the invention, such as variant proteins that are encoded by nucleic acids that contain at least one polymorphic marker of the invention, can be used to identify individuals that require modified treatment modalities.

- 5 Antibodies can furthermore be useful for assessing expression of variant proteins in disease states, such as in active stages of a disease, or in an individual with a predisposition to a disease related to the function of the protein, in particular schizophrenia. Antibodies specific for a variant protein of the present invention that is encoded by a nucleic acid that comprises at least one polymorphic marker or haplotype as described herein can be used to screen for the presence
10 of the variant protein, for example to screen for a predisposition to schizophrenia as indicated by the presence of the variant protein.

- Antibodies can be used in other methods. Thus, antibodies are useful as diagnostic tools for evaluating proteins, such as variant proteins of the invention, in conjunction with analysis by electrophoretic mobility, isoelectric point, tryptic or other protease digest, or for use in other
15 physical assays known to those skilled in the art. Antibodies may also be used in tissue typing. In one such embodiment, a specific variant protein has been correlated with expression in a specific tissue type, and antibodies specific for the variant protein can then be used to identify the specific tissue type.

- Subcellular localization of proteins, including variant proteins, can also be determined using
20 antibodies, and can be applied to assess aberrant subcellular localization of the protein in cells in various tissues. Such use can be applied in genetic testing, but also in monitoring a particular treatment modality. In the case where treatment is aimed at correcting the expression level or presence of the variant protein or aberrant tissue distribution or developmental expression of the variant protein, antibodies specific for the variant protein or fragments thereof can be used to
25 monitor therapeutic efficacy.

- Antibodies are further useful for inhibiting variant protein function, for example by blocking the binding of a variant protein to a binding molecule or partner. Such uses can also be applied in a therapeutic context in which treatment involves inhibiting a variant protein's function. An antibody can be for example be used to block or competitively inhibit binding, thereby
30 modulating (i.e., agonizing or antagonizing) the activity of the protein. Antibodies can be prepared against specific protein fragments containing sites required for specific function or against an intact protein that is associated with a cell or cell membrane. For administration *in vivo*, an antibody may be linked with an additional therapeutic payload, such as radionuclide, an enzyme, an immunogenic epitope, or a cytotoxic agent, including bacterial toxins (diphtheria or plant toxins, such as ricin). The *in vivo* half-life of an antibody or a fragment thereof may be
35 increased by pegylation through conjugation to polyethylene glycol.

The present invention further relates to kits for using antibodies in the methods described herein. This includes, but is not limited to, kits for detecting the presence of a variant protein in a test sample. One preferred embodiment comprises antibodies such as a labelled or labelable antibody and a compound or agent for detecting variant proteins in a biological sample, means
5 for determining the amount or the presence and/or absence of variant protein in the sample, and means for comparing the amount of variant protein in the sample with a standard, as well as instructions for use of the kit.

The present invention will now be exemplified by the following non-limiting examples.

EXAMPLE 1. Large recurrent microdeletions at 1q21.1, 15q11.2 and 15q13.3 associated with Schizophrenia

Reduced fecundity, associated with severe mental disorders, places negative selection pressure on risk alleles and may explain in part why common variants have not been found conferring risk of disorders such as autism, schizophrenia and mental retardation. Thus, rare variants may account for a larger fraction of the overall genetic risk than previously assumed. In contrast to rare single nucleotide mutations, rare copy number variations (CNVs) can be detected using genome-wide SNP arrays. This has led to the identification of CNVs associated with mental retardation and autism.

- 10 The approach we employed here was to use a large population-based discovery sample to identify *de novo* CNVs, followed by testing for association in a sample of schizophrenia and psychoses patients (phase I) and finally replicating the most promising variants from phase I in a second larger sample (phase II). The discovery phase, where we searched for *de novo* CNVs, enriches for those regions that mutate most often. If the CNVs identified are in very low frequency in the population despite relatively high mutation rate ($> 1/10,000$ meiosis), they are likely to be under negative selection pressure. Such variants may confer risk of disorders that reduce the fecundity of those affected.

- To uncover *de novo* CNVs genome-wide we analyzed data from a population based sample (2,160 trios and 5,558 parent offspring pairs, none of which were known to have schizophrenia, Table 1) providing information on 9,878 transmissions. Of the 66 *de novo* CNVs identified, 23 were flanked by low copy repeats (LCRs) and nine additional had a LCR flanking only one of the deletion breakpoints. Of the remaining 34 CNVs (not flanked by LCRs), 27 were only found in a single control sample (the discovery trio) out of the 33,250 tested whereas 18 out of the 23 CNVs flanked by LCRs were found in higher frequency in the large control sample (Table 2).

- 25 The 66 CNVs were tested for association in our phase I sample of 1,433 schizophrenia and related psychoses patients and 33,250 controls from the SGENE consortium (<http://sgene.eu/>), all typed at deCODE genetics using the HumanHap300 chip. For eight of the 66 CNVs tested, at least one schizophrenia patient carried the CNV, and for three large deletions, nominal association with schizophrenia was detected (uncorrected P -value < 0.05 , Table 3). The three deletions nominally associating with schizophrenia in the first sample (Table 3) were followed up in as many as six samples consisting in total of 3,293 cases and 7,951 controls (Table 4). All three deletions, at 1q21.1, 15q11.2 and 15q13.3, significantly associate with schizophrenia and psychosis in the combined sample ($P=2.9 \times 10^{-5}$, OR=14.83, $P=6.0 \times 10^{-4}$, OR=2.73 and $P=5.4 \times 10^{-4}$, OR=11.51, respectively). Removing cases with psychosis, other than DSMIV and RDC defined schizophrenia (in total 161 cases, 49 with unspecified functional psychoses, 89 with schizoaffective disorder, 17 with schizophreniform and six with persistent delusional disorders), gave comparable results for the 1q21.1 deletion ($P=2.31 \times 10^{-5}$, OR =15.44) while the association for 15q11.2 and 15q13.3 deletions was no longer significant ($P=9.57 \times 10^{-4}$, OR=2.66, and

$P=1.02 \times 10^{-3}$, OR=11.29, respectively (uncorrected for 66 tests)). Historically, classification schemes tend to group diseases by their signs and symptoms. There is, however, no reason why the phenotypes associating with a particular CNV should be confined to the current nosological boundaries of any single psychiatric disorder. Our findings, in this respect, resemble those from the 16p11.2 deletion (Weiss, L. A. *et al.* Association between Microdeletion and Microduplication at 16p11.2 and Autism. *N Engl J Med* (2008)) and the translocation disrupting the *DISC1* gene in a large Scottish pedigree (Millar, J. K. *et al.* Disruption of two novel genes by a translocation co-segregating with schizophrenia. *Hum Mol Genet* 9, 1415-23 (2000)) and support the idea that the same mutation can increase risk of a broad range of clinical psychopathology. It is therefore worth noting that among the eight controls carrying the 15q13.3 deletion there is one autistic individual (there are samples from 299 autistic individuals among the 39,800 control samples genotyped for this CNV).

Eleven out of the 4,726 cases tested (0.23%) carry the 1q21.1 deletion compared to eight of the 41,199 controls tested (0.02%). In seven of the eleven patients, the deletion spans about 1.38 Mb (chr1:144,943,150-146,293,282). Four cases have a larger form of the deletion (Table 5). The larger form contains the shorter form and extends to 144,106,312 Mb, about 2.19 Mb (Figure 1A and Figure 2). Seven of the eight Icelandic controls have the shorter form of the deletion and one control has the longer form. Previously reported 1q21.1 deletions in two cases of mental retardation Inoue, K. & Lupski, J. R. Molecular mechanisms for genomic disorders. *Annu Rev Genomics Hum Genet* 3, 199-242 (2002), Lee, J. A., Carvalho, C. M. & Lupski, J. R. A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. *Cell* 131, 1235-47 (2007)), two autistic individuals (Ni, X. *et al.* Connexin 50 gene on human chromosome 1q21 is associated with schizophrenia in matched case control and family-based studies. *J Med Genet* 44, 532-6 (2007)) and one schizophrenia case (Walsh, T. *et al.* Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science* 320, 539-43 (2008)) are consistent with the shorter form of the deletion.

The 1.38 Mb deleted segment common to both the large and the small form of the 1q21.1 deletion is gene rich (Figure 1A). The *GJA8* gene has previously been reported as associated with schizophrenia (Ni, X. *et al.* Connexin 50 gene on human chromosome 1q21 is associated with schizophrenia in matched case control and family-based studies. *J Med Genet* 44, 532-6 (2007)). On the HumanHap300 chip there are no SNP markers within this gene that is located in a repeat region within the boundary of the 1.38 Mb deletion segment. In at least four reports (Brzustowicz, L. *et al.*, *Science* 288, 678-82 (2000); Gurling, H. M. *et al.*, *Am J Hum Genet* 68, 661-73 (2001); Hwu, H. G., *et al.*, *Mol Psychiatry* 8, 445-52 (2003); Zheng, Y. *et al.*, *Biochem Biophys Res Commun* 342, 1049-57 (2006)), the 1q21 locus has been linked to schizophrenia, however, the deletion is rare and therefore unlikely to account for much of the linkage previously reported. Analysis of cells from a case with the 1q21.1 deletion and a case with the reciprocal duplication, using FISH (Figure 3), show that other rearrangements, such as chromosomal translocations, are unlikely to be associated with the deletion.

The deletion at 15q11.2 was significant in the combined schizophrenia and related psychosis sample (Table 4). In the combined sample 26 of 4726 cases (0.55%) carry the deletion and 79 of 41,190 controls (0.19%). The deletion spans approximately 470 kb (chr15:20,306,549-20,777,695) and several genes are deleted (Figure 1B and Figure 4). A single case with mental retardation and severe speech impairment has previously been reported with the 15q11.2 deletion (Murthy, S. K. *et al.*, *Cytogenet Genome Res* 116, 135-40 (2007). Although the region is not Imprinted, it is deleted in a minority of cases of Angelman syndrome (AS) and Prader Willi syndrome (PWS). Recent analysis show that AS cases with class I deletions (includes the 15q11.2 deletion) are significantly more likely to meet criteria for autism. PWS type I deletions are associated with increased risk of preservative/obsessive compulsive behavior, deficits in adaptive skills and lower intellectual ability. Thus, the autistic features in AS and the preservative behavior of PWS may arise from deletion of the genes in the proximal portion of the region, the site at the breakpoints of the chromosome 15 deletions found in the current study. The gene deletions in the 15q11.2 region are most likely to be responsible for both the autistic and obsessive compulsive features observed in AS and PWS with class one deletions, and the schizophrenia phenotype in this study is *CYFIP1* (Figure 1C). *CYFIP1* interacts with fragile X mental retardation protein (FMRP) as well as with the Rho GTPase Rac1, which is involved in regulating axonal and dendritic outgrowth and the development and maintenance of neuronal structures. Over 30% of children with Fragile X syndrome meet criteria for autism (Rogers, S. J., *et al.*, The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. *J Dev Behav Pediatr* 22, 409-17 (2001)) with highest rates observed in cases with Prader Willi features without the deletion on 15q. Notably, the Fragile X mutation results in a reduction in expression levels of the *CYFIP1* gene (Nowicki, S. T. *et al.* The Prader-Willi phenotype of fragile X syndrome. *J Dev Behav Pediatr* 28, 133-8 (2007) and Fragile X syndrome behavioral abnormalities resemble features of schizophrenia. Fragile X syndrome is due to complete loss of function of FMRP, whereas the hemizygous deletion of *CYFIP1* would only cause partial disturbance of FMRP function, in which case an effect similar to that observed in Fragile X in females and obligate carriers might be expected. These women have attentional deficit and extreme shyness and anxiety, and they may also present with psychiatric disturbances of which psychotic behavior is the most frequent (Borghgraef, M., *et al.*, The female and the fragile X syndrome: data on clinical and psychological findings in 7 fra(X) carriers. *Clin Genet* 37, 341-6 (1990), Thompson, N. M. *et al.*, Neurobehavioral characteristics of CGG amplification status in fragile X females. *Am J Med Genet* 54, 378-83 (1994).

The 15q13.3 deletion is also significantly associated with schizophrenia and related psychoses in the combined samples (Table 4). Seven of 4,221 cases (0.17%) carry the deletion and 8 of 39,800 controls (0.02%). One of several affected genes (Figure 1C and Figure 5), the alpha7 nicotinic receptor gene (*CHRNA7*), is targeted to axons by Neuregulin 1 (Hancock, M. L., *et al.*, Presynaptic type III neuregulin1-ErbB signaling targets {alpha}7 nicotinic acetylcholine receptors to axons. *J Cell Biol* 181, 511-21 (2008), has been implicated in schizophrenia (Freedman, R. *et al.*, Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. *Proc Natl*

Acad Sci U S A 94, 587-92 (1997) and also in mental retardation (Sharp, A. J. *et al.*, Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. *Nat Genet* 38, 1038-42 (2006). Mice lacking the alpha7 subunit of the neural nicotinic receptor show a minor impairment in the matching-to-place task of the Morris water maze, taking longer to find the hidden platform than their wild type controls. This suggests a role for CHRNA7 in working/episodic memory and a potential role for CHRNA7 in schizophrenia and its endophenotypes (Fernandes, C., *et al.*, Performance deficit of alpha7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory. *Genes Brain Behav* 5, 433-40 (2006).

On the HumanHap300 array, 99 SNPs are affected by the deletion on 1q21.1, 54 by the 15q11.2 deletion and 166 by the 15q13.3 deletion. Statistically significant association, after correction for the number of tests performed, was not found with schizophrenia and individual SNPs at the three deletion loci, although some of the markers show nominally significant association (Tables 6 - 8). It is however possible that some of these markers represent real association signals that may show statistically significant association given a larger sample size. Furthermore, rare variants at these loci might still associate with schizophrenia as they are not tagged by markers on the HumanHap300 chip. Finding such variants probably requires re-sequencing of the deleted interval in a large sample of cases and testing identified variants for enrichment in schizophrenia.

From available records, we see that cases carrying the 1q21.1, 15q11.2 and 15q13.3 deletions have clinical response rates to neuroleptics that are comparable to the general schizophrenic patient population. Family history of schizophrenia in close relatives is also comparable to other schizophrenia patients in our sample (although these affected relatives are not available for genotyping) and there is no obvious sex bias, as both males and females carrying the deletions are affected. Assessment of cognitive abilities was only available for a fraction of the cases with deletions. None of the cases carrying the three deletions were known to be mentally retarded; however, three cases carrying the 1q21.1 deletion had learning disabilities and two controls had dyslexia (Tables 5, 9 and 10).

The frequency of the deletions identified here are comparable to the frequency of the VCFS deletion on 22q11, previously shown to associate with schizophrenia (Murphy, K. C. Schizophrenia and velo-cardio-facial syndrome. *Lancet* 359, 426-30 (2002), Ousley, O., *et al.*, A review of neurocognitive and behavioral profiles associated with 22q11 deletion syndrome: implications for clinical evaluation and treatment. *Curr Psychiatry Rep* 9, 148-58 (2007). The large VCFS deletion was present in eight out of 3,846 cases tested (0.2%) (Icelandic (N=1), Scottish (N=5), Dutch (N=1) and German (Bonn, N=1)) but was absent in 39,299 controls ($P=4.2 \times 10^{-5}$, OR=Inf).

Apart from association to schizophrenia, the deletions at 1q21.1, 15q11.2 and 15q13.3 also otherwise exhibited a pattern of negative selection. In the 33,090 Icelanders (648 schizophrenia patients and 32,442 controls) who are CNV typed, nine carry the deletion on 1q21.1 and 62

carry the deletion on 15q11.2. But not all of these cases resulted from 'first-generation' *de novo* events, i.e. some cases inherited the deletions from their parents. Specifically, by examining the haplotype (sequence of SNPs) background of the deletions and the known familial relationship between the carriers, we deduced that the nine 1q21.1 deletions correspond to six independent mutation/deletion events, the eight 15q13.3 deletions correspond to six independent mutation/deletion events and the 62 15q11.2 deletions correspond to approximately 32 separate events (It is noted that the 15q11.2 deletions in the four Icelandic schizophrenia cases correspond to four separate events, which are shared by a few of the controls). Two conclusions could be drawn from these observations. Firstly, carriers of these deletions are not infertile and, moreover, could pass on the deletion to their children. However, the probability that the carriers could pass on the deletion to a child appears to be substantially lower than that under a model of neutrality and fecundity of carriers therefore reduced. All three deletions, particularly the 15q11.2, occurred rather frequently as a *de novo* event. Assuming that the deletions do not repair themselves (or only doing so with very low probability) during successive meioses, being neutral, the deletions would be expected to have a much higher frequency in the population than observed. Consider the 15q11.2 deletion. When we study the carriers pair-wise, we found that if two carriers are separated by six meioses (second cousins) or less, their deletions are very likely to result from the same deletion event. For example, if two cousins both carry the deletion, they probably both inherited it from a common grandparent who is also a carrier. However, for two carriers that are separated by more than six meioses, it is nearly always that the deletions they carry are results from two separate deletion events. This implies that the deletions that we observe in carriers, if not first generation *de novo*, would only go back a few generations. If we assume that each deletion carried could be traced back on average five generations, the 62 carriers observed out of 33,090 would correspond to an estimated mutation/deletion rate of $62/(5 \times 33090 \times 2)$ (notice that the factor 2 comes in because a person carries two chromosomes), or about 1.9 events in 10,000. This is slightly higher, but not inconsistent, with the 1 in 9878 transmissions that we directly observed. Suppose we assume a mutation rate of 1 in 10,000. Notice that the chromosome a person carried would include all mutations that happened in its history. Even if we consider only the past 30 meioses (or tracing back to about 900 years ago), under a neutral model, the carrier frequency of 15q11.2 in the population would be expected to be around $30 \times (1/10,000) \times 2 = 0.006$, or about 198 carriers in 33090 individuals examined. This is substantially higher than the 62 carriers we actually observed.

We emphasize that the analysis described above is only meant to be descriptive. More rigorous investigation is needed to fully understand the selection pressure on the 1q21.1, 15q11.2 and 15q13.3 deletions. Given that the deletions are associated with schizophrenia patients, who are known to have fewer children than the general population, a pattern of negative selection might be expected. However, further negative selection pressure could result from reduced fecundity of carriers due to other phenotypes, and also transmission disequilibrium from carrier to child, i.e. the normal chromosome had a higher probability to be passed on than the chromosome with the deletion.

All the CNVs are flanked by large and complex LCRs sequences (Figures 2, 4 and 5). The LCR can mediate non-allelic homologous recombination (NAHR) which may result in loss or gain of genomic segments (Inoue, K. & Lupski, J. R. Molecular mechanisms for genomic disorders. *Annu Rev Genomics Hum Genet* 3, 199-242 (2002). Through this process CNVs under negative selection can be maintained at low frequency in the population. Other mechanisms for generating rearrangements (Lee, J. A. et al., A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. *Cell* 131, 1235-47 (2007)) cannot be excluded. For none of the deletions, associating with schizophrenia, are we able to pinpoint which LCRs are mediating the NAHR due to the complexity of the regions flanking the deletions. It is noteworthy that the same CNVs are implicated in schizophrenia and autism and an important area for future study is to determine whether deletions conferring schizophrenia-like syndrome should be considered as classical schizophrenia or a new microdeletion syndromes.

In the present study we searched for variants we think are most likely to confer risk of schizophrenia, namely large recurrent CNVs likely to be under negative selection pressure, rather than testing a large number of selectively neutral CNVs. It is important to identify all recurrent CNVs under negative selection and test those variants for enrichment in well powered samples of schizophrenia cases as well as cases of autism and mental retardation. To determine diagnostic and treatment implications it is also important to study the CNVs conferring risk with respect to drug response, disease progression and symptomatology. Two of the three deletions described here confer high risk of schizophrenia ($OR > 11$) whereas the third is more common and with modest risk ($OR = 2.73$). Already identified CNVs associating with schizophrenia may point the way towards underlying pathogenic pathways in the disease; furthermore, high resolution scans for copy number variants may well identify more CNVs associated with the disease, and given the high odds ratio, these are likely to be clinically useful in diagnosis and risk assessment. Although the CNVs reported here only account for a very small fraction of the genetic risk of schizophrenia this is an exciting step toward what promises to be a fruitful field for further investigation.

30 METHODS

Subjects. This study was approved by the National Bioethics Committees or the Local Research Ethical Committees and Data Protection Commissions or laws in the respective countries, Iceland, Scotland, UK, Germany, Finland, Italy, Denmark, Norway, The Netherlands and China. Informed consent was obtained from all patients. Of the 4,726 genotyped cases, 4,565 were diagnosed with schizophrenia, 49 with unspecified functional psychosis, 89 with schizoaffective disorder, 17 with schizophreniform and six with persistent delusional disorders.

Genotyping. The SGENE samples (samples from seven European groups, <http://www.SGENE.eu>) typed on the HumanHap300 chip, were used in phase I of the study (Table 3). In phase II, (Table 4) CNV data were derived from: the HumanHap300 chip, the HumanHap550 chip, the Affymetrix GeneChip(r) GenomeWide SNP 6.0 or dosage measured using Taqman probes (Bleche, I. *et al.*, Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. *Int J Cancer* 78, 661-6 (1998). The Scottish samples in Table 4, were typed at Duke University (HumanHap550) in collaboration with GSK as were 420 of the German samples all from Munich (HumanHap300). The remaining CNV data (HumanHap550) from Germany (Table 4, N=491) were obtained from the University of Bonn. Norwegian samples (Affymetrix GeneChip(r) GenomeWide SNP 6.0 array) were analyzed using the Affymetrix Power Tools 1.8.0. Dosage data for Danish and Chinese samples were generated at deCODE using Taqman assays (Bleche, I. *et al.* Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. *Int J Cancer* 78, 661-6 (1998)). Samples with CNVs were verified by genotyping respective samples using the HumanCNV370 chip.

Statistical analysis. For the genome-wide study of *de novo* CNV associating with schizophrenia the significance threshold was set at 7.6×10^{-4} , which is approximately 0.05/66, the number of *de novo* CNVs identified and tested. All *P*-values are two-sided and there is no overlap between samples in Tables 3 and 4. An exact conditional Cochran-Mantel-Haenszel test (conditional on the strata margins) was used to test for association of schizophrenia and the various CNVs.

De novo CNV analysis and Dosage measurements

De novo CNV analysis. To uncover *de novo* CNVs genome-wide we analyzed data from a population based sample of 2,160 trios and 5,558 parent offspring pairs, totaling 9,878 transmissions. Samples were genotyped using the Illumina HumanHap300 or the HumanCNV370 chips. To identify *de novo* deletions, we combined two complementary methods: DosageMiner, a Hidden Markov Model algorithm based on intensity data that is similar to that reported by Colella *et al.* (QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. *Nucleic Acids Res* 35, 2013-25 (2007)) and a procedure utilizing inheritance errors and the neighboring genotype configurations comparable to that described by Conrad *et al.* (A high-resolution survey of deletion polymorphism in the human genome. *Nat Genet* 38, 75-81 (2006)). When only one parent was typed, using genotype information allowed us to identify deletions as putatively *de novo* by assessment of regional parental heterozygosity. To identify *de novo* duplications we analyzed CNV data from the 2,160 trios using DosageMiner.

CNVs in phase I were identified by using the DosageMiner software developed by deCODE genetics and loss of heterozygosity analysis. CNV events stand out in the data from two perspectives. First, all sample intensities for SNPs/probes within a CNV should be increased or decreased relative to neighboring SNPs/probes that are not in a CNV region, secondly CNVs can be detected from the transmission from parent to child. To determine deviations in signal intensity we start by normalizing the intensities. The normalized intensities for each color channel were determined by a fit of the following equation:

$$\log(x_{ij}) = f(\alpha_i, gc(j)) + \mu_{j,gen(i,j)} + \beta_i + \varepsilon_{ij}$$

- where i is sample Index, j is SNP Index, x_{ij} is colour intensity for sample i in SNP j , $gc(j)$ is an Indicator of GC-content around SNP j , f is a smooth function of GC-content, α_i are sample specific parameters for GC content, $gen(i,j)$ is the genotype for sample i for SNP j , $\mu_{j,gt}$ is the SNP effect for genotype gt and SNP j , β_i is sample effect, ε_{ij} is the unexplained part of the signal, including noise. The same model with another set of parameters is used for the other colour y_{ij} . A generalized additive model (Hastie, T. a. T., R. Generalized additive models (with discussion). *Statist Sci* 1, 297-318 (1986)) is used to fit the smooth function f . After fitting the model, the data is normalized by removing the systematic model components. We consider a region to be a deletion/duplication if the average intensity over at least ten markers in a region falls below/above an empirically determined threshold.
- To identify regions demonstrating loss of heterozygosity (LOH) markers are split into three classes: 1) Shows LOH, 2) Inconsistent with LOH, 3) Consistent with LOH. Class 3 is further split into these subclasses: a) consistent with transmitted LOH b) consistent with *de novo* LOH. A marker shows LOH if a child is homozygous for one allele and a parent is homozygous for the other allele. A marker is inconsistent with LOH if the child is heterozygous. A marker is consistent with LOH if the child is homozygous and the parent is homozygous for the same allele or heterozygous. In case the parent is homozygous for the same allele as the child the marker is consistent with transmitted LOH and In case the parent is homozygous for the other allele the marker is only consistent with *de novo* LOH.

- A stretch containing a single marker showing LOH is likely be due to a genotyping error but as our genotyping error rate is low and independent of position on the genome the occurrence of more than one marker showing LOH in a consecutive stretch on the genome is more likely to be evidence of a deletion in the child. We consider a region to be a putative deletion if at least two markers are showing LOH and *de novo* if consistent with *de novo* LOH.

- We analyzed 9,878 offspring/parent pairs consisting of a total of 7,718 offspring and 7,121 parents. Using LOH analysis we define a candidate deleted region if more than one marker shows inheritance error within a region of homozygous markers. We identified a total of 270 candidate *de novo* deletions using this approach. Of these, 80 belong to six distinct individuals which all

had multiple regions identified as *de novo* deletions on the same chromosome. Upon further inspection of the data for these individuals we concluded that they were examples of uniparental disomy. Once these individuals were removed, the remaining 190 putative *de novo* deletions were compared with the output of DosageMiner, and 55 were consistently called deletions by both approaches. These 55 *de novo* deletions represent 51 loci. In addition 15 large duplications, of 20 or more consecutive markers, were also identified in the trio sample by DosageMiner.

Dosage measurements – Taqman. The Danish and Chinese samples in Table 4 were typed using Taqman assays (Bieche, I. *et al.*, Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. *Int J Cancer* 78, 661-6 (1998)). The 1q21.1 assay (PRK assay) and 15q11.2 (NIPA2 assay) were designed using Primer Express software. Applied Biosystems provided FAM labeled probes for the assay which were run as described by Bieche (Bieche, I. *et al.* Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. *Int J Cancer* 78, 661-6 (1998)). For the reference assay we used a probe in the CFTR gene and use the same protocol. The second reference assay, RNASEP ready to use assay, was supplied by Applied Biosystems (Foster City, CA, USA). Samples identified with deletions or duplications by the Taqman dosage measurements were confirmed by typing the sample on the Illumina HumanCNV370 array.

Probe and primers used for the 1q21.1 assay: 6FAM - CCTGCTGTGTGGGCT - MGB,

PRK - F CCTTCAGACCAGCGGATAACA and PRK-R CATGGCAGCAGGATTTGGA

Probe and primers used for the 15q11.2 assay: 6FAM - CAGAGCAGATTGTTATGTAC - MGB,

NIPA2 - F GACTGAAAACGCGCCGATT and NIPA2 - R CCATGGACAGACAAACATTCTTG

Probe and primers used for the CFTR assay: 6FAM - ATT AAG CAC AGT GGA AGA A - MGBNFQ, CFTR-F AACTGGAGCCTTCAGAGGGTAA and CFTR-R CCAGGAAAACCTGAGAACAGAATGA

Plates were sealed with optical adhesive cover (Applied Biosystems) and the Real time PCR carried out on an ABI 7900 HT machine, for 40 cycles of 15 seconds at 95° and 1 min at 60° starting out with an initial step of 10 min at 95°.

30 SUBJECTS AND ASCERTAINMENT

Iceland. The Icelandic sample consists of 646 schizophrenics and 32,442 controls. Patients and controls are all Icelandic and were recruited from all over Iceland. Diagnoses were assigned according to Research Diagnostic Criteria (RDC) (Spitzer, RL., *et al.* Research diagnostic criteria: rationale and reliability. *Arch Gen Psychiatry* 35, 773-82 (1978)) through the use of the lifetime

version of the Schizophrenia and Affective Disorders Schedule (SADS-L) (Spitzer RL., *et al.* *The schedule for affective disorders and schizophrenia, lifetime version*, New York State Psychiatric Institute, New York, 1977). Of the 646 subjects, 617 were diagnosed with schizophrenia, 24 with schizoaffective disorder and five with unspecified functional psychosis.

- 5 The 32,250 Icelandic controls used for this study were recruited as a part of various genetic programs at deCODE and were not screened for psychiatric disorders. The individuals came from genetic programs in the following diseases (approximate number of participants in brackets):
- 10 Abdominal Aortic Aneurism (400), Addiction (5400), Age-related Macular Degeneration (600), Alzheimer's Disease (700), Anxiety and Panic Disorder (1100), Asthma (1400), Attention Deficit Hyperactivity Disorder (500), Benign Prostatic Hyperplasia (900), Breast Cancer (1600), Chronic Obstructive Pulmonary Disease (900), Colon Cancer (1000), Coronary Artery Disease (4000), Deep Vein Thrombosis (1000), Dyslexia (700), Endometriosis (300), Enuresis (900), Obesity (800), Glaucoma (200), Hypertension (2400), Infectious Diseases (2500), Longevity (1600), Lung Cancer (300), Melanoma (500), Migraine (1300), Osteoarthritis (2600), Osteoporosis (3000), Polycystic Ovary Syndrome (1400), Peripheral Artery Disease (1500), Preeclampsia (800), Prostate Cancer (1400), Psoriasis (900), Restless Legs Syndrome (500), Rheumatoid Arthritis (700), Stroke (1900), Essential Tremor (400), Type II Diabetes (1500), Autism (299) and a set of population controls (900). Because some of the individuals used as controls were participants in more than one program, the numbers of participants in individual programs sum
- 20 to more than 32,442.

- Finland. The Finnish sample consists of 191 schizophrenics and 200 regionally selected controls that had no medical history of schizophrenia. Approximately half of the sample originated from an internal isolate of Finland having a 3 % age corrected lifetime risk for schizophrenia compared to the 1.1% of the general population. Two independent psychiatrist blind to family structures
- 25 made a consensus diagnosis to give a best-estimate lifetime diagnoses according to the criteria of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (*Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV)*, American Psychiatric Press, Inc, Washington DC, 1994).

- Scotland. The Scottish sample is comprised of 211 schizophrenia cases and 229 controls used in phase I and a replication cohort, 451 schizophrenia cases and 441 controls. All participants self-identified as born in the British Isles (95% in Scotland). All cases met DSM-IV and an ICD-10 criteria for schizophrenia. Diagnosis was made by OPCRIT. Controls were volunteers recruited through general practices in Scotland. Practice lists were screened for potentially suitable
- 30 volunteers by age and sex and by exclusion of subjects with major mental illness or use of antipsychotic medication.
- 35

UK. Samples from the UK subjects (N=105) were drawn from the Maudsley Family Study of psychosis (Rosa, A., *et al.* Further evidence that congenital dermatoglyphic abnormalities are associated with psychosis: a twin study. *Schizophr Bull* 28, 697-701 (2002)),

the psychosis twin study (Toulopoulou, T., *et al.* Episodic memory in schizophrenic patients and their relatives. *Schizophr Res* 63, 261-71 (2003)), and the genetics and psychosis (GAP) study. All controls were unrelated white European Caucasians (N=96). All patients were interviewed with the Schedule for Affective Disorders and Schizophrenia Lifetime Version (SADS-L; Endicott and Spitzer, 1978) which was supplemented with information from case notes and other relatives to assign a lifetime DSM-IV diagnosis of schizophrenia. The GAP cases were diagnosed using the Item Group Checklist (IGC) of the Schedule for Clinical Assessment in Neuropsychiatry (SCAN, Manual, World Health Organization, 1994). Only patients with an ICD-10 research diagnosis of schizophrenia were finally included as cases. Patients were receiving a variety of antipsychotic medications at the time of assessment. The study received approval from the Ethics Committee of the South London and Maudsley Trust and after complete description of the study to the participants, written informed consent was obtained.

Italy. Diagnosis of the 85 Italian subjects was identical to that for the GAP sample (See UK subjects). Patients with a diagnosis of psychotic disorders (ICD-10, F20-F25) attending the South Verona CMHS were identified from the South Verona Psychiatric Case Register, and cases with ICD-10 research diagnosis of schizophrenia were finally included. The controls (N=91) were unrelated volunteers randomly selected from the general population of South Verona. The study received ethical approval and after complete description of the study to the participants, written informed consent was obtained.

Germany - Munich. The Munich sample consisted of Caucasian 615 cases and 614 controls. Cases diagnosed with DSM-IV schizophrenia were ascertained from the Munich area in Germany. Samples from 195 cases and 192 controls were typed for phase I and the remaining samples used in the replication phase. Detailed medical and psychiatric histories were collected, including a clinical interview using the Structured Clinical Interview for Axis I DSM-IV Disorders (SCID) (First, MB., *et al.* *Structured Clinical Interview for Axis I DSM-IV Disorders*, Biometrics Research, New York, 1994). Exclusion criteria included a history of head injury or neurological diseases. The controls were unrelated volunteers randomly selected from the general population of Munich.

Germany - Bonn. The Bonn sample is comprised of 491 patients and 875 controls. Patients were recruited from consecutive hospital admissions and were all of German descent. In patients, lifetime best estimate diagnoses according to DSM-IV criteria were based on multiple sources of information including structured interview with the SCID (First, MB., *et al.* *Structured Clinical Interview for Axis I DSM-IV Disorders*, Biometrics Research, New York, 1994) or SADS-L (Endicott and Spitzer, 1978) the OPCRIT (McGuffin, P., *et al.* A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT

system. *Arch Gen Psychiatry* 48, 764-70 (1991)), medical records and the family history. Best estimate diagnoses were obtained from at least two experienced psychiatrists/psychologists. Controls were derived from two German population-based cohorts, PopGen (N=492) and Heinz Nixdorf Recall (N=383). Ethical approval was obtained from the local Ethics Committees. All participants gave written informed consent.

The Netherlands – Utrecht/ Nijmegen. The Dutch sample consisted of 806 patients and 706 controls from Utrecht and additional 3,333 control individuals from Nijmegen in the Netherlands. Inpatients and outpatients were recruited from different psychiatric hospitals and institutions throughout the Netherlands, coordinated via academic hospitals in Amsterdam, Groningen, Maastricht and Utrecht. Detailed medical and psychiatric histories were collected, including the Comprehensive Assessment of Symptoms and History (CASH), an instrument for assessing diagnosis and psychopathology. To exclude related patients and controls, all subjects were fingerprinted (Illumina DNA panel, 400 SNPs). Only patients with a DSM-IV diagnosis of schizophrenia were included as cases. All patients and controls were of Dutch descent, with at least three out of four grandparents of Dutch ancestry. The controls were volunteers and were free of any psychiatric history. Ethical approval was obtained from the local Ethics Committees. All participants gave written informed consent.

The additional controls consisted of 3,333 samples, collected by the Radboud University Nijmegen Medical Centre (RUNMC) for genetic studies (cancer and control samples). All 3,333 participants used in the present study are of self-reported European descent. The study protocol was approved by the Institutional Review Board of Radboud University and all study subjects gave written informed consent.

Denmark. The Danish sample included 442 patients who have been recruited to Danish Psychiatric Biobank from the psychiatric departments at the six hospitals in the Copenhagen region. All patients had been clinically diagnosed with schizophrenia according to ICD-10 (F20 and F25) without ever having received a diagnosis of mania or bipolar illness (F30-31). An experienced research- and consultant psychiatrist verified high reliability of the clinical diagnoses, using OPCRIT. Of the 442 patients 30 were schizoaffective, and six persistent delusional disorder. 994 healthy controls subjects were recruited through the Danish Blood Donor Corps in the Copenhagen area. Apparent behavioral abnormality was an exclusion criterion and all individuals stated that they felt completely healthy and were able to discuss health related issues with a physician. Additional 445 population control samples from the Copenhagen area Population controls were recruited by the Danish Headache Center. The Danish Scientific Committees and the Danish Data Protection Agency approved the study and all the patients have given written informed consent prior to inclusion into the project.

Norway. The Norwegian sample included 245 patients who had been recruited to the TOP study from all the psychiatric hospitals in the Oslo area. The patients were diagnosed according to Structural Clinical Interview for DSM-IV (SCID) as schizophrenia (N=154) schizoaffective (N=35), schizophreniform disorder (N=12) and psychosis NOS (N=44). The healthy control subjects (N=272) were randomly selected from statistical records of persons from the same catchments area as the patient groups. Only subjects born in Norway, all of Caucasian origin, were contacted by letter and invited to participate. All subjects have given written informed consent prior to inclusion into the project and The Norwegian Scientific-Ethical Committee and the Norwegian Data Protection Agency approved the study.

China. The Chinese sample was from Sichuan Province, Southwest China. Cases (N=438) were ascertained from West China Hospital, and were interviewed by a psychiatrist using the SCID. Diagnosis of schizophrenia was assigned on the basis of the interview and medical records according to DSM-IV criteria. Patients were excluded if they had a history of neurological disorders or head injury, or reported intellectual disability. The unrelated controls (N=463) were volunteers from the local population and were free of major mental illness. Ethical approval for the project was granted by West China Hospital and written informed consent was obtained from all participants.

The phase I samples were all typed at deCODE using the HumanHap300 chip. The additional samples (phase II) were typed at Duke University (HumanHap300 or HumanHap550), Bonn University (HumanHap550), UCLA (HumanHap550) and Expression Analysis, Durham (Affymetrix GeneChip(r) GenomeWide SNP 6.0 array) and at deCODE (Dosage analysis, Taqman assays). All subjects identified with a CNV using the Taqman assays were confirmed by typing the respective samples on HumanCNV370 chip. Data from the individual follow up (phase II) samples are shown in Table 4 and a summary of the samples used in the various stages of the study can be found in Table 1.

FLUORESCENT IN SITU HYBRIDIZATION (FISH)

FISH was carried out at deCODE genetics. Interphases were harvested according to standard CYTOGENETIC methods from human B-lymphoblastoid cell lines (EBV transformed) from six individuals, based on information from the Taqman dosage analysis done previously. We used two BAC probes, RP11-431G14 (covers PRK gene on chromosome 1q21) labelled with biotin (green) and an anchor BAC, RP11-458I7 labelled with digoxigenin (red). The BAC probes were labelled with either Biotin-16-dUTP or Digoxigenin-11-dUTP utilizing a nick translation kit (Roche Applied Science).

The hybridization procedure followed a standard protocol. In short the probes were denatured at 72°C for 5 minutes and pre-annealed at 37°C for 15 minutes, before being applied to denatured slides. The slides were denatured in 70% formamide at 70°C for 2 minutes, quenched in 2xSSC at 4°C and then dehydrated in an ethanol series. Following an overnight hybridization the slides

were washed in 50% formamide at 42°C for 10 minutes and 2xSSC at 42°C for 5 minutes. The biotinylated probe was detected with avidin/streptavidin FITC (Vector Lab) followed by a layer of biotinylated Anti Avidin (Vector Lab) and again one layer of avidin FITC was added. The digoxigenin probe was detected using Sheep anti Digoxigenin Rhodamine (Roche Applied science) followed by a layer of Donkey anti Sheep Texas red (Jackson Immuno Research). After 5 detection the interphases were counter-stained with $9 \times 10^{-3} \mu\text{g}$ 4',6-Diamidino-2-phenylindole Dihydrochloride:Hydrate (DAPI) (Sigma) in AF1 mounting medium (Citifluor). The digital imaging was done using a Zeiss AxioPlan 2 microscope with Asiocam MRm Zeiss camera, automatic Scanning System Metafer software from Metasystems.

Table 1. Summary of the samples used in the various stages of the study

Site	CNV Identification		Phase I		Phase II	
	Aff	Ctrl	Aff	Ctrl	Aff	Ctrl
Iceland	-	17596	646	32442	-	-
Scotland	-	-	211	229	451	441
Germany (Munich)	-	-	195	192	420	422
Germany (Bonn)	-	-	-	-	491	875
UK	-	-	105	96	-	-
The Netherlands	-	-	-	-	806	4039
Italy	-	-	85	91	-	-
Finland	-	-	191	200	-	-
Denmark	-	-	-	-	442	1439
Norway	-	-	-	-	245	272
China	-	-	-	-	438	463

Table 2. Low copy repeats flanking CNVs found *de novo*.

Of the 66 identified CNVs tested for association 23 are flanked by large repetitive segments (distal or proximal) likely to harbor LCRs. Those flanked by repetitive segments are in most cases seen in more (count) of the 32,442 controls tested. Reference is given where we have found the CNV in a CNV database. Coordinates are based on Build 36 of the human genome.

Iafrate: BAC microarray analysis of 236 putative CNP regions in 55 individuals⁹.

Tuzun: Fosmid mapping paired-end sequences from a human fosmid DN A library (297 ISV sites)¹⁰.

Redon: SNP and BAC microarray analysis of HapMap data phase II (270 Individuals)¹¹.

Locke: CNP in duplication-rich regions using array CGH in the HapMap populations (269 individuals)¹².

McCarroll: Deletions from analysis of SNP genotypes, using the HapMap Phase I data, release 16a. (269 individuals)¹³.

Chromosomal Regions in NCBI Build 36	CNV	Carriers found in Phase I	Number of flanking LCRs Distal Proximal		Homology	Reference if present in CNV databases
chr1:144943150..146293282	del	8	>5	>5	many different	
chr1:144943150..146293282	dup	12	>5	>5	many different	
chr1:241675290..241777030	del	1	-	>5	many different	
chr1:66487172..66981676	del	2	-	-		
chr2:19443..11594900	dup	1	-	-		
chr2:197605805..204072966	dup	1	-	-		
chr2:198783049..199060613	del	1	-	-		
chr2:239980943..242692820	del	1	-	1	99.30%	
chr2:50947040..51164471	del	1	-	-		
chr2:95514686..97033113	del	1	>5	-	many different	
chr3:174806420..176937369	del	1	-	-		
chr3:197326041..197704191	del	1	>5	>5	many different	Iafrate/Tuzun:196918333- 198862488
chr3:71223511..71819797	dup	1	-	-		
chr3:95019980..99373057	del	1	-	-		
chr3:97879021..101883423	del	1	-	-		
chr4:151856718..151884547	del	4	-	-		
chr5:34603067..34668956	del	1	>5	-	many different	
chr5:58116787..72845587	del	1	-	-		
chr6:162767020..162943840	del	35	-	-		Redon: 162760913-163153251
chr6:16699739..16803452	del	1	-	-		
chr7:146077700..147445123	del	1	4	-	98%	
chr7:149081..295765	del	1	-	-		Redon: 106472-298664
chr7:15609872..16251148	dup	1	-	-		
chr7:157553706..158812247	del	1	-	-		
chr7:5050267..5190933	del	1	-	2	99.1%	
chr7:5229720..5653268	dup	1	-	2	99.1%	Iafrate: 5431460-5671684
chr7:57212608..57659300	dup	74	>5	>5	many different	
chr7:72388281..73777987	del	1	>5	>5	many different	
chr7:83887393..85199723	del	1	-	-		
chr8:3931576..4252805	del	1	2	-	98.7	Iafrate:3586932-5909600 & 3611006-4928252 & 3671288-

chr9:194201..5739305	del	1	>5	-		
chr10:67880428..68013385	del	1	-	-		
chr10:7917790..8021528	del	2	-	-		
chr10:81567594..81962366	del	3	>5	>5	many different	
chr11:128201807..134435899	del	1	-	-		
chr11:84603291..85465999	dup	1	-	-		
chr12:115338506..115813464	dup	1	-	-		
chr12:98512325..98707024	del	1	-	-		
chr15:20306549..20777695	del	58	>5	>5	many different	Redon/lafrate: 18263733-21365850 & lafrate:18403666-21241985
chr15:20306549..20777695	dup	128	>5	>5	many different	Redon/lafrate: 18263733-21365850 & lafrate:18403666-21241985
chr15:20306549..26208861	dup	6	>5	>5	many different	
chr15:28723577..30302218	del	7	>5	>5	many different	
chr15:47635303..47679448	del	94	-	-		
chr16:15032942..16197033	del	10	>5	>5	many different	
chr16:21515973..21647775	del	31	>5	>5	many different	lafrate:21241957-21833734 & Tuzun:21485317-22595351 & Tuzun:21485317-22595351 & 21500522-22586272
chr16:21856623..22331199	del	17	>5	>5	many different	
chr16:29563365..30085308	del	11	>5	>5	many different	
chr16:77757915..78273834	del	1	-	-		
chr16:81429793..81491808	del	1	-	-		
chr16:86921984..87097884	del	1	-	-		Redon: 86986674-87137417
chr17:14041754..15390352	del	5	2	>5	many different	
chr17:15390352..20231611	del	1	>5	>5	many different	
chr17:31889664..33323543	dup	11	>5	>5	many different	
chr17:796976..1155912	del	1	2	4	many different	
chr17:9071043..9382978	del	1	-	-		
chr18:75020837..75408356	dup	1	-	-		
chr19:20844764..20914290	dup	6	2	1	98%	
chr19:267040..1822341	del	1	-	-		
chr19:54264641..54560863	del	1	>5	>5	many different	
chr20:14610721..14884935	del	1	-	-		
chr20:14849776..15034277	del	22	-	-		
chr20:14874333..15174767	del	5	-	-		
chr21:34846103..35391627	dup	1	-	-		
chr22:17257787..17373128	del	56	>5	>5	many different	lafrate: 16931796-17441713 & 17011366-17417535
chr22:19063495..19792353	del	3	>5	>5	many different	
chr22:21063401..21394287	del	3	>5	>5	many different	McCarroll: 21032391-21564096 & lafrate: 20487965-21442582 & 20759608-21442582 & 21032391-21564096

Table 3. Nominal association of deletions at 1q21.1, 15q11.2 and 15q13.3 with Schizophrenia in the phase I sample.

Three deletions show nominal association with schizophrenia and related psychoses in the first sample of 1433 patients and 33,250 controls. These deletions are large, the 1q21 deletion spans approximately 1.38 Mb, the one on 15q11.2 approximately 0.58 Mb and the one on 15q13.3 approximately 1.57 Mb. P-values (uncorrected for the 66 tests) are from the exact Cochran-Mantel-Haenszel test and are two-sided. Coordinates are based on Build 36 assembly of the human genome. 95% CI are given within brackets.

Locus	chr1:144.94-146.29		chr15:20.31-20.78		chr15:28.72-30.30	
	Aff	Ctrl	Aff	Ctrl	Aff	Ctrl
Iceland	1/646	8/32442	4/646	58/32442	1/646	7/32442
Scotland	2/211	0/229	2/211	0/229	1/211	0/229
Germany	1/195	0/192	3/195	0/192	1/195	0/192
UK	0/105	0/96	1/105	0/96	0/105	0/96
Italy	0/85	0/91	0/85	0/91	0/85	0/91
Finland	0/191	0/200	0/191	1/200	0/191	0/200
OR	8.68 (1.02, 49.76)		3.90 (1.42, 9.37)		8.94 (0.79, 58.15)	
P-value	0.024		0.007		0.040	

Table 4. Significant association of deletions at 1q21.1, 15q11.2 and 15q13.3 with Schizophrenia in the combined phase I and phase II samples

Locus	chr1:144.94-146.29		chr15:20.31-20.78		chr15:28.72-30.30	
	Aff	Ctrl	Aff	Ctrl	Aff	Ctrl
Germany	2/911	0/1297	3/911	4/1297	0/911	0/1297
Scotland	2/451	0/441	5/451	1/441	0/451	0/441
The Netherlands	0/806	0/4039	4/806	12/4039	3/806	1/4039
Norway	0/245	0/272	0/245	0/272	1/245	0/272
Denmark*	3/442	0/1437	4/442	3/1432	0/375	0/501
China*	0/438	0/463	0/438	0/463	na	na
Phase II						
OR	Inf (2.85, Inf)		2.18 (1.01, 4.60)		16.43 (1.51, 831.91)	
P-value	5.6x10 ⁻⁴		0.032		8.0x10 ⁻³	
Phase I & II						
OR	14.83 (3.55, 60.40)		2.73 (1.50, 4.89)		11.51 (2.51, 49.52)	
P-value	2.9x10 ⁻⁵		6.0x10 ⁻⁴		5.4x10 ⁻⁴	

Table 5. Diagnosis, family history, age of onset, response to neuroleptics based on available records and learning ability in cases carrying the 1q21.1 deletion associating with schizophrenia.

Case ID	Diagnosis	Family history	Age of onset	Gender	Response	Other
Munich 1	DSMIV:295.3	Yes	24	male	Yes	Aggressive, learning disability, Not MR
Bonn 1*	DSMIV:295.3	No	33	female	Yes	Not MR
Bonn 2	DSMIV:295.3	No	16	female	relapse under medication	Not MR, depressive symptoms
Iceland 1	RDC:126.3	No	26	female	Yes	Not MR
Scotland 1	DSMIV:295	No	43	female	Yes	Not MR
Scotland 2*	DSMIV:295	Yes	21	male	Yes	Not MR
Scotland 3*	DSMIV:295	No	32	male	Yes	Not MR, mother with low IQ
Scotland 4*	DSMIV:295	No	33	female	Yes	Not MR, borderline learning disability
Denmark 1	DSMIV: 295	Yes	24	female	Yes	Not MR
Denmark 2	DSMIV: 295	No	23	male	Yes	Boarderline metal retardation
Denmark 3	ICD10: Scz (F20)	No	20	male	No	Not MR

* There are two forms of the 1q21.1 deletion, long and short. Those marked with an asterisk in the table above have the larger form. MR=mentally retarded.

Table 6. Markers on the Illumina HumanHap300 within the 1q21.1 deletion. Shown are results of association of the markers with schizophrenia, and genes associated with the marker are also indicated. Data from 2,687 cases and 13,484 controls were used in the association analysis.

Marker	Allele	OR	P-value	Chr	Pos. In Build 36	Gene
rs12406844	C	1.14	0.001	1	145436035	
rs12141187	C	1.13	0.0023	1	145449387	
rs10465885	C	1.12	0.0033	1	145699364	GJA5
rs6684174	C	1.11	0.0067	1	145683484	
rs2644577	C	0.9	0.0075	1	145409110	
rs4950437	A	0.9	0.0076	1	145394019	OR13Z2P
rs952477	A	1.1	0.0113	1	145716820	GJA5
rs10793705	C	1.1	0.015	1	145706931	GJA5
rs4132958	C	1.09	0.0258	1	145430649	
rs12755965	C	0.92	0.03	1	145658465	
rs12022413	A	0.92	0.0328	1	145463869	BCL9
rs613089	C	1.09	0.0356	1	145547811	BCL9
rs4950322	A	1.1	0.0372	1	145321460	
rs10900321	C	0.92	0.0431	1	145096540	PRKAB2,LOC400780
rs1342709	C	1.08	0.0432	1	145744388	
rs3766510	A	0.89	0.0434	1	145596846	ACP6
rs4950361	A	1.09	0.0472	1	145025789	LOC441904,LOC440677
rs2236570	A	0.92	0.0495	1	145560511	BCL9
rs1932977	A	0.92	0.0603	1	145155565	FMO5
rs11240007	C	1.08	0.0662	1	145304073	
rs945742	A	0.93	0.0728	1	145251781	
rs4950402	G	1.08	0.0787	1	145258026	
rs903786	C	1.09	0.0839	1	145830625	LOC391092,GJA8
rs11240147	A	1.13	0.0856	1	145824905	LOC391092,GJA8
rs10494251	A	1.14	0.1012	1	145490518	BCL9
rs903784	A	0.92	0.102	1	145830723	LOC391092,GJA8
rs999095	A	0.92	0.1048	1	145676851	
rs11811023	C	1.07	0.1075	1	145047742	LOC440678
rs21327	C	1.07	0.1119	1	144995145	LOC440677
rs3820129	A	1.06	0.1145	1	145558596	BCL9
rs11239984	A	0.94	0.1174	1	145258353	
rs1417279	A	1.09	0.1212	1	145574517	BCL9
rs2883318	G	1.06	0.1216	1	145315767	
rs2353974	A	1.06	0.1297	1	145322880	
rs1932978	C	0.95	0.1532	1	145194387	CHD1L
rs12408395	A	1.07	0.1535	1	145372992	
rs11239953	T	1.06	0.1559	1	145184188	CHD1L
rs2275552	C	1.06	0.1566	1	145598569	ACP6
rs647596	G	1.05	0.1593	1	145002018	LOC440677
rs6593752	C	1.06	0.1766	1	145196592	CHD1L
rs2353986	C	0.95	0.1781	1	145286493	
rs2077749	A	1.05	0.181	1	145119261	PRKAB2, LOC400780,FMO5
rs11576760	C	1.09	0.1956	1	145806592	LOC391092
rs2353987	G	0.95	0.202	1	145294180	
rs4950328	C	1.05	0.2235	1	145471435	BCL9
rs2353544	A	0.95	0.2365	1	145515224	BCL9
rs2353983	C	1.04	0.2809	1	145279761	
rs7541090	C	1.04	0.3058	1	145353686	OR13Z1P
rs627219	G	0.92	0.3068	1	145539979	BCL9
rs10900403	G	0.95	0.3305	1	145807358	
rs2999613	A	1.06	0.3586	1	146286966	
rs10494246	A	1.1	0.3592	1	145614928	ACP6
rs2354432	A	1.05	0.3811	1	145159853	FMO5
rs885239	A	0.95	0.3831	1	145594226	ACP6
rs1353431	C	0.94	0.3928	1	145784604	LOC391092
rs1390510	A	1.07	0.3975	1	145497947	BCL9

Marker	Allele	OR	P-value	Chr	Pos. In Build 36	Gene
rs4950392	G	0.96	0.4064	1	145203172	CHD1L
rs10494245	A	1.04	0.4135	1	145637476	
rs1853782	C	1.04	0.43	1	144975398	LOC440677
rs4504949	A	1.06	0.4304	1	145368301	OR13Z2P
rs584323	C	0.97	0.4348	1	145442845	
rs1541187	A	1.04	0.4534	1	145518117	BCL9
rs1572825	A	0.97	0.4567	1	145473996	BCL9
rs6664767	G	1.03	0.4681	1	145776067	LOC391092
rs1814653	A	0.96	0.4757	1	146209659	LOC440679,LOC388684
rs894469	A	1.05	0.4853	1	145139530	FMO5
rs1015235	A	0.97	0.5032	1	145510166	BCL9
rs894467	C	0.94	0.5305	1	145128642	PRKAB2,FMO5
rs1908627	C	0.95	0.5319	1	145727389	GJA5
rs4950574	A	1.03	0.5358	1	146216845	LOC440679,LOC388684
rs6937	A	0.97	0.5686	1	145093546	PRKAB2
rs946904	C	0.98	0.5768	1	145589455	ACP6
rs2992453	A	0.98	0.5966	1	146253348	LOC440680
rs596561	C	0.97	0.611	1	145447612	
rs1353428	G	0.98	0.6115	1	145792846	
rs7526407	C	1.03	0.6163	1	145537233	BCL9
rs11804045	A	1.03	0.6551	1	145628401	ACP6
rs4950494	A	1.02	0.6672	1	145838200	LOC391092,GJA8
rs10494257	A	0.98	0.6923	1	145721193	GJA5
rs1495956	C	1.02	0.7095	1	145705110	GJA5
rs1344	A	1.01	0.7439	1	145585897	ACP6
rs12141387	A	1.01	0.7529	1	144970465	LOC440677
rs11261254	C	0.98	0.7631	1	146185099	
rs10494243	C	1.03	0.7723	1	145146427	FMO5
rs6593746	A	1.03	0.8049	1	145153273	FMO5
rs2932454	G	1.01	0.8354	1	146293282	FLJ39739,RNU1P10
rs12061877	C	0.99	0.8369	1	145730876	GJA5
rs1763457	C	0.99	0.8455	1	146262302	LOC440680
rs7530962	A	1.01	0.8523	1	145614797	ACP6
rs2452	A	0.99	0.8609	1	145220003	CHD1L
rs6693109	A	1.01	0.8686	1	145287960	
rs11240009	A	0.99	0.8697	1	145308966	
rs9661159	A	0.99	0.874	1	145224547	CHD1L
rs1001193	C	1.01	0.8784	1	145633001	
rs1857208	A	1.01	0.907	1	145758611	
rs671205	C	1	0.9479	1	144989346	LOC440677
rs2000072	A	1	0.9581	1	145437192	

Table 7. Markers on the Illumina HumanHap300 within the 15q11.2 deletion. Shown are results of association of the markers with schizophrenia, and genes associated with the marker are also indicated. Data from 2,687 cases and 13,484 controls were used in the association analysis.

Marker	Allele	OR	P-value	Chr	Pos. in Build 36	Gene
rs8029320	A	1.17	0.0008	15	20437666	CYFIP1
rs1897786	A	1.15	0.0061	15	20545323	CYFIP1
rs999842	C	0.91	0.0163	15	20551713	CYFIP1,NIPA2
rs4778413	C	1.09	0.0507	15	20560833	NIPA2,CYFIP1
rs6606817	C	1.08	0.0647	15	20567999	NIPA2
rs4778370	C	0.91	0.0764	15	20578289	NIPA2
rs8034210	C	0.93	0.081	15	20347960	
rs12911925	C	1.1	0.0917	15	20568493	NIPA2
rs4778334	A	0.93	0.11	15	20592297	
rs7168000	G	1.08	0.1283	15	20584567	CYFIP1,NIPA2
rs7170838	C	0.93	0.1334	15	20572679	NIPA2
rs4778464	A	0.93	0.1518	15	20537129	CYFIP1
rs2289819	C	0.93	0.1522	15	20512379	CYFIP1
rs4778575	T	0.95	0.2031	15	20605280	NIPA2,NIPA1
rs1009153	C	0.95	0.2039	15	20528352	CYFIP1
rs4293342	C	1.05	0.2069	15	20455753	CYFIP1
rs1991922	C	0.92	0.2168	15	20610835	NIPA1
rs12594495	A	1.05	0.2193	15	20499445	CYFIP1
rs7181789	A	0.96	0.2454	15	20595337	NIPA2,NIPA1
rs12441373	A	1.13	0.2619	15	20541359	CYFIP1
rs2289824	C	0.94	0.268	15	20477670	CYFIP1
rs2028794	A	0.96	0.2818	15	20470856	CYFIP1
rs2278458	A	0.9	0.3075	15	20551298	CYFIP1,NIPA2
rs8031642	C	1.04	0.3118	15	20351272	LOC390544
rs3693	A	1.04	0.329	15	20556334	CYFIP1,NIPA2
rs2289815	G	0.96	0.3483	15	20421301	TUBGCP5
rs4778470	C	0.96	0.3797	15	20523005	CYFIP1
rs7167658	C	1.04	0.421	15	20460862	CYFIP1
rs1347314	C	0.94	0.445	15	20585443	NIPA2,NIPA1
rs7168367	C	1.04	0.4805	15	20618177	NIPA1
rs5006363	A	0.95	0.4848	15	20398953	TUBGCP5
rs722410	A	1.03	0.4896	15	20475538	CYFIP1
rs765763	C	0.97	0.5022	15	20428330	TUBGCP5,CYFIP1
rs6606825	A	1.04	0.5038	15	20614243	NIPA1
rs4932679	C	1.03	0.5296	15	20322108	LOC390544
rs2289823	A	0.97	0.539	15	20479393	CYFIP1
rs956120	C	1.02	0.5545	15	20489279	CYFIP1
rs4592619	C	0.97	0.562	15	20585244	NIPA2,NIPA1
rs8040193	C	1.05	0.6146	15	20306549	LOC390544
rs7182576	G	0.98	0.6284	15	20546036	CYFIP1
rs1579821	C	1.02	0.6338	15	20501269	CYFIP1
rs3812924	A	1.02	0.6381	15	20599983	NIPA2,NIPA1
rs3751566	C	0.98	0.6918	15	20492111	CYFIP1
rs2304341	C	0.97	0.7614	15	20542471	CYFIP1
rs722411	A	1.01	0.7741	15	20475585	CYFIP1
rs7174982	C	1.01	0.8269	15	20517099	CYFIP1
rs7168653	C	0.99	0.8308	15	20516088	CYFIP1
rs3883043	A	1.01	0.8321	15	20777695	LOC339005
rs11636068	A	0.99	0.8639	15	20629449	NIPA1,LOC400320
rs8043036	A	1	0.9396	15	20434983	CYFIP1
rs1544285	A	1	0.9665	15	20405438	TUBGCP5
rs4778298	A	1	0.974	15	20505022	CYFIP1
rs11263687	G	1	0.9838	15	20635884	LOC400320,NIPA1
rs2289816	G	1	0.9906	15	20506454	CYFIP1

Table 8. Markers on the Illumina HumanHap300 within the 15q13.3 deletion. Shown are results of association of the markers with schizophrenia, and genes associated with the marker are also indicated. Data from 2,687 cases and 13,484 controls were used in the association analysis.

Marker	Allele	OR	P-value	Chr	Pos. In Build 36	Gene
rs1463408	A	0.88	0.0055	15	29243936	
rs12915265	C	0.89	0.0089	15	30196358	CHRNA7
rs8038654	C	0.83	0.0095	15	30072156	
rs10438342	A	0.91	0.0169	15	30189338	
rs4779824	C	0.91	0.0174	15	29191586	TRPM1
rs1223889	A	0.92	0.0243	15	29258764	
rs2241494	A	0.92	0.0301	15	29155896	TRPM1
rs10152238	A	1.15	0.0377	15	30057610	
rs1647992	A	0.91	0.0459	15	29245430	
rs4779984	A	0.89	0.052	15	30302218	
rs1863279	A	1.08	0.053	15	29282405	
rs1477534	A	0.93	0.0539	15	29271979	
rs4779536	A	1.08	0.0598	15	29574400	C15orf16
rs2651418	A	0.93	0.0642	15	30226573	CHRNA7
rs999876	A	0.93	0.0642	15	29272626	
rs7173280	C	0.93	0.0759	15	29128656	TRPM1
rs1035706	A	1.1	0.0795	15	29130377	TRPM1
rs1978801	A	0.94	0.088	15	29294328	LOC283710
rs919001	A	1.07	0.0893	15	29144430	TRPM1
rs6493543	G	0.94	0.0923	15	29324788	LOC283710
rs8042511	A	1.16	0.0971	15	29222034	
rs803534	C	0.94	0.1062	15	29215548	
rs6493688	A	0.94	0.1139	15	29560167	LOC400347,C15orf16
rs4779937	C	1.06	0.1178	15	29975287	
rs7162289	C	1.08	0.131	15	29373158	
rs1672407	C	1.06	0.1344	15	29227096	
rs12442141	C	1.16	0.1345	15	29266578	
rs1672409	A	0.95	0.1446	15	29228600	
rs1001555	A	1.12	0.1452	15	30080958	
rs1514254	A	0.94	0.1456	15	29998226	
rs1465778	C	1.06	0.146	15	29408613	KLF13
rs1580141	A	1.05	0.1981	15	29232062	
rs3784595	A	1.07	0.2043	15	29129507	TRPM1
rs6493540	A	1.05	0.2115	15	29321882	LOC283710
rs1465779	C	1.07	0.2226	15	29397182	KLF13
rs1865873	C	1.05	0.2226	15	29303300	LOC283710
rs2278133	A	1.05	0.2238	15	29140680	TRPM1
rs8034505	A	1.05	0.227	15	29460239	KLF13,LOC440262
rs2241493	C	1.06	0.2296	15	29149644	TRPM1
rs8035668	A	0.94	0.2296	15	30178638	CHRNA7
rs2879262	C	0.95	0.2459	15	29344873	
rs4417522	C	1.04	0.2735	15	29874412	
rs7179733	C	0.96	0.2814	15	30160985	CHRNA7
rs1459200	A	1.04	0.2991	15	29594877	C15orf16
rs2288242	A	1.05	0.3062	15	29117572	TRPM1
rs2338834	C	1.04	0.3069	15	29125017	TRPM1
rs890158	C	1.04	0.3097	15	29157929	TRPM1
rs12900301	C	0.95	0.3122	15	29619936	C15orf16
rs1503004	A	1.06	0.3286	15	29827425	
rs3964705	C	0.96	0.3343	15	28822861	LOC440261
rs6494039	C	1.07	0.3401	15	29979194	
rs12440180	C	1.04	0.3677	15	30072148	
rs1606659	A	0.96	0.3731	15	30119745	CHRNA7
rs4779939	C	0.95	0.3764	15	29985165	
rs4779814	C	0.97	0.3814	15	29143717	TRPM1
rs7169523	A	0.96	0.3831	15	29250670	
rs2137856	A	0.97	0.3882	15	30016646	
rs7163696	C	0.96	0.3902	15	29313681	LOC283710
rs11630449	C	0.96	0.3953	15	29402033	KLF13
rs7163763	A	0.94	0.3977	15	29609507	C15orf16

Marker	Allele	OR	P-value	Chr	Pos. In Build 36	Gene
rs953326	C	1.03	0.409	15	30004979	
rs3784601	C	0.96	0.4097	15	29180766	TRPM1
rs3096464	C	1.03	0.4122	15	29256215	
rs898212	G	1.03	0.4134	15	29579128	C15orf16
rs4779862	C	1.03	0.42	15	29420453	KLF13
rs4779759	A	1.03	0.4212	15	28751864	
rs1456212	A	1.05	0.4215	15	29211346	
rs3743234	A	1.03	0.4329	15	29126965	TRPM1
rs1459198	A	1.03	0.4337	15	29649740	C15orf16
rs12901022	C	0.97	0.4341	15	29100035	TRPM1
rs11638348	A	1.03	0.4352	15	29714219	C15orf16
rs1524878	G	1.03	0.437	15	28941992	
rs2125615	A	1.03	0.4493	15	29587441	C15orf16
rs2046362	C	0.97	0.4581	15	28723577	
rs8041717	G	1.03	0.4719	15	29063737	FLJ20313
rs4779816	A	0.97	0.473	15	29156415	TRPM1
rs3865090	C	1.06	0.4734	15	29319602	LOC283710
rs8026705	A	0.97	0.4835	15	29704566	C15orf16
rs16956362	A	1.07	0.4848	15	28986264	KIAA1018
rs12439925	C	1.03	0.4852	15	29386793	KLF13
rs9711330	C	1.03	0.4885	15	29538956	LOC400347
rs7174744	A	0.97	0.4961	15	28971039	KIAA1018,LOC388104
rs12442622	A	1.03	0.4971	15	30045195	
rs11071179	C	0.97	0.4975	15	29635750	C15orf16
rs7175258	A	1.04	0.518	15	29484934	LOC440262
rs2337980	C	0.98	0.5194	15	30231488	CHRNA7
rs10519712	A	1.03	0.523	15	29997162	
rs4779889	G	1.03	0.5245	15	29601495	C15orf16
rs7169662	A	0.98	0.5292	15	29438608	KLF13
rs11632955	C	0.98	0.54	15	29336409	
rs9672615	A	1.03	0.5436	15	30298847	
rs8025698	C	1.02	0.5444	15	29186010	TRPM1
rs7175507	C	1.02	0.5606	15	30007740	
rs6493623	A	1.03	0.5622	15	29444540	KLF13
rs4779809	C	0.98	0.5771	15	29131323	TRPM1
rs12439621	C	1.05	0.5937	15	30096476	CHRNA7
rs12442954	A	0.98	0.5955	15	30029658	
rs1060493	G	1.02	0.602	15	29303762	LOC283710
rs7402321	C	1.02	0.6061	15	30207700	CHRNA7
rs16956762	A	0.98	0.614	15	29539275	LOC400347
rs964925	C	1.02	0.6145	15	29093271	TRPM1
rs2337233	C	0.98	0.6206	15	30094507	CHRNA7
rs7182946	G	0.98	0.6232	15	29182160	TRPM1
rs7178760	C	0.97	0.6243	15	29318665	LOC283710
rs17228178	C	0.98	0.6295	15	29257220	
rs6493352	C	1.02	0.6331	15	29021356	FLJ20313,KIAA1018
rs11070871	C	0.97	0.6503	15	29299944	LOC283710
rs11636101	A	0.98	0.6721	15	30061449	
rs1524876	C	0.98	0.6726	15	29050564	FLJ20313
rs4779948	C	0.98	0.673	15	30046352	
rs8042404	A	0.98	0.6904	15	29467308	KLF13,LOC440262
rs2113945	C	0.98	0.6905	15	29111823	TRPM1
rs7174211	A	0.98	0.693	15	29425288	KLF13
rs1474380	A	0.98	0.6997	15	29056527	FLJ20313
rs2338679	A	0.99	0.7029	15	29608133	C15orf16
rs13329490	A	1.02	0.7102	15	30195523	CHRNA7
rs4321165	A	0.98	0.7117	15	29863575	LOC440263
rs12323980	C	0.97	0.7147	15	29363969	
rs4238558	A	0.99	0.7193	15	29933027	
rs11636160	C	0.98	0.7239	15	29489142	LOC440262
rs4268714	A	0.99	0.7304	15	29462745	KLF13,LOC440262
rs965435	C	1.02	0.74	15	30104501	CHRNA7
rs7167632	A	1.01	0.7425	15	29935438	
rs4779520	C	0.99	0.7456	15	29452735	KLF13

Marker	Allele	OR	P-value	Chr	Pos. In Build 36	Gene
rs8028220	A	1.01	0.7461	15	29214684	
rs12441324	A	1.01	0.7535	15	28830254	LOC440261
rs7182547	C	1.01	0.7558	15	29084964	FLJ20313,TRPM1
rs9302175	C	0.99	0.7596	15	29530870	LOC400347
rs2289126	G	0.99	0.771	15	29308957	LOC283710
rs798081	A	0.98	0.7775	15	28910527	LOC390561
rs2611605	C	0.99	0.7856	15	30228925	CHRNA7
rs11070619	C	1.02	0.7926	15	28896081	LOC390561
rs753636	A	0.98	0.7935	15	29478345	LOC440262
rs1514260	A	1.01	0.7981	15	30086242	
rs1567885	A	1.01	0.8297	15	30088094	
rs2063722	A	0.99	0.8311	15	30083665	
rs10519688	C	0.99	0.8362	15	29921270	
rs10519726	A	0.99	0.8404	15	29109167	TRPM1
rs12594231	C	0.99	0.854	15	29963596	
rs17816055	C	1.01	0.8543	15	29619386	C15orf16
rs4779527	C	1.01	0.8566	15	29523383	LOC440262,LOC400347
rs1524877	C	0.99	0.8618	15	29058472	FLJ20313
rs2293314	A	0.99	0.868	15	28997943	KIAA1018
rs1035707	C	1.01	0.8721	15	29172089	TRPM1
rs2081455	C	0.99	0.8741	15	29210624	
rs6493741	C	1.01	0.8747	15	29609127	C15orf16
rs11638086	A	0.99	0.8765	15	28853522	LOC440261,LOC390561
rs9672180	C	1.01	0.8818	15	30300468	
rs1088475	C	1.01	0.888	15	28927992	LOC390561
rs2219507	A	1.01	0.8928	15	29646927	C15orf16
rs2873	A	1	0.9116	15	29018547	FLJ20313,KIAA1018
rs2339046	A	1.01	0.9146	15	29059962	FLJ20313
rs798104	C	1.01	0.9313	15	28894118	LOC390561
rs3784589	A	0.99	0.9331	15	29082006	FLJ20313,TRPM1
rs8027035	C	1.01	0.9334	15	30149996	CHRNA7
rs1392808	G	1	0.9471	15	30198807	CHRNA7
rs4779556	C	1	0.9564	15	29960537	
rs4779910	C	1	0.9612	15	29734334	C15orf16
rs1075232	A	1	0.9619	15	29528508	LOC400347
rs1378847	C	1	0.9674	15	29234640	
rs12898600	A	1	0.9694	15	29816985	
rs6494223	C	1	0.9697	15	30183749	CHRNA7
rs1983459	A	1	0.9703	15	28996041	KIAA1018
rs7178637	C	1	0.9774	15	29665644	C15orf16
rs4779794	A	1	0.9844	15	28984856	KIAA1018
rs905426	A	1	0.9955	15	29870041	

Table 9. Diagnosis, family history, age of onset, response to neuroleptics based on available

Case ID	Diagnosis	Family history	Age of onset	Gender	Response	Other
Munich 1	DSMIV: 295	monozygotic twin brother with unknown psychiatric diagnosis	24	Male	yes	Not MR, very aggressive as child
Munich 2	DSMIV: 295	no	25	Female	yes	Not MR
Munich 3	DSMIV: 295	mother depression	32	Male	yes	Not MR
Munich 4	DSMIV: 295	no	17	Male	yes	Not MR
Munich 5	DSMIV: 295	no	23	Female	yes	Not MR
Bonn 1				Male		Not MR
Iceland 1		no	39	Male	yes	Not MR
Iceland 2		no	29	Female	yes	Not MR
Iceland 3	RDC: 126.3	Yes, schizophrenia	33	Male	Yes	Not MR
Iceland 4	RDC: 126	Yes, schizophrenia	16	Female	Yes	Not MR
Scotland 1	DSMIV: 295	No	37	Female	Yes	Not MR, borderline learning difficulties
Scotland 2	DSMIV: 295		23	Female	Yes	Not MR
Scotland 3	DSMIV: 295	?	32	Female	Yes	Not MR
Scotland 4	DSMIV: 295	No	22	Male	Yes	Not MR
Scotland 5	DSMIV: 295	No	31	Female	Yes	Not MR, Nervous breakdown at 22
Scotland 6	DSMIV: 295	No	15	Male	Yes	Not MR, heroin Not MR, addiction
Scotland 7		Yes, schizophrenia	24	Female		
England 1		Yes, schizophrenia (co-twin)	25	Male	Yes	Not MR, No drug abuse, primarily
Denmark 1	ICD10: F20	No	26	Male	No	Not MR
Denmark 2	ICD10: F20	No	(27, afa)	Male		Not MR
Denmark 3	ICD10: F20	No	21	Male		Not MR, cannabis abuse
Denmark 4	ICD10: F25	Yes	16	Male	Yes	Not MR
Holland 1	DSMIV: 295.30		19	Female		Not MR
Holland 2	DSMIV: 295.30	No	20	Male		Not MR
Holland 3	DSMIV: 295.30	No	20	Male		Not MR
Holland 4	DSMIV: 295.30		22	Male		Not MR

MR=mentally retarded.

Table 10. Diagnosis, family history, age of onset, response to neuroleptics based on available records and learning ability in cases carrying the 15q13.3 deletion associating with schizophrenia.

5

Case ID	Diagnosis	Family history	Age of onset	Gender	Response	Other
Munich 1	DSMIV: 295	Yes	24	Male	yes	Not MR
Iceland 1		Yes	30	Male	Yes	Not MR
Scotland 1	DSMIV: 295		20	Male	Yes	Not MR , IQ 83
Norway 1	DSMIV: 295.4		(31, afa)	Female	Yes	Not MR, No cannabis use or head injury
Holland 1	DSMIV: 295.20		23	Male		Not MR
Holland 2	DSMIV: 295.30	yes	39	Female		Not MR
Holland 3	DSMIV: 295.30			Male		Not MR

MR=mentally retarded.

EXAMPLE 2. Recurrent duplications of chromosome 16p13.1 associated with schizophrenia

A sub-microscopic duplication on chromosome 16p13.1 was recently found in two unrelated patients diagnosed with autism (Ullman *et al.*, *Human Mutation* 28:674-682,(2007)). The duplication encompassed an interval of 1.5 Megabases (Mb), spanning positions 14.89 to 16.39 Mb (NCBI Build 36). A third duplication was identified by quantitative PCR in a second Australian cohort of 112 patients. Two of the duplications were familial, and in one family a severely autistic brother also carried the duplication. One of the brothers was continuously hyperactive, destructive and aggressive, whereas the younger brother was passive and easy to manage. Other carriers included a sister, who had learning difficulties (sister) and a mother who had learning difficulties coupled with obsessive compulsive disorder. The two deletion patients had severe mental retardation. The former was de novo; the latter had a mildly affected carrier mother.

The chromosome 16p13.1 duplication/deletion interval is located in a region previously reported linked to bipolar disorder (McInness *et al.*, *Proc. Natl. Sci. USA* 493(23):13060-13065 (1996), Ewald *et al.*, *Mol Psychiatry* 7(7): 734-744 (2002), Ekholm *et al.*, *Hum. Mol. Genet.* 12(15):1907-1915 (2003), Kassem *et al.*, *Am. J. Psychiatry*, 163(10):1099- 104(2006) and to puerperal psychosis (Jones *et al.*, *Am. J. Psychiatry*, 164(2):248-258 (2007)). Furthermore, in a genome wide scan of 458 Finnish schizophrenia families, linkage was reported to DISC1 locus (Ekelund *et al.*, *Mol. Psychiatry*, 9(11): 1037-1041(2004)). When these families were later conditioned for a risk haplotype spanning Intron 1 and exon 2 of the DISC1 gene, linkage was found to 16p13.1 (lod 3.17)(Hennah *et al.*, *Hum. Mol. Genet.* 16(5):453-462 (2007)). The duplicated/deleted region contains the gene coding the DISC1 binding protein NDE1. The authors found significant allelic association between NDE1 and schizophrenia. However this association was not confirmed in a recent Japanese study (Numata S *et al.*, *Schizophr. Res.* 99(1-3): 367-369 (2008)). Finally, association was recently reported between NDE1 and schizophrenia, when schizophrenia cases and controls were conditioned by the presence of Cys residue at codon Ser 704Cys of DISC1 gene. (Burdick *et al.*, *Hum. Mol. Genet.*(2008)).

In the present study, we assessed association of CNVs in the 16p13.1 region with schizophrenia as part of a genome-wide scan using the Illumina HumanHap300 and Human Hap550 and Affymetrix SNP 6.0 genotyping arrays in a sample of 3,843 schizophrenia patients and 34,602 controls from seven European populations (Iceland, Finland, Germany, Holland, Norway, Italy and the UK).

RESULTS

We limited our search on 16p13.1 to the region between Mb 14.66 and 18.70 Mb (Build36). For comparison, the duplications and deletions reported by Ullman *et al.* (*Human Mutation* 28:674-682- (2007)) span Mb 14.89-16.39 (NCBI Build36). We subdivided the region into three single

copy sequence intervals which we called 1, 2 and 3. Each was flanked by substantial low copy repeats (LCRs) extending approximately 15.23-15.38; 16.38-16.53 and 18.19-18.34 respectively.

Figure 6 displays the region on USCC browser and gives examples of the duplications and deletions we observed. Duplicated intervals are identified by the numbers 1, 2 and 3. Interval 1 is a small island of single copy sequence embedded in a large cluster of LCRs. Table 11 lists the duplications and deletions found in our series plus country of origin. None were found in cases and controls from the UK samples from Institute of Psychiatry (n=108 and 92), Italy (n=86 and 92), Finland (n=191 and 200) and Norway (n=245 and 272). Accordingly, these samples were not included in Cochran-Mantel-Haentzel analysis.

We found a three fold excess of duplications and deletions in cases compared to controls (Table 12). Duplications were present in 0.36% of schizophrenia cases versus 0.08% controls ($P < 0.0032$). Deletions were present in 0.12% cases and 0.04% controls ($p > 0.05$). Due to varying geographical origin of the samples we analysed the data for association using Cochran-Mantel-Haentzel to correct for stratification. Total duplications were significantly associated with schizophrenia ($p < 0.0045$). When analysis was restricted to duplications containing intervals 1 and 2, the significance increased further ($p < 0.00018$). Duplications of intervals 1 plus 2 were present in 4 male and 2 female Scottish cases, 2 male Icelandic and 3 Dutch male cases; duplications were found in 12 female and 6 male Icelandic controls, and 2 Dutch male controls. Odds ratio was 8.50 (males) and 3.63 (females). The two Icelandic cases were independently ascertained and are included in the analysis as separate probands. However, when genealogical analysis was later performed unexpectedly we found that the two schizophrenia cases were second degree relatives. Other carriers in the family included single cases of alcoholism (under treatment), dyslexia and ADHD.

A 1 plus 2 deletion was present in 3 German schizophrenia cases, one German and ten Icelandic controls ($P > 0.05$) and a 2 plus 3 deletion was present in one Scottish schizophrenia case, two German and two Icelandic controls ($P > 0.05$).

We tested allelic association for all SNP markers on the Illumina microarrays that spanned the 16p13.1 region in 2,687 schizophrenia cases and 13,484 controls. One marker, rs2283508 was significantly associated ($p < 1.5E-05$) and remained significant after locus wide correction with a P-value of 0.0043. This marker is located within Intron of ABCC6 gene.

In view of the report (Burdick et al *Hum. Mol. Genet.* 2008) of association between NDE1 and schizophrenia when schizophrenia cases were stratified by the presence of Cys residue at Ser 704Cys of DISC1 gene, we also conditioned our schizophrenia cases. The DISC1 Ser704Cys SNP, rs821616, is not on the Illumina 317K chip. However, a SNP that has $r^2 = 1$ with rs821616 (i.e., a perfect surrogate) in the CEU, rs821596, was present. We therefore used rs821596 to divide the schizophrenia cases into

Cys-carrier and non carrier groups, and then looked for allelic association with SNPs at the NDE1 locus in the two groups. None were significantly associated. The data for 51 SNPs in, or within 200 kilobases of NDE1 for the Cys carrier and non carrier groups are in supplementary Table 12.

Since the majority of the duplicated cases were Scottish in origin, we examined the haplotype background of the duplicated regions. The CNV occurred on a different haplotype background in each individual. Indeed none of the non Icelandic individuals for which we had genotype data had a CNV on same haplotype background as any of the Icelandic cases. This suggests there was no founder, and each of the events is likely to have arisen independently. Within Iceland itself, for each of the CNV duplication and deletion subtypes found in more than one individual, there was no founder mutation. There were enough individuals in the Icelandic population with 1 plus 2 duplications to look at clustering patterns. Clustering occurred at a rate of 3 to 4 fold less than expected if the duplications were selectively neutral. However the maximum meiotic distance between individuals with the 1+2 duplication was longer than with the other 16p13.1 CNV categories we looked at here or among the deletions associated with schizophrenia on other chromosomal regions we have examined.

DISCUSSION

We have examined chromosome 16p13.1 region for recurrent duplications and deletions in a large set of European schizophrenia cases and controls. We find a three to four fold over-representation of both duplications and deletions in schizophrenia cases compared to controls. The over-representation of duplications is statistically significant ($P < 0.0045$). The great majority of duplications and deletions we found using Illumina micro-arrays are identical to those reported by Ulmann et al (*Human Mutation* 28:674-682(2007)) using BAC tiling pathway. They span the same 1.5 Mb region that includes intervals we call 1 and 2. However a minority of duplications and deletions in our cases and controls have breakpoints spanning intervals 2 and 3. These have not been previously reported.

The breakpoints for both types of deletion/duplication are located in areas with high LCR content. The region appears to be a region of genomic instability (Shaw and Lupski, *Hum. Mol. Genet.* 13: Spec No 1:R57-64 (2004)). There are several paralogous repeats in the region. The repeats are in the same orientation, and non allelic homologous recombination (NAHR) between these LCRs seems to be the most likely explanation for the recurrence of these rearrangements and for their identical size. Three inversion polymorphisms have previously been described in the 16p13.1 region (Tuzun et al., *Nat. Genet.* 37(7):727-732 (2005) and Database of Human variants Zhang et al., *Cytogen Genome Research* (2006)). A large duplication in a patient with mental retardation has also been reported (Sharp et al., *Nat Genet.* Sep;38(9):1038-1042(2006)), and a smaller de novo duplication (Kriek et al., *J. Med. Genet.* 41(4):249-255 (2004)). However in the latter report, since the father also had learning difficulties interpretation is problematic. A

much larger duplication (8Mb) of the region has also been reported in two unrelated patients with autistic features (Finelli *et al.*, *J. Med. Genet.* 41(7):e90 (2004)).

Our most striking finding is the increased risk of schizophrenia associated with duplications at the 16p13.1 locus. Recurrent deletions at several loci have now been reported significantly associated with schizophrenia but to date duplications associated with schizophrenia have mostly been isolated case reports. This is the first locus to our knowledge where there is statistically significant evidence of association between a duplication and schizophrenia. The different sizes of the duplications and deletions we have identified at the 16p13.1 locus presents difficulties when it comes to assessing association with schizophrenia. Statistically, we have used the straightforward approach of counting all duplications as equivalent events, and only then tried to condition on those duplications that have the same breakpoints as the original ones reported by Ullman *et al.* (*Human Mutation* 28:674-682 (2007)). Although caution must be exercised when interpreting results from such a small number of cases, there are several grounds for thinking that our findings are genuine. First given the rarity of the duplications the association with schizophrenia is remarkably statistically significant, especially if the 1 plus 2 duplications are considered separately ($P < 0.0045$ and $P < 0.00018$ respectively). Also identical duplications at the 16p13.1 locus have already been associated with autism. What is more, three of the schizophrenia duplication cases had an early onset of illness (12, 17 and 19 years) and in this respect resembled the 16p13.1 deletion cases where three of the five cases also had early onset of illness (15, 17 and 18 years) see Table 13. This seems unlikely to be due to chance. The duplication co-segregates with schizophrenia in the Icelandic pedigree and also with other neuropsychiatric disorders including ADHD. This is not unexpected since an overlap of phenotypic features between autism and ADHD has been extensively reported, and individuals with ADHD are at increased risk of schizophrenia. (Ammlinger *et al.*, *Am. J. Psychiatry* 156(4):525-530(1999), Keshavan *et al.*, *Schizophr. Res.* 59(1):85-92 (2003), Oner *et al.*, *Schizophr. Res.* 76(2-3):293-299(2005)). It is also perhaps noteworthy that nine of the eleven 1 plus 2 schizophrenia cases were males. This cannot be accounted for by the excess of males in the schizophrenia series under investigation, and resembles the sex ratios observed in autism. The duplications at this locus appear to be under negative selection. Cluster analysis of the 1 plus 2 duplication events in the Icelandic population finds considerably fewer clusters than if the duplications were selectively neutral. This negative selection is not as pronounced as for the high penetrant recurrent deletions we have recently described at other loci but it is present nevertheless. It is consistent with the lower odds ratio we also observe. Finally the duplicated region contains two strong candidate genes over- or under-expression of one or both of which at key stages of neurodevelopment could predispose to autism and/or schizophrenia.

NTAN1 gene is located in the small island of single sequence called interval one. It encodes an N-terminal asparagine amidase that has been implicated in social behaviour and memory. Over-expression of NTAN1 leads to reduction in MAP2 protein expression through the ubiquitin-proteasome pathway. Reduced expression of MAP2 may be a useful marker for diagnosis of schizophrenia and bipolar disorder *in vivo* (Whitaker-Azmitia *et al.*,

- Neuropsychopharmacology*12(3):269-272(1995); Mazer *et al.*, *Brain Res.*760(1-2): 68-73(1997)) and *In vitro* (Marx *et al.*, *Biol. Psychiatry*50(10):743-749(2001); Bouras *et al.*, *Acta Neuropathol.*102(4): 373-379(2001)). Mutations of UBE3 ubiquitinprotein ligase gene, cause Angelman syndrome, a neurodevelopmental disorder with associated autistic features.
- 5 Recently, decreased expression of genes involved in ubiquitin metabolism has been reported in dorsal prefrontal cortex and laser sorted dentate granule neurons from schizophrenia patients (Middleton *et al.*, *J. Neurosci.*22(7): 2718-2729 (2002); Vawter *et al.*, *Schizophr. Res.*58(1):11-20(2002); Altar *et al.*, *Biol. Psychiatry*58(2):85-96(2005)). The neuronal ubiquitin-proteasome system controls the assembly, connectivity, function and signaling of the synapse, including the
- 10 turnover of pre and postsynaptic proteins (Hedge and Antonio, *Neuroscience*3:854-861(2002); Collins CA and Di Antonio A, *Current Opinion Neurobiology.* 17:35-42 (2007)). Mice with disrupted NTAN1 gene show less locomotion in an open field and impairment of several spatial memory tasks (Kwon *et al.*, *Mol. Cell Biol.*20(11):4135-4148 (2000); Balogh *et al.*, *Learn Mem.*7(5): 279-286 (2000)).
- 15 NDE1 and NDEL are highly homologous genes involved in brain development, neuronal proliferation, migration and synapse formation. They encode for proteins that biologically interact with DISC1 and LIS1 proteins, with NDE1 appearing to be interchangeable with its homolog NDEL, except that NDE1 is expressed earlier in development. The LIS1/NDEL pathway is involved in brain development and regulated by RELN, another candidate gene for
- 20 schizophrenia. Mutations in RELN/ LIS1 pathway cause lissencephaly. NDE1 null mice are viable and display microcephaly with thinning cortical layering and reduced numbers of neurones. Interestingly two out of three reported autism cases with the duplication had increased head circumference. Mice display defects in neuronal proliferation and neuronal migration. NDE1 protein directly interacts with DISC1 protein at the C terminal end that is distal to the truncating
- 25 mutation reported in the Scottish DISC1 translocation family. (Kamiya *et al.*, *Hum. Mol. Genet.*15(22):3313-3323 (2006)). Phenotypes in this family include schizophrenia, schizoaffective disorder, major depression and severe adolescent conduct disorder. (St Clair *et al.*, *Lancet*336(8706):13-16 (1990); Blackwood *et al.*, *Am. J. Hum. Genet.* 69(2):428-433 (2001)). Sachs *et al.* (*Am. J. Hum. Genet.* 69(2):428-433 (2005)) reported a frameshift
- 30 mutation in DISC1 gene in an American pedigree. In addition to cases of schizophrenia and major depression the pedigree contains two cases of autistic spectrum disorder and two cases of mental retardation. The DISC1 gene has also recently been found associated with autism spectrum and Asperger's syndrome (Kilpinen *et al.*, *Mol. Psychiatry* 13(2):187-196 (2008)). Since DISC1 is known to inhibit NDE1/NDEL activity, the duplications we report here might
- 35 therefore be expected to have a similar biological effect as the truncating mutation associated with schizophrenia in the Scottish family, of increasing NDE1 activity.

All duplications and deletions in our study involve interval 2 that harbours the NDE1 gene and this makes dys-regulation of NDE1 expression the most parsimonious explanation for the increased risk of the schizophrenia phenotypes we associate with the region. On the other hand

40 the strongest association is with duplication cases that also involves interval 1. It is possible that

combined changes in expression of NTAN1 and NDE1 increase susceptibility over changes in expression of NDE1 alone. We found evidence of allelic association with only one marker, located in an intron of ABCC6, spanning the region present on the Illumina micro-array. We were unable to replicate association with NDE1 when our samples were conditioned DISC1 ser704cys and cys704cys carrier status. Further examination of the region will be necessary to determine if it contains rare variants that increase risk of schizophrenia. It will also be necessary to analyse mRNA and protein levels using relative allelic expression to try to define which individuals may be able to compensate for dosage gain/ loss, for example through a high/low expressing residual copy of the gene or other modifying loci. These, along with as yet unidentified environmental influences, perhaps acting epigenetically eg on RELN gene, may help to determine the penetrance and expressivity of the phenotypes observed at the locus.

Further work is required before the clinical implications of our findings become clear. On the one hand the data strongly suggest that recurrent duplications at 16p13.1 locus increase risk of schizophrenia. They also strengthen the hypothesis that there are shared genetic risk factors between schizophrenia and autism. However the odds ratios, even for the 1 plus 2 duplications, are substantially less than the increased risks we have observed for recurrent deletions on chromosomes 1, 15 and 22. Whether the lesser odds ratio we observe for duplications is a feature of the 16p13.1 locus itself, or it is part of a broader rule than recurrent duplications are generally less penetrant than recurrent deletions remains to be determined. The 16p13.1 duplications we observe are rare, at a rate of about 3 or 4 per 1000 cases, and, from the control population in the present study, about 0.08 % of live births. This makes it difficult to obtain precise measurements of schizophrenia and/or autism risk. Analysis of CNV data from sets of cases and controls considerably larger than the sets we report in this paper, which itself to date is one of the largest assembled, will be required. These and many other questions will need to be answered before the exciting findings arising from CNV analysis can be used in clinical practice for diagnostics, disease classification or genetic testing.

MATERIALS AND METHODS

Samples

A total of 3843 affected and 34602 controls from six European populations were successfully examined for CNVs at the two loci studied here; 1435 schizophrenia patients and 28554 control individuals from the Iceland, Scotland, Germany, England, Italy and Finland (The SGENE sample; <http://www.SGENE.eu>), additional 866 schizophrenics and 856 controls from Aberdeen, Scotland and Munich, Germany which have been collected with support from GSK and were genotyped at Duke University, 491 affected and 881 controls from Bonn, Germany, genotyped at Bonn University and 806 Dutch cases and 4039 controls. The Icelandic sample consists of 648 schizophrenics and 27747 controls. A further 5630 genotyped samples were examined but

excluded from association analysis due to other psychiatric disorders (autism, bipolar disorder, ADHD, dyslexia and alcoholism) and/or first degree relationships to schizophrenic patients. Patients and controls were all Icelandic and diagnoses were assigned according to Research Diagnostic Criteria (RDC) (Spitzer et al., *Arch. Gen. Psychiatry* 35, 773-782 (1978)) through the use of the lifetime version of the Schizophrenia and Affective Disorders Schedule (SADS-L) (Spitzer, *New York State Psychiatric Institute, New York, (1977)*). The Icelandic controls were chosen from persons who have participated in other genetic studies at deCODE Genetics. The Scottish sample is comprised of 661 schizophrenia cases and 665 controls. All participants self-identified as born in the British Isles (95% in Scotland) and met DSMIV and ICD-10 (American Psychiatric Association, 1994; WHO, 1994 48) criteria for schizophrenia. Diagnosis was made by OPCRIT (McGuffin et al., *Arch. Gen. Psychiatry* 764-770, (1991)). Controls were volunteers recruited through general practices in Scotland, and subjects with major mental illness were excluded. The Munich sample consisted of 611 Caucasian cases and 612 Caucasian controls. Cases diagnosed with DSMIV schizophrenia were ascertained from the Munich area in Germany. Diagnosis was made according to DSMIV criteria using the Structured Clinical Interview for Axis I DSM-IV Disorders (SCID) (First et al., *Biometrics Research, New York, 1994*). The controls were unrelated volunteers randomly selected from the general population of Munich. The Finnish sample consisted of 191 schizophrenics and 200 regionally selected controls that had no medical history of schizophrenia. Diagnosis was according to the criteria of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). The sample from the UK consisted of cases (n = 104) and controls (n = 95) who were unrelated white European Caucasians. All patients were interviewed with the Schedule for Affective Disorders and Schizophrenia Lifetime Version or the Item Group Checklist (IGC) of the Schedule for Clinical Assessment in Neuropsychiatry (SCAN) (WHO, *Schedules for Clinical Assessment in Neuropsychiatry (SCAN) Manual, 1994*) and diagnosed according to ICD-10 RDC. UK controls were unrelated individuals with no history of major mental illness. Diagnosis of the 85 Italian cases from the local population of South Verona was also by IGC and ICD-10 RDC for schizophrenia, and the 91 controls were unrelated healthy volunteers randomly selected from the same population. The Bonn sample is comprised of 491 patients and 881 controls. Patients were recruited from consecutive hospital admissions and were all of German descent. In patients, lifetime best estimate diagnoses according to DSM-IV criteria were based on multiple sources of information including structured interview with the SCID (First et al., 1994) or SADS-L (Endicott and Spitzer, 1978), the OPCRIT (McGuffin et al., 1991), medical records, and the family history. Best estimate diagnoses were obtained from at least two experienced psychiatrists/psychologists. Controls were derived from two German population-based cohorts, PopGen (N=492) and Heinz Nixdorf Recall (N=383). The Norwegian sample included 245 patients who had been recruited to the TOP study from all the psychiatric hospitals in the Oslo area. The patients were diagnosed according to Structural Clinical Interview for DSM-IV (SCID). The healthy control subjects (N=272) were randomly selected from the same catchments area as the patient groups. Only subjects born in Norway, all of Caucasian origin, were contacted by letter and invited to participate. Ethical approval was obtained from the local Ethics Committees. All participants gave written informed consent. One part of the Dutch sample consisted of 806 patients and 706 controls. Inpatients and outpatients were recruited

from different psychiatric hospitals and institutions throughout the Netherlands, coordinated via academic hospitals in Amsterdam, Groningen, Maastricht and Utrecht. Detailed medical and psychiatric histories were collected, including the Comprehensive Assessment of Symptoms and History (CASH), an instrument for assessing diagnosis and psychopathology. To exclude related patients and controls, all subjects were fingerprinted (Illumina DNA panel, 400 SNPs). Only patients with a DSM-IV diagnosis of schizophrenia were finally included as cases (295.xx). All patients and controls were of Dutch descent, with at least three out of four grandparents of Dutch ancestry. The controls were volunteers and were free of any psychiatric history. Ethical approval was obtained from the local Ethics Committees. All participants gave written informed consent. The remaining Dutch control sample consisted of 3,333 individuals collected by the Radboud University Nijmegen Medical Centre (RUNMC) for genetic studies. All 3,333 participants used in the present study are of self-reported European descent. The study protocol was approved by the Institutional Review Board of Radboud University and all study subjects gave written informed consent.

15

The SGENE samples were typed on the HumanHap300 BeadArray™ (Illumina, San Diego, USA) at deCODE genetics. The additional samples from Aberdeen and Munich were typed at Duke University in collaboration with GlaxoSmithKline on HumanHap550v3 and HumanHap300 BeadArray™ (Illumina, San Diego, USA, respectively). The samples from Bonn were typed at Bonn University on HumanHap550v3 BeadArray™ (Illumina, San Diego, USA). The Dutch samples from Utrecht University were genotyped at the University of California, Los Angeles, on HumanHap550v3 BeadArray™ (Illumina, San Diego, USA). The remaining Dutch samples were genotyped at deCODE genetics on HumanHap300 BeadArray™ (Illumina, San Diego, USA). The Norwegian samples were genotyped on Affymetrix GeneChip(r) GenomeWide SNP 6.0 array and analyzed using the Affymetrix Power Tools 1.8.0. Samples with Contrast QC below 0.4 were excluded as recommended by the manufactory.

25

CNV detection

DosageMiner software developed at deCODE genetics and QuantiSNP software developed at Wellcome Trust Centre for Human Genetics and the University of Oxford (<http://www.well.ox.ac.uk/QuantiSNP/>) was used to identify deletions and duplications within the region reported by Ullman *et al.* (2007) in all samples except the Norwegian samples. Dosage miner, described in detail elsewhere (Stefansson *et al.*, submitted), uses the intensities from SNP probes on the Illumina microarrays to estimate copy number of genomic regions, and models factors such as SNP effect, sample effect and GC-content in the neighbouring region to normalise the intensities. The software then automatically registers SNP loci where intensities fall above or below an empirical threshold.

35

The QuantiSNP program relies on an Objective Bayes Hidden-Markov Model to estimate copy number variations (Colella and Yau et al., *Nucleic Acids Research* 2007). In this model, the hidden states denote the unknown copy number at the Inspected SNPs. Genotype data was used to compute different states. Based on the ratio of fluorescent dye ratios (logR) and stretches of, the algorithm computes a Bayes factor that is used to calibrate the model to a fixed type I (false-positive) error rate. A Bayes factor threshold of 10 is considered as a promising value for the possible presence of a CNV. Usually, such values occur when 5-10 consecutive SNPs are deleted/duplicated. Differences in GC base pairs may result in biased hybridization behaviour of SNP probes bearing the risk of miscalling genotypes. To normalize for this, QuantiSNP assigns a locus-specific GC value to each probe. All potential CNVs detected by both softwares were subsequently visually inspected and confirmed.

Association analysis

A Cochran-Mantel-Haenszel analysis assuming common odds ratios was performed, stratifying samples by country of origin to take account of the possible effect of geographical variation on the results of the analysis.

Table 11. Duplications and deletions of 16p 13.1 In European populations

Status No of cases	Iceland		Scotland		Germany		Holland	
	Scz (648)	Ctrl (27747)	Scz (661)	Ctrl (665)	Scz (1102)	Ctrl (1493)	Scz (806)	Ctrl (4039)
% Male	63	39	72	58	57	49	76	60
All Dupl	2	24	6	1	1	0	3	8
All Del	0	12	1	0	3	3	0	0
Dup_1+2	2	18	6	0	0	0	3	2
Dup_2	0	3	0	1	0	0	0	1
Dup_2+3	0	3	0	0	1	0	0	3
Del_1+2	0	10	0	0	3	1	0	0
Del_2	0	0	0	0	0	0	0	0
Del_2+3	0	2	1	0	0	2	0	0

Table 12. P values, odds ratios and confidence intervals for recurrent duplications and deletions of chromosome 16p13.1

16p13.11 CNV	All samples			Male only			Female only		
	P-value	common OR	95% CI	P-value	common OR	95% CI	P-value	common OR	95% CI
All deletions & all duplications	0.011	2.72	1.22-5.9	0.016	3.03	1.15-7.77	0.43	1.72	0.25-8.16
All duplications	0.0045	3.58	1.38-8.76	0.0078	4.12	1.32-12.39	0.59	2.05	0.17-12.89
All deletions	0.73	1.39	0.26-6.45	1	1.34	0.17-9.18	1	1.24	0.02-20.5
Duplications regions 1&2	0.00018	7.07	2.37-19.55	0.00054	8.50	2.24-31.81	0.24	3.63	0.22-28.74
Deletions regions 1&2	0.38	2.26	0.28-14.36	0.28	3.66	0.18-45.46	1	1.28	0.02-22.78
Duplications regions 2&3	1	1.01	0.02-11.47	1	1.86	0.02-60.28	1	0	0-29.09
Deletions regions 2&3	1	0.59	0.01-9.48	1	0.50	0.01-8.59	1	0	0-2623.69

Table 13. Description of cases

Case No		Gender	Dup/del	Diagnosis	Age of onset	Family history	Other
584584/ AA02IK2/ GSK0253	Scotland	M	2+3 del	Schizophrenia	17	Had a breakdown aged 16/17 when he saw a psychiatrist. Mother suffered a "nervous breakdown". 1959 contact with psychiatric services ?Anxiety and? Schizoid personality.	14.05.96 grief reaction, following death of mother
583786/ ABSZ1389/ Opcrit no 3885	Scotland	F	1+2 dupl	Schizophrenia	12	Paternal mother is 'odd'	
583447/ ABSZ1728/ Opcrit no 7020	Scotland	M	1+2 dupl	Chronic schizophrenia/paranoia	19	Father Bipolar illness. Paternal uncle schizophrenia. Mother died MI 1994. Oldest sister murdered 1995, known drug abuser.	1993 Low mood (poor social circumstances). Drug abuse. 1995 odd behaviour /laughing inappropriately/ talking to himself/(month after sister died)
ABSZ1323/ GSK0329	Scotland	M	1+2 dupl	Schizophrenia	30		Obsessional traits-specific routes and routines
536751 GSK0183	Scotland	M	1+2 dupl.	Paranoid schizophrenia	34	Mother treated in Dundee Royal for depression. Brother drinks excessively and has abnormal personality.	
536747	Scotland	M	1+2 dupl	Paranoid schizophrenia	23	Father suffered from nervous breakdown 1956, inpatient.	
543523/ AA02C4T/ GSK3102	Scotland	F	1+2 dupl	Paranoid schizophrenia	29	Father died alcoholic, cirrhosis of liver	
WG0012761- DNAC05	Germany	F	1+2 del	Schizophrenia	23	No FH Behavioural disturbance since childhood	chronic
586835	Germany	M	1+2 del	Schizophrenia	15	mother depression, father alcohol abuse, brother heroin dependence; grandfather (father's side) possible schizophrenia	chronic
WG0012763- DNAD07	Germany	M	1+2 del	Schizophrenia	18	Mother depression	chronic
WG0012761- DNAB11	Germany	M	2+3 dupl	Schizophrenia	17	No FH behavioural disturbance since childhood	chronic
NE50218	Holland	M	1+2 dupl.	Schizophrenia	x	x	x

NE71493	Holland	M	1+2	dupl.	Schizophrenia	x	x	x
NE980503	Holland	M	1+2	dupl	Schizophrenia	34	Psychosis and depression sisters	x
Ice014	Iceland	M		dupl	Schizophrenia	x	Yes, see pedigree	x
Ice032	Iceland	M		dupl	Schizophrenia	23	Yes, see pedigree	chronic

EXAMPLE 3. Duplication on chr 5q35 associated with schizophrenia

By assessment of CNVs using SNP markers on the Illumina HumanHap300 chip in samples from Iceland, we have identified a region on chromosome 5q35.2 that is duplicated in individuals diagnosed with schizophrenia. The 5q35.2 duplication spans a region flanked by markers rs1545976 and rs2220368, between position 175,939,217 and 176,073,058, on chromosome 5 (Figure 7).

Several genes in the duplicated region may contribute to the development of schizophrenia in individuals carrying the 5q35.2 duplication.

The duplicated region contains the Protocadherin LKC precursor gene (PCLKC), a gene encoding G protein-regulated inducer of neurite outgrowth (GPRIN1), a beta-synuclein gene (SNCB) and a gene encoding transmembrane 4 super family member 17 isoform b (TSPAN17).

Protocadherin LKC precursor belongs to the protocadherin family. Members of the protocadherin family encode non-classical cadherins that function as calcium-dependent cell-cell adhesion molecules.

Northern blot analysis of human brain regions shows wide distribution in brain tissue and the central nervous system with highest expression in the spinal cord. Northern blot analysis of mouse tissues detected expression in brain only, and Western analysis detected the GPRIN1 protein in mouse neuroblastoma and rat pheochromocytoma cells. Using immunofluorescence studies and Western analysis of cell fractions, it has been found that GPRIN1 is a membrane-bound protein that is enriched in the growth cones of neurites, and as such is a possible schizophrenia candidate.

Beta synuclein is concentrated in presynaptic nerve terminals. It has been found that mice doubly transgenic for human alpha- and beta-synuclein have decreased accumulation of alpha-synuclein-immunoreactive neuronal inclusions and less severe neurodegenerative alterations compared to mice singly transgenic for human alpha-synuclein. In vitro cell culture studies showed that beta-synuclein coimmunoprecipitated with alpha-synuclein and that cells transfected with beta-synuclein were resistant to alpha-synuclein accumulation. The findings suggested that beta-synuclein may be a natural negative regulator of alpha-synuclein aggregation. Further, it has been found that cultured neurons overexpressing beta-synuclein had increased Akt signaling activity and were resistant to neurotoxic effects of the pesticide rotenone compared to cells overexpressing alpha-synuclein and control cells. Downregulation of Akt activity using Akt siRNA resulted in increased susceptibility to the neurotoxic effects of rotenone. Coimmunoprecipitation studies suggested a direct molecular interaction between beta-synuclein and Akt.

WHAT IS CLAIMED IS

1. A method of determining a susceptibility to a schizophrenia condition in a human individual, the method comprising:

analyzing nucleic acid sequence information about a human individual and identifying the chromosome 15q11.2 deletion that includes markers rs8040193 and rs3883043 in the genome of the individual, wherein the presence and absence of the chromosome 15q11.2 deletion are associated with different susceptibilities to the condition in humans, and

determining a susceptibility to the condition for the individual from the nucleic acid sequence data.
2. The method of claim 1, wherein determination of a susceptibility comprises comparing the nucleic acid sequence information to a database containing correlation data between the chromosome 15q11.2 deletion and susceptibility to the condition.
3. The method of claim 2, wherein the database comprises at least one risk measure of susceptibility to the condition for the chromosome 15q11.2 deletion.
4. The method of claim 2, wherein the database comprises a look-up table containing at least one risk measure of the condition for the chromosome 15q11.2 deletion.
5. The method of any one of the preceding claims, wherein analyzing nucleic acid sequence information comprises analyzing at least one polymorphic marker in a nucleic acid in a biological sample from the human individual.
6. The method of claim 5, wherein analyzing the at least one polymorphic marker comprises analyzing at least one polymorphic marker representative of the chromosome 15q11.2 deletion.
7. The method of claim 5, wherein the at least one polymorphic marker is in linkage disequilibrium with the chromosome 15q11.2 deletion.
8. The method of claim 6 or 7, wherein the at least one polymorphic marker is located within the chromosome 15q11.2 deletion.
9. The method of any one of claims 5-8, wherein analyzing the at least one polymorphic marker comprises obtaining dosage measurement data for the at least one polymorphic marker representative of the chromosome 15q11.2 deletion.

10. The method of any one of the preceding claims, wherein analyzing the nucleic acid sequence information comprises identifying the chromosome 15q11.2 deletion using a nucleic acid probe selective for a nucleic acid segment that comprises the chromosome 15q11.2 deletion.
11. The method of claim 10, wherein the nucleic acid probe comprises a label, and wherein identifying the chromosome 15q11.2 deletion comprises allowing the nucleic acid probe to hybridize to the nucleic acid segment, such that when bound to the nucleic acid segment, the label is representative of the number of copies of the segment in the individual.
12. The method of any one of claims 1-4, wherein the nucleic acid sequence information is obtained from a preexisting record.
13. The method of any one of the preceding claims, further comprising reporting the susceptibility to at least one entity selected from the group consisting of the individual, a guardian of the individual, a representative of the individual, a genetic service provider, a physician, a medical organization, and a medical insurer.
14. The method of any one of the preceding claims, wherein the chromosome 15q11.2 deletion is indicated by a genetic marker in linkage disequilibrium with the chromosome 15q11.2 deletion.
15. The method of Claim 14, wherein the genetic marker is a single nucleotide polymorphism.
16. The method of any one of the preceding claims, further comprising determining whether an additional genetic risk variant for schizophrenia is present in the genome of the individual.
17. A computer program for determining a genetic indicator for a schizophrenia condition in a human individual:

wherein the computer program is adapted to be executed on the processor to analyze information about the chromosome 15q11.2 deletion that includes markers rs8040193 and rs3883043, and

generate an output based on the information about the chromosome 15q11.2 deletion, wherein the output comprises a risk measure of the chromosome 15q11.2 deletion as a genetic indicator of the schizophrenia condition for the human individual.

18. The computer program of Claim 17, wherein the computer readable memory further comprises data for at least one polymorphic marker in a plurality of individuals diagnosed with the schizophrenia condition, and data for the at least one polymorphic marker in a plurality of reference individuals, wherein the data is representative of the chromosome 15q11.2 deletion, and wherein a risk measure is based on a comparison of marker data for the at least one marker for the human individual to marker data for the plurality of individuals with the schizophrenia condition.
19. The computer program of claim 18, wherein the data for the at least one polymorphic marker is dosage data for the at least one marker.
20. The computer program of any one of the claims 17 - 19, wherein the computer readable memory further comprises data indicative of the risk of developing the schizophrenia condition associated with the chromosome 15q11.2 deletion, and wherein a risk measure for the human individual is based on a comparison of status of the chromosome 15q11.2 deletion for the human individual to the risk associated with the chromosome 15q11.2 deletion.
21. The computer program according to Claim 20, wherein the computer readable memory further comprises data indicative of the frequency of the chromosome 15q11.2 deletion in a plurality of individuals diagnosed with the schizophrenia condition, and data indicative of the frequency of the chromosome 15q11.2 deletion in a plurality of reference individuals, and wherein risk of developing the schizophrenia condition is based on a comparison of the frequency of the chromosome 15q11.2 deletion in individuals diagnosed with the schizophrenia condition and reference individuals.
22. The computer program according to any one of the claims 17 -21, wherein the risk measure is characterized by an Odds Ratio (OR) or a Relative Risk (RR).
23. A method of determining a susceptibility to a schizophrenia condition in a human individual, the method comprising determining whether a copy number variation polymorphism is present in the genome of the individual, wherein the copy number variation is the chromosome 15q11.2 deletion that includes markers rs8040193 and rs3883043, and wherein the presence of the copy number variation in the genome of the individual is indicative of an increased susceptibility to the condition.
24. The method of claim 1, substantially as herein described with reference to any one of the Examples and/or Figures thereof.
25. The method of any one of claims 1 to 16, substantially as herein described.

26. The computer program of claim 17, substantially as herein described with reference to any one of the Examples and/or Figures thereof.
27. The computer program of any one of claims 17 to 22, substantially as herein described.
28. The method of claim 23, substantially as herein described with reference to any one of the Examples and/or Figures thereof.
29. The method of claim 23, substantially as herein described.